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A b s t r a c t  
The aim of this study was to systematically investigate the contributions of 
various amino acids within the prion protein, on prion propagation. To test 
this in a cellular system, we used a sub-cloned population of N2a cells 
(PK1) that are highly susceptible to RML mouse prions. A library of stable 
PK1 cells was generated, which expressed the full length mouse prion 
protein (moPrP) bearing either point, double, or triple alanine replacements. 
The effects these changes in the prion protein sequence had on the ability 
of PK1 cells to propagate RML was tested using a previously established 
cell based assay.  
We found that: (i) in the unstructured region of the protein, alanine 
replacements in CC2 region 90-111 of the prion protein severely diminish, 
but do not abrogate the ability of cells to propagate prions whilst 
substitutions K23A.K24A.R25A and Q41A exerted a moderate inhibitory 
effect on propagation; (ii) alanine replacements in CC2 displayed a 
dominant negative effect by imposing their propagation inhibition phenotype 
in the presence of the wild-type protein; (iii) the diminished propagation 
abilities of cells expressing CC2 alanine mutants were a result of these cells 
being less susceptible to infection than their wild-type counterparts (iv) all 
alanine replacements tested in the structured region of the protein appeared 
to hamper prion propagation, regardless of their positioning within this 
globular domain.  
Taken together, these results suggest that integrity of the structured region 
is vital for successful prion propagation, and that although the flexible region 
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of the prion protein alone (residues 23-111), does not exclusively confer 
infectivity and/or propagative capacity, charge interactions in this region 
govern the efficacy with which propagation ensues.  
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A b b r e v i a t i o n s   
14-3-3 A class of regulatory proteins ubiquitously expressed in 
eukaryotic cells 
β-PrP Beta-sheet-rich form of the prion protein 
A600 Sample absorbance at 600 nm 
AmpR Ampicillin resistance gene 
Aβ  Amyloid beta, a 40-42 amino acid-long peptide generated 
via sequential cleavage of the amyloid precursor protein by 
β- and γ-secretases 
ANOVA Analysis of variance 
AP Alkaline phosphatase 
APP Amyloid precursor protein 
Bax Bcl-2-associated X protein 
BSE Bovine Spongiform Encephalopathy 
C1 Fragment corresponding to residues 110-230 of prion 
protein (mouse numbering) 
CaCl2 Calcium chloride 
CC1 Charge cluster 1 
CC2 Charge cluster 2 
CJD Creutzfeldt-Jakob disease 
CMV Cytomegalovirus 
CNS Central nervous system 
CO2 Carbon dioxide 
CtmPrP PrP peptide with C-terminal half of the protein in the ER 
lumen 
DAPI 4',6-diamidino-2-phenylindole 
DMEM  Dulbecco’s Modified Eagle’s Medium 
DNA Deoxyribonucleic acid 
dNTPs Deoxyribonucleotide triphosphates 
DpnI Restriction endonuclease GATC recognition site 
ECL Enhanced chemiluminescence 
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EDTA Ethylenediaminetetraacetic acid 
EGFP Enhanced GFP 
ELISA Enzyme-linked immunosorbent assay 
ER Endoplasmic reticulum 
EtOH Ethanol 
FCS Foetal calf serum 
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GAG Glycosaminoglycan 
GFP Green fluorescent protein 
GPI Glycosylphosphatidylinositol 
GSCN Guanidinium thiocyanate 
GSS Gerstmann-Sträussler-Scheinker 
HC Hydrophobic core 
HCl Hydrochloric acid 
HDX Hydrogen-deuterium exchange 
HindIII Restriction endonuclease AAGCTT recognition site  
HRP Horseradish peroxidase 
huPrP Human prion protein (cellular form) 
ICSM35b Biotinylated form of ICSM35 
ID Intrinsic disorder 
IDP Intrinsically disordered protein 
IgG Immunoglobulin G isotype 
IMAC Immobilised metal-affinity chromatography 
Indel Insertion/deletion mutation 
iPK1 Chronically infected PK1 cells 
iPK1moPrPAla Chronically infected PK1 cells expressing alanine-mutant 
forms of murine PrP 
KanR Kanamycin resistance gene 
KD Knockdown 
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KDmoPrPAla Knockdown PK1 cells expressing the full-length, form of the 
murine prion protein (cellular form) with single, double or 
triple alanine mutations 
KDmoPrPWT Knockdown PK1 cells expressing the full-length, wild-type 
form of the murine prion protein (cellular form) 
LB Luria Broth 
LRP1 Low-density lipoprotein receptor-related protein 1 
LTR Long terminal repeat 
MCS Multiple cloning sites 
MgCl2 Magnesium chloride 
mGluR5 Metabotropic glutamate receptor 5 
MMLV Moloney Murine Leukemia Virus 
moPrP Mouse prion protein (cellular form) 
moPrPAla Alanine-mutant forms of the prion protein (cellular form) 
moPrPWT Full-length, wild-type form of the murine prion protein 
(cellular form) 
moPrPWT(Sc) Full-length, wild-type form of the murine prion protein 
(disease-associated form) 
N-SS  N-terminal signal sequence 
N1 Fragment corresponding to residues 23-109 of prion protein 
(mouse numbering) 
N2a Neuro-2a, a murine neural crest-derived cell line 
NaCl Sodium chloride 
NaN3 Sodium azide 
NaOH Sodium hydroxide 
NeoR Neomycin resistance gene 
NI Non-infected 
NMDAR  N-methyl-D-aspartate receptor 
NMR Nuclear magnetic resonance 
NR2B  N-methyl D-aspartate receptor sub-type 2B 
NtmPrP PrP peptide with N-terminal half of the protein in the ER 
lumen 
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o/n Overnight 
OFCS Opti-MEM containing 10% FCS and 1% 
penicillin/streptomycin 
OPR Octapeptide repeat 
OPRI Octapeptide repeat insertions 
ORF Open reading frame 
PAGE Polyacrylamide gel electrophoresis 
PBS Phosphate buffered saline 
PBST PBS containing 0.1% Tween-20 
PCR Polymerase chain reaction 
PFA Paraformaldehyde   
PK ProteinaseK 
PK1 A highly RML prion-susceptible sub-clone of N2a cells 
PK1moPrPAla PK1 cells expressing alanine-mutant forms of moPrP   
PMSF Phenylmethylsulfonyl fluoride 
POPG 1-palmitoyl-2-oleoylphosphatidylglycerol 
SecPrP PrP peptide fully secreted into the ER lumen 
Prnp Gene encoding murine prion protein 
PrPC Cellular form of the prion protein 
PrPSc Scrapie form of the prion protein (disease-associated) 
PTM Putative transmembrane domain 
PVDF Polyvinylidene fluoride 
recA Protein involved in DNA repair and maintenance 
RML Rocky Mountain Laboratory prion strain (mouse-derived) 
RNA Ribonucleic acid 
rPrP Recombinant prion protein 
RT Room temperature 
SalI Restriction endonuclease GTCGAC recognition site 
ScN2a Constitutively infected N2a cells 
SCA Scrapie cell assay 
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SCEPA Scrapie cell end-point assay 
SDS Sodium dodecyl sulfate 
SH2 Src Homology 2 
ShaPrP Syrian hamster prion protein 
shRNA Short hairpin RNA 
siRNA Small interfering RNA 
SmaI Restriction endonuclease CCCGGG recognition site 
SOD Superoxide dismutase 
SS-C  C-terminal signal sequence 
SSC Single-cell clone 
ssNMR Solid-state NMR 
Stat3 Signal transducer and activator of transcription 3 
TBST Tris-buffered saline containing 0.1% Tween-20 
TC Tetracysteine 
TCIU Tissue culture infectious units 
TSE Transmissible spongiform encephalopathy 
Tris  Tris(hydroxymethyl)aminomethane 
U Units 
UTR Untranslated region 
WB Western blot 
WT Wild-type 
XhoI Restriction endonuclease CTCGAG recognition site 
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1 . 1  I n t r o d u c t i o n  t o  A m y l o i d s  
1.1.1 Protein misfolding and the amyloid cascade hypothesis 
In an optimal cellular system, all newly synthesised proteins would be made 
error-free, follow correct localisation patterns and never misfold. In reality, 
cellular systems work hard to maintain proteostasis with the help of 
chaperones and the proteasome network1. There is still an underlying low 
error-rate in protein biosynthesis, but these are usually silent mutations with 
minimal effects on the finished protein product2. However, as the cell ages, 
its protein synthesis and degradation pathways become increasingly error-
prone1. In some cases, deviation from the native protein sequence further 
compounds the issue, often resulting in higher propensities for protein 
misfolding3, exerting extra stress upon the proteasomal degradation 
pathway4.  
Continued stress on the proteasomal systems lead to accumulation of 
misfolded, aggregated proteins: a characteristic of neurodegenerative 
diseases, such as Alzheimer’s, Parkinson’s and prion diseases. Most 
protein misfolding diseases appear to share mechanisms where the native 
protein is altered from a fully-functional soluble form, to a conformer with 
increased beta-sheet content and lower solubility5, 6. This study is focused 
on the prion protein which shows a remarkable and unique ability of 
nucleotide-free, self-propagation in the misfolded, disease-associated 
state6.  
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1.1.2 Folded, unfolded and misfolded protein states 
In order to grasp the flux of conformational states occupied by the prion 
protein from its synthesis to production of the disease-associated state, 
general principles of protein folding are revised. Upon protein transcription 
and translation, the nascent polypeptide assembles into its native folded 
state that allows it to exercise its encoded function. The fold adopted is 
determined wholly, by the amino acid sequence encoded by the protein7; 
polypeptide chains usually follow the rule of hydrophobic collapse, where 
core hydrophobic residues are clustered in the centre of the protein fold, 
leaving the charged/ hydrophilic residues to interact with the cytosolic 
surroundings7. Exceptions arise in the case of membrane-spanning proteins 
that have outer residues forming contacts with the hydrophobic lipid bilayer8. 
For large and complex proteins, or those with a highly hydrophobic 
sequence, molecular chaperones assist in assembling the protein correctly9. 
Most living cells maintain networks of chaperone proteins, which work 
synergistically to maintain protein homeostasis. They carry out their function 
by ‘sensing’ short segments of hydrophobicity in nascent protein chains and 
guide their correct folding. Protein folding can happen co-translationally, but 
only reaches completion upon peptide release from the ribosome10. 
Chaperones protect the newly released proteins from non-native 
interactions, both intra-protein and with existing entities of the crowded 
cytosolic environment9. Broadly speaking, there are two classes of 
chaperone proteins: chaperones linked in protein synthesis and chaperones 
triggered by stress response which work in different ways to establish the 
native fold of their target protein11. All proteins pass certain quality-control 
26 
 
before delivery to their respective cellular destinations. Such checks include 
presence of exposed hydrophobic residues, unpaired (reduced) cysteine 
groups and immature glycans9. Proteins that escape this stringent quality-
control are targeted for degradation via the proteasomal network11. Build-up 
of misfolded proteins however, drains the proteasomal system of its 
maximal efficiency, slowing down the cellular machinery, eventually 
exacerbating the existing problem1. If the rate of misfolding and aggregation 
exceeds that of proteasomal clearance, intracellular aggregates 
accumulate, overwhelming the pressured cellular machinery and ultimately 
cause cell death. This somewhat summarises the amyloid cascade 
hypothesis12. 
The amyloid cascade hypothesis was first proposed by John Hardy and 
Gerald Higgins in 1992, when describing the molecular events leading up to 
Alzheimer’s disease12. They suggested that following translation, improper 
processing of the precursor protein renders it amenable to misfolding and 
initiates a cascade of events that culminate in the accumulation of protein 
aggregates followed inevitably by neurodegeneration12. Initial hypotheses in 
the field of protein misfolding centred around the belief that it is mostly 
proteins involved in misfolding diseases that show a propensity for aberrant 
folding and aggregation. Current opinions highlight the fact that all proteins 
have the capacity to misfold, albeit to varying degrees and various triggers 
can alter the probability of the protein entering such misfolding pathways13. 
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1.1.3 Intrinsic disorder in proteins 
In 1935, Astbury, Dickinson and Bailey, accurately described what we now 
call folded and misfolded states when describing the conformation of 
globular proteins as native and misfolded14. A widely accepted theory then, 
was that proteins associated with misfolding disorders actually underwent 
misfolding, while other ‘non-suspect’ proteins were exempt from such 
inclinations14. Later work by Glenner, led to the discovery that biological 
amyloids can arise from proteins not usually associated with amyloid 
diseases, and a case in favour of the present-day hypothesis was born15. 
We now acknowledge that most proteins are soluble in nature and although 
they possess the potential to misfold, homeostasis is maintained unless 
under exceptional cellular stresses. This concept has held true for many 
soluble proteins that have no links to protein misfolding diseases; in fact, the 
process of ageing itself makes some amyloid accumulation inexorable16. 
Viewed through the energy landscape for protein folding, there are a 
multitude of conformations that a protein can adopt at the primary sequence 
level, allowing for correct folding through hydrophobic collapse17. As it gets 
post-translationally modified, it is restricted to certain folds depending on 
rotation of the backbone carbons in the polypeptide, steric hindrance due to 
glycans and bulky side chains, disulphide bridge constraints and so on. As 
we move down the hypothetical folding funnel, the protein has access to a 
much diminished scope of conformations, searching for the lowest energy 
state, which represents the ground state17. Free energy values around this 
state often correspond folded states marginally different to the ground state 
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which allow greater freedom for parts of the protein that execute its 
function18. 
How do native proteins then, overcome this energy barrier to exit the ground 
state and enter misfolding pathways? This can occur as protein 
intermediates form in the folding funnel, and through non-native 
interactions, fall down the aggregation pathway through a random 
process18; the probability of this happening increases for some proteins 
bearing disease-associated mutations19. Equally, a small fraction may 
unfold to expose ‘amyloidogenic’ segments that form a stable nucleus which 
other intermediates may simulate, thus templating formation of new 
intermediates and attaching to one another, forming protofibrils20. Repetition 
of this process leads to an assembly of highly ordered structures, called 
amyloid fibrils20. One well-known example of a disease-associated protein in 
which fibrils are formed is the huntingtin protein. In Huntington’s disease, 
the huntingtin protein is rich in poly-Glu repeats whose length correlates 
with age of disease onset21. Based on parameters such as protein 
hydrophobic content and backbone flexibility, a number of aggregation 
prediction algorithms have been written. These include, but are not limited 
to: ZipperDB20, Paircoil222, Waltz23, TANGO24, PASTA25, Zyggregator26, 
PAPA (a prion-specific algorithm)27 and AMYLPRED228 for use with 
proteins implicated in amyloidoses. Most of them propose partial protein 
unfolding which exposes otherwise ‘hidden’ residues to solvent and form 
non-native interactions tallying with the notion of native fold destabilisation. 
The availability of bioinformatics tools in this sense is incredibly useful for 
scanning thousands of variations in sequence, which may not be 
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experimentally possible in a reasonable time-frame in a wet-lab 
environment, and almost unrealistic in terms of animal studies. 
1.1.4 Amyloids: toxic or protective? 
Interestingly, not all amyloids are detrimental. Certain cellular systems 
express functional amyloids and in some cases researchers believe 
amyloids form, so as to lower the amounts of neurotoxic pre-fibrillar forms of 
misfolded protein by accumulating these species into one cluster13. Studies 
on functional amyloids follow from data-mining of all intrinsically disordered 
proteins (IDP) available in the literature29. Regions of intrinsic disorder (ID) 
are involved in pathways associated with regulation, signalling and control 
in particular29, 30. Some examples of ID regions include the N-terminal 
domain of the prion protein31, N-terminal activation domain of heat-shock 
transcription factors32, and the C-terminal domains of α- and β-tubulin33 
binding domains. The significance of natively disordered proteins has been 
well studied and thought to be a prerequisite to the diversity of functions 
employed by the same protein; most IDPs transition from a state of 
disorder-to-order upon activation of function (this may be upon association 
to binding partners or sensing changes in the microenvironment)34, 35. There 
are a number of advantages to possessing some degree of disorder: (i) high 
specificity yet low affinity reactions; (ii) one-to-many signalling; (iii) 
countermand steric restrictions; (iv) regulation of binding thermodynamics; 
(v) increased rate of specific macromolecular association; (vi) rapid protein 
turnover35. Dunker et al. proposed The Protein Trinity Paradigm, a model for 
protein structure-function relations which entails the existence of three 
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thermodynamic protein states: ordered, molten globule, and random coil36. 
Function of the protein is then predetermined by the presence of these 
states, each of which can be referred to as a ‘native’ state from which a 
multiplicity of functions can be executed, the predominant function arising 
from the ratio of the native states available36. In the instance of the prion 
protein, the largely disordered N-terminus undergoes a disorder-to-order 
transition upon copper binding, which is achieved through coordination of 
the metal ions through histidine side chains37; this can in turn facilitate PrPC 
endocytosis in a clathrin-dependent manner38.  
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1.1.5 Shared features of amyloids 
The reigning hypothesis in the protein misfolding field is that almost all 
proteins can misfold and precipitate out of solution under certain conditions; 
this usually ends in amyloid formation20. In all forms of amyloidosis 
recorded, this catastrophic cascade of molecular events occurs many years 
and often decades before disease onset39. For all known amyloids, 
regardless of sequence, fibril formation in the offending protein is preceded 
by a myriad of soluble oligomers, pre-fibrillar aggregate and protofibril 
states40. Varied as they may be in primary sequence, all amyloids display 
high β-sheet content, form stacking interactions of hydrophobic groups and 
hydrogen bonds at the protein backbone level, making them incredibly 
stable and indeed resistant to most conventional forms of protein 
degradation40. Furthermore, amyloids demonstrate Thioflavin T 
birefringence and are positive for Congo Red staining5. They also exhibit 
templating and conversion abilities5.  
The characteristic cross-β X-ray diffraction pattern of amyloids is seen 
perpendicular to the fibre axis. β-strands are normal to the long axis while 
the amyloidogenic segments form interdigitating side chains, forming the 
steric zipper of the growing fibrils40. The fibril spine is almost always a dual 
β-sheet steric zipper, with the non-spine forming regions of the protein 
remaining natively structured. The spine is calculated to be 4.7Å along the 
fibrillar axis and 10Å along the equatorial axis (between the β-sheets). It is 
widely accepted that a short sterically complementary sequence is 
necessary, but not sufficient for fibril formation20, 40. Additional parameters 
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for successful fibrillation include conformational freedom (usually achieved 
with the presence of glycine residues) on the protein surface. The presence 
of one such segment in a protein can drive fibrillation of the whole protein, 
provided it is properly positioned20. 
Another amyloid signature is the ability of protofibrils to bore holes in cell 
membranes41, 42. This is akin to modes of bacterial pathogenesis such as 
crystal toxins from Clostridium bifermentans (α-helical conformation) or 
more likely, cylolysin (β-conformation) from Vibrio cholera, which are soluble 
proteins that can assemble into pore forming complexes at the cell 
membrane43. How toxicity is elicited by protofibrils is unclear, but is thought 
to take effect through an assortment of factors such as glutamate 
dysregulation leading to excitotoxicity, ER stress and disruption of 
intracellular calcium levels, protease inhibition, upregulation of toxic 
extracellular proteins, production of reactive oxygen species, altered axonal 
transport, synaptic vesicle defects and loss of tight junction proteins43. 
Seminal work by David Eisenberg’s group provided evidence of multiple 
tertiary forms of aggregated proteins; as the amyloids are characteristically 
high in β-sheet content, they may be formed by β-sheets in parallel or 
antiparallel register; face-to-face or face-to-back; up-up or up-down with 
respect to each other40. Using their methods of categorising steric zippers, 
the human prion protein segment SNQNNF which falls in the loop region N-
terminal to α2, is the only known example of a class 2 zipper: face-to-face, 
up-up40. This multiplicity of available conformations may provide answers to 
elusive traits such as the varying degrees of neurotoxicity elicited in amyloid 
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diseases and strain specificity in prion diseases. It is important to bear in 
mind however, that such experiments subject the protein sample to non-
native conditions which may not always arise in a cellular context. 
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1 . 2  T h e  p r i o n  p r o t e i n  
The prion protein, and specifically its propagation, has long been a topic of 
heated debate, as it represents the first instance of nucleic acid-free protein 
replication44. The idea of protein replication in the absence of nucleic acid is 
not in agreement with the central dogma, which states the genetic 
information must be passed from DNA, to RNA, to protein45 and not ever 
protein-to-protein, as is suggested in prion diseases. The most concrete 
evidence for this was the ability to generate infectious, conversion-
supporting, peptides nucleotide-free in vitro46, that demonstrated 
pathogenesis and transmissibility in vivo47. It is well established that the 
native cellular protein, PrPC, must be present for the disease-associated 
form, PrPSc, to form48. Just like the amyloid precursor protein, the prion 
protein undergoes N-terminal cleavage49, 50; mutations in the protein that 
reside at or around the cleavage site correspond to disease states in which 
amyloid deposition is observed50, 51. 
In prion diseases, formation of PrPSc is thought to impinge on the 
surrounding population of native PrPC proteins, encouraging formation of 
the disease-associated conformer and essentially shifting the equilibrium in 
favour of PrPSc52. The initial conversion step is considered to be one of the 
earliest and most fundamental events in disease progression. The current 
study aims to assess the contributions of various amino acids along the 
length of the native moPrP sequence that promote/discourage this 
equilibrium shift in favour of PrPSc. Getting a better understanding of this 
process at the cellular and molecular level may provide insights into the 
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mechanism of protein-to-protein replication, thereby pin-pointing key areas 
that could be targeted to hinder PrPSc replication, and aid in the 
development of therapeutics to delay or even prevent disease onset and 
progression. To identify minimal residues that are crucial for this protein-to-
protein replication phenomenon to occur efficiently, we generated a library 
of alanine mutants that essentially work as a method of removing individual 
side chain contributions53. This was then applied in a cellular setting and 
target spots for prion propagation identified. 
To date, the exact biological function of the prion protein remains unknown. 
Ablation of the prion protein gene (Prnp) in mice produces no stand-out 
phenotype, from which gene function may be inferred; the mice display 
‘normal’ appearance and behaviour profiles48. There is however, compelling 
evidence in the literature to suggest that whereas removal of the entire 
protein does not supress normal cellular function, mutations or deletions 
within the central hydrophobic regions of the protein give rise to an 
inexorably neurotoxic phenotype48. This supports a toxic gain-of-function 
hypothesis. Most inherited forms of the disease are found in individuals 
expressing a mutated version of the protein, which argues that deviation 
from the native sequence is not well tolerated and increases chances of 
misfolding in this protein54. 
Prion research in recent years has linked the native role of PrP to neural 
signalling networks; knockdown studies of the prion protein homolog in 
zebra fish resulted in increased mortality rates post-fertilisation and impaired 
brain development, suggesting a role of PrPC in neurogenesis and 
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embryogenesis55. The cellular function(s) for PrP may not be clear-cut, but 
of the many propositions put forward, oxidative stress responses56, 57, metal 
ion transport37, 58, 59, central nervous system (CNS) development and 
neuroprotection/neurotoxicity60, 61 top the list.  
Although maximal localisation of the prion protein lies in neurons of the 
CNS6, it is expressed ubiquitously in the nervous system; expression 
pattern varies with brain region, cell type and cell biochemistry6. Mature PrP 
is found predominantly as a cell-surface protein, tethered to the outer leaflet 
of the lipid bilayer by a glycophosphatidylinositol (GPI)-anchor at its C-
terminus62 (Figure I1); other topologies of intracellular forms of the protein 
(pertaining to nascent chains) have been reported to be associated with 
known disease-related mutations63 (Figure I2). The pro-protein contains an 
N-terminal signal sequence, which codes for localisation at the cell 
membrane, while the C-terminal signal sequence encodes a motif that 
allows for attachment of a GPI membrane anchor. The mature prion protein 
is produced following cleavage of the N-terminal (residues 1-22) and C-
terminal (residues 231-254) signal sequences of the pro-protein6, 62. It may 
then be glycosylated at either/both residues Asn180 and Asn196, or left un-
glycosylated. 
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FIGURE I1: THE CELLULAR PRION PROTEIN 
PrPC is expressed on cells of the nervous system. (A) The nascent polypeptide chain is synthesises and processed, with the N-
terminal signal sequence guiding protein localisation at the cell surface; the C-terminal signal sequence allows for attachment of the 
folded protein to the outer leaflet of the lipid bilayer using a GPI anchor. (B) When cells expressing PrPC are subjected to infection with 
PrPSc (depicted in green), it is postulated that conversion of the cellular form of the protein to the misfolded (PrPSc) state occurs at the 
cell surface in a matter of minutes. (C)As more PrPSc molecules accumulate, propagation inevitably affects surrounding cells and prion 
infection is established. (1) nascent peptide trafficked from ER to Golgi for post-translational modifications; (2) N- and C-terminal signal 
sequences processed for cell surface localisation and GPI-anchor attachment respectively; (3) Glycosylation events; (4) Cell surface 
localisation; (5)Alternative topologies at the ER membrane, associated with aberrant protein forms; (6)PrPSc-PrPC interaction at the cell 
membrane; (7) propagation; (8) lysosome. 
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FIGURE I2: TOPOLOGIES OF THE PRION PROTEIN  
A number of transmembrane forms have been reported for PrP where the protein 
is able to span the membrane through its putative transmembrane domain, region 
111-135. Shown in A-C are various forms of PrP-transmembrane topologies, 
namely: (A) CtmPrP; (B) NtmPrP; (C) this alternative topology is reported by Wang F 
et al.64, as a possible other transmembrane form; (D) the cellular, native form of the 
prion protein is fully translocated in the ER lumen as it is processed; this is termed 
SecPrP fully secreted form of the protein, SecPrP. Other topologies of the protein are 
linked to prion disease states.  
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Variation in glycosylation gives PrP a distinct three-band pattern when 
analysed by Western blot, with protein bands corresponding to di-
glycosylated, mono-glycosylated, and un-glycosylated PrP species.  
From a structural perspective, only the cellular form of the protein has ever 
been acquired as a high-resolution structure, and this is limited to the C-
terminal globular half of the protein65. This structure is well defined using X-
ray crystallography (residues 117-230)66 and giving a slightly wider picture, 
NMR techniques (residues 90-230)19, 67. The amino-proximal half (residues 
23-120) of the protein is enriched with glycines, which greatly contribute to 
its flexibility by allowing maximal rotation of the protein backbone at these 
points. Additionally, resolving NMR data of the wild-type protein is 
complicated by the large number of possible conformations sampled in the 
flexible regions for accurate structure determination19. 
As for the structure of the disease-associated form of the protein, the 
caveats remain common to all proteins involved in protein misfolding 
diseases: obtaining enough of the sample that is of useable quality, sample 
uniformity and most importantly, solubility. Nevertheless, attempts have 
been made to attain the ultrastructure of the misfolded prion protein 
conformer using methods such as electron microscopy, which do not allow 
detailed distinction at the atomic level, but provide an overall 3D image, 
outlining the electron density68. When discussing the sequence and 
structure of the prion protein, it may be divided into three distinct domains: 
(i) the flexible, glycine rich, N-terminal domain (23-120) which encompasses 
two regions of charge clusters CC1 and CC2 and five octapeptide repeats 
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(OPRs); (ii) a highly hydrophobic region  that has sequence characteristics 
of a membrane-traversing helix and is referred to here as the putative 
transmembrane domain (PTM, 110-134); (iii) and a globular structured 
domain (121-230) thought to be the principal proliferating component in 
prion disease. The following chapters bear the aforementioned subdivisions 
of the protein in mind (Figure I3). 
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FIGURE I3: STRUCTURAL FEATURES AND DOMAINS OF THE PRION PROTEIN 
(A) The folded state of PrPC shows a doubly-glycosylated molecule (carbohydrate 
chains at residues Asn180 and Asn196); PrPC can be categorised into (i) a largely 
flexible amino terminal domain which encompasses two charge clusters, (ii) an 
octapeptide region which has been linked to disease stated when there is an 
increase in the number of octapeptide repeats expressed, (iii) A globular structured 
domain that is preceded by a stretch of hydrophobic residues that bear semblance 
to a membrane traversing segment. (B) The carboxy terminal regions (pink) are 
thought to be the principle proliferating agent in prion diseases. However, there is 
also evidence to suggest that N-terminal segments influence the efficiency of prion 
infection. N-terminal regions pertinent to this study are indicated. 
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1.2.1 Sequence conservation of the prion protein 
The prion protein is remarkably conserved across mammalian species. In 
an excellent paper by van Rheede et al., it was shown that protein 
glycosylation sites, residues across the hydrophobic core region and the 
cysteines that form a disulphide link between α2 and 3 are perfectly 
conserved across twenty-six mammalian prion proteins54. Such widespread 
and complete conservation would suggest that these amino acids in 
particular play an essential role in the function of the normal cellular prion 
protein. Alternatively, we could reason that the strong conservation may be 
due to any mutations in the regions specified, being deleterious. It is 
interesting to consider that the species barrier phenomenon exists when 
there is so much sequence homology between prion protein sequences of 
species that are highly susceptible to prion infection such as the bank vole, 
and conversely, those that are comparatively more resistant, like rabbits69. 
When comparing the mouse prion protein sequence used in this study to 
the rabbit homolog, there are a total of 22 differences in the 254 residue 
protein chain54. Certainly conversion rate is achievable at high efficiencies 
when there is maximal sequence homology between the infectious prions 
and the cellular forms, but even at low homologies, it happens nonetheless 
albeit at a much diminished rate70. 
In vivo and in vitro studies have shown that the flexible region 23-88 of the 
prion protein can be removed altogether, without impeding PrPSc 
formation71. The authors of that study suggested that this effect, as it lies 
within the unstructured flexible part of the molecule, may be involved in 
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intra- or inter- molecular interactions that influence the efficiency of prion 
propagation71. It is emphasised nonetheless, that the overall tertiary 
structure is the main determining factor for PrPSc susceptibility, rather than 
individual amino acids71.  
In the context of cell death, overexpression of apoptotic stimuli such as Bax 
induces cell death in neuroblastoma cells and co-expression of the full 
length PrP but not that lacking the OPR region reversed this Bax-mediated 
apoptotic event72. The N-terminal tail of the protein is probably a multi-
functional domain of PrPC as it is unlikely to only be randomly coiled in 
vivo31. Experimental evidence shows that transgenic mice with deletion of 
this flexible region display a phenotype of cerebellar lesions and ataxia48. 
Naslavsky and others propose that the lipid environment acts as a 
framework supporting some defined structure for this otherwise highly 
flexible region73, 74.  
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1.2.2 Toxicity of the prion protein: oligomers, protofibrils and fibrils  
The cellular prion protein can misfold and assume β-sheet-rich structures 
which in turn contribute to fibril formation40. Studies done as early as 1993 
had identified fibril-forming regions 106-14775 and alluded to the now widely 
accepted concept of the miniprion as the minimal segment of the protein 
required for infection: with the miniprion defined as bearing two deletions, 
one in the flexible N-terminal tail of the prion protein Δ23-88 and another 
that entirely removes the first α-helix and second β-sheet in the structured 
domain of the protein, Δ141-17676. 
 
 
FIGURE I4: SCHEMATIC OF FIBRIL FORMATION 
(A) A small segment within a protein, thought to be amyloidogenic, has a high 
propensity to alter its conformation to drive local conformations to a more β-sheet 
state. (B) When individual amyloidogenic segments are free from self-association 
they are referred to as monomeric species, and (C) Oligomers when they form self-
associations. (D) Propagation of such self-assemblies, leads to fibril formation.   
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The same laboratory showed that synthetic peptides of human PrP (huPrP) 
sequence 106-126 which encompasses the PTM domain formed straight 
fibrils similar to those found in the brains of Gerstmann-Sträussler-
Scheinker syndrome (GSS) patients, whereas peptides corresponding to 
β1-α1 (sequence 127-147) formed twisted fibrils resembling scrapie-
associated fibrils isolated from patients with Prion diseases75. Peptides 
corresponding to the PTM domain or β1-α1, but not OPR (residues 57-64) 
or CC2 (89-106), were only sparingly soluble in water and readily formed 
fibrils75. The amyloid core was further delineated to residues 127-143 in an 
amyloid seeding assay by Chatterjee et al., who showed using recombinant 
mouse prion protein (moPrP) that fibrils formed from region 127-143, but not 
107-126 were able to seed amyloid fibril formation in the full length peptide, 
moPrP 23-23077.  
PrP can form long straight 8 – 10nm-wide amyloid fibrils at under neutral 
pH, salt and denaturant conditions; smaller fibrils are formed under more 
acidic conditions (2nm) and are associated with a higher toxicity potential in 
amyloid diseases78-81. β-rich oligomers formed from recombinant moPrP are 
composed of monomers, as well as small and large oligomers78-81. All three 
species of aggregates described irrespective of their morphological and 
mass differences, were shown to be capable of eliciting toxicity by 
disrupting cell membrane integrity82, a common feature of amyloids83. It is 
not known whether the cellular toxicity elicited in prion diseases is a matter 
of PrPC dysregulation leading to atypical and detrimental signalling 
interactions, or a result of PrPSc formation and propagation. It is clear 
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however, that once fibrils are formed, for propagation to ensue, pre-formed 
fibrils must dissociate in order for further fibril formation to proceed 84, 85.  
Hydrogen-deuterium exchange (HDX) experiments on the aggregated 
proteins illustrated that residues between β2 and α2 are at the start of the 
amyloid core86. Additionally, worm-like fibrils display a higher degree of HDX 
protection suggesting that these forms of aggregates are more ordered and 
compact than the oligomeric forms. The moPrP sequence spanning α2-α3 
forms the core of both small and large oligomers, with formation of worm-
like fibrils linked to the expansion of this core region78. The primary 
difference between the straight fibrils and the worm-like ones is the 
presence of, or lack of a continuous stretch of core sequence respectively78. 
PrP domains PTM, α1-β2 and to a lesser extent region 32-55 (between 
CC1 and OPR1), are also shown to be structured in the aggregated forms, 
but with much lower stability than the C-terminal domain77. Most structural 
studies of PrP use N-terminally truncated proteins, so the finding that region 
32-55 possesses structure and can adopt multiple conformations in the 
worm-like fibrils could implicate the flexible region of the protein in important 
functions of PrPC stability and PrPSc assembly77. Indeed, a study by Qi et al. 
highlighted the role for the flexible region N-terminal to CC2 as being 
important for propagation of prions, as they observed fibril dissociation in full 
length recombinant protein, but not in a Δ23-90 mutant87. They 
hypothesised that the flexible N-terminal tail of the protein (missing in the 
Δ23-90 mutant) could contribute to charge repulsion between CC2 and pre-
α1 regions, following protonation (acid-induced) of the histidine side chains 
at OPR and CC2, and promote fibril dissociation87. Norstrom and Mastrianni 
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studied a PrP construct with a deletion in the palindromic sequence 112-
AGAAAAGA-119 and found it to be aggregation-compatible88. Altering the 
polarity within this sequence was found to reduce the stability of the 
hydrophobic core and consequently its ability to fibrilise when alanine 
residues were replaced by serine groups88. Additionally, Walsh, Simonetti 
and Sharpe undertook rigorous tests to show by ssNMR that segment 102-
126 forms in-register parallel β-sheets, stacked in an anti-parallel fashion89. 
The PTM region is purported to form a tight inter-digitating interface 
between the β-sheets89. 
 
48 
 
 
FIGURE I5: Β-SHEET STRUCTURE OF AMYLOIDS  
Electron micrographs of fibrous crystals of peptide AAAK incubated in PBS. (A) 
Negative-stain transmission electron microscopy shows fibrous crystals in a field 
view at low magnification (left) and at higher resolution showing striations running 
parallel to the fibre axis(right). (B) X-ray diffraction pattern obtained by synchrotron 
radiation from partially aligned, bundled fibres. (C) Electron diffraction patterns 
obtained with incident beam parallel to the [0 1 0] zone axis showing high 
resolution crystalline order pre- (left) and post- (right) contrast enhancement. 
Adapted from Makin et al. 90  
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1.2.3 Prion disease: clinical manifestation 
Prion diseases are not immediately apparent in patients suffering from 
them, as they have remarkably long periods before any noticeable signs 
appear. This is referred to as a long incubation time6. Patients often present 
with early symptoms of depression, anxiety, memory impairment, insomnia, 
compromised motor coordination, erratic behaviour, fatigue and visual 
disturbances44. These symptoms can vary between patients and disease 
can be remarkably difficult to diagnose as it is often misdiagnosed for other 
neurodegenerative diseases such as Alzheimer’s and Huntington’s 
disease44, 91. Once successfully diagnosed however, better scales for 
monitoring prion disease severity have been established92. As the disease 
progresses patients show signs of muscle paralysis, slurred speech, 
difficulty with swallowing, dementia and even coma. There is marked clinical 
heterogeneity in prion disease and though not fully understood, they 
correlate to some extent with the type of prion disease that is active: variant, 
iatrogenic, Kuru, inherent or sporadic92. The ‘spongiform encephalopathy’ 
nomenclature in TSEs comes from the sponge-like appearance in the 
brains of deceased prion disease patients51. These ‘holes’ are caused by 
cell death amassed over time, most frequently in the cerebellar regions of 
the brain with focal Purkinje cell loss, moderate loss of granular layer cells 
and gliosis of the astrocytes and Bergmann glia93. Visualised by 
immunohistochemistry, dense amyloid plaques and inclusions can be 
identified in patients with prion disease; however, the nature varied with 
prion disease type93.  
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1.2.4 Cell models of prion disease and prion strains 
 PrPSc arises from a conformational change in PrPC that favours a higher β-
sheet structure5. In turn, the type of PrPSc that forms and the ease with 
which this occurs depends on the sequence similarity between the 
infectious protein and the cellular protein94. Moreover, PrPSc forms can differ 
in (i) their infectious capacities depending on cell line (tropism); (ii) 
glycoform ratios expressed; (iii) incubation times; (iv) resistance to 
ProteinaseK. These biochemical features define prion strains46. Typically, 
the PrPSc formed in cells de novo is identical to the form used to initially 
infect the population of PrPC expressing cells. This is known as faithful 
propagation: the strain type is preserved94. 
When PrPSc proliferates in mammals, the term prion diseases define the 
malady in humans, Bovine Spongiform Encephalopathy (BSE) in cattle, 
Scrapie in sheep and Chronic Wasting Disease (CWD) in deer and elk. For 
research purposes, these prion strains are often serially mouse-passaged 
so as to make them infectious to murine cell lines and study their properties 
through both cell culture and transgenic mouse models48, 95. RML is a 
mouse-adapted prion strain derived from sheep infected with Scrapie by W. 
Hadlow at the Rocky Mountain Laboratories in Hamilton, Montana96. This 
strain is used extensively in prion research along with 22L and Me7 strains, 
when studying mouse prions as it has the ability to infect a multiplicity of cell 
lines compared to other available strains (Table 1) and propagate 
faithfully95, 97. Since cells of the nervous system are predominantly the target 
of PrPSc, neuronal cell types such as N2a, SHSY-5Y, GT1, PC12 and SN59 
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are widely used as cell culture models in prion research, with a number of 
non-neuronal cell types such as LD9 and CAD5 to study peripheral 
infection98, 99. N2a cells are particularly susceptible to prion infection when 
the inoculum is from mouse-adapted strains as they were originally derived 
from a spontaneous mutation in A/J mice, a Prnpa/a (allele of the mouse 
prion gene associated with short incubation times: Leu108, Thr189) mouse 
strain96, 97.  
GT1 cells originate from hypothalamic neurons immortalised by genetically 
targeted tumourigenesis in transgenic mice. It appears as though GT1 cells 
are more readily infected than standard N2a cells and retain infectivity for a 
longer passage than N2a cells. They are also the only CNS-derived 
population of cells susceptible to prion infection99. Nonetheless, N2a cells 
can be cultured to be 80-90% infectious maintaining susceptibility and 
producing high infectious titres95, 97; N2a cells have been tremendously 
useful in researching prion biology and available within the MRC Prion Unit 
as: (i) subclones that are highly susceptible to RML prions (PK1); (ii) 
silenced PK1 cells for suppression of endogenous PrPC expression (KD) 
and (iii) chronically infected PK1 cells (iPK1)97. PK1 cells report sensitivity to 
RML prions at a thousand fold higher than non-cloned cells97. KD lines 
supress the expression of endogenous PrPC via maintenance of shRNA 
that binds the 3’ Untranslated Region (UTR) of Prnp. iPK1 represent 
Scrapie-infected PK1 cells that persistently propagate PrPSc100. 
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TABLE I1: PRION PROTEIN STRAINS AND THEIR PROPAGATION IN CELL CULTURE  
A wide range of prion strains and cell lines are used in prion research; only a 
subset of these have been shown for clarity. White spaces are indicative of an 
‘incompatible’ combination where the cell line is resistant to infection from the prion 
strain and accents of red represent the strength of the strain-cell line compatibility. 
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1 . 3 .  R o l e s  o f  i n d i v i d u a l  d o m a i n s  w i t h i n  t h e  
p r i o n  p r o t e i n  
1.3.1 Charge cluster 1 (CC1) residues 23-27 
 
FIGURE I6: CC1 
Schematic of the prion protein with its various domains; N-SS: N-terminal signal 
sequence; CC1: charge cluster 1; OPR: octapeptide repeat region; CC2: charge 
cluster 2; PTM: putative transmembrane region; α1: helix 1; β1: strand 1; α2: helix 
2; α3: helix 3; SS-C: C-terminal signal sequence. Highlighted in red are residues of 
CC1. 
When compared to the rest of the protein, the flexible unstructured region of 
the prion protein is responsible for the highest number of interactions or 
association to various cellular factors31. This may be because of the 
inherent flexibility within the 23-111 domain, allowing this region greater 
access to these components; it may also be due to charge interactions 
arising from CC1 and CC231. The majority of molecules that bind this region 
are reported to affect the cellular form of the prion protein in a number of 
ways, including: conformational preference101, endocytosis37, 102, reactive 
oxygen species (ROS) response50, metal binding37,, GAG binding103, 
tubulin binding33, 104, Aβ interactions105-107 and lipid binding73, 108 to name but 
a few. 
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1.3.2 Clathrin-dependent endocytosis  
One of the earliest indications of prion protein recycling between the plasma 
membrane and the endocytic compartments came from the Harris 
laboratory in 1994109. They showed, using immunogold labelling of chicken 
PrP, up to five-fold higher expression within clathrin-coated vesicles in 
neuroblastoma cells109. This experiment was later repeated by the same 
group using the mouse prion protein and the N-terminal region of the protein 
was deemed essential for endocytosis via clathrin-mediated pathways110.  
CC1 consists of basic residues that are fundamental to endocytosis via 
coated pits38, 110. It is usual for GPI-anchored proteins that are devoid of any 
cytoplasmic segments, to engage in endocytosis through extracellular 
binding of transmembrane receptors, which possess the required 
endocytosis motifs111; CC1 may therefore regulate some aspects of PrPC 
recycling via this mechanism, with an as yet unidentified transmembrane 
receptor112.  
Transgenic mice expressing PrP with a large N-terminal deletion, Δ23-88, 
were able to propagate PrPSc and though this evidence might appear to 
nullify the role of CC1 in prion protein recycling, it is not the case if CC1 is 
only partially responsible for recycling, with compensatory mechanisms at 
hand to handle proper trafficking in the CC1 deletion mutant48, 102. For 
example, low-density lipoprotein receptor-related protein 1 (LRP1) has been 
shown to regulate PrPC endocytosis via CC1 interactions. Additionally, 
heparin sulphate proteoglycans have also been shown to co-internalise with 
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PrPC in N2a cells, following addition of copper ions to stimulate PrP 
endocytosis113.  
1.3.3 CC1 as a modulator of PrPSc propagation  
The concentration of positive charge in this cluster is thought to act in 
synergy with CC2 in a number of instances where PrPC interacts with itself 
and other cellular factors114, 115, including Aβ (Section 1.4.2)107. With respect 
to prion propagation following infection, deletion mutants in CC1 are found 
to exhibit higher protein expression compared to wild-type controls, 
presumably due to lower rates of internalisation115. When analysed by 
immunoblotting, CC1 deletion mutants of PrPC gave rise to markedly lower 
levels of ProteinaseK-resistant forms of the protein than wild-type controls, 
when scrapie-infected cells were transiently transfected with plasmids 
encoding these constructs116. Furthermore, transgenic mice expressing 
CC1 deletions had longer survival times and expressed less ProteinaseK-
resistant material than those expressing the wild-type sequence following 
RML scrapie infections48, 116. Still, once PrPSc was formed from a CC1 
deletion mutant, this was able to infect susceptible cells with the same 
efficiency as wild-type PrPSc116. The authors highlight the importance of this 
region in the initial PrPC-PrPSc interaction and state that the reduced PrPSc 
in the CC1 deletion state is not a result of differential trafficking or 
localisation of the mutant protein116. Another way to view this phenomenon 
is in light of evidence implicating CC1 as an essential factor governing the 
overall prion protein fold117. In CC1 deletion mutants of PrP, the protein was 
reported to have reduced conformational stability. Moreover, in the 
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presence of salt PrP lacking CC1 showed a greater loss of stability than its 
full length counterpart, indicating that the small charged region CC1 can 
make an impression on the overall fold of the globular protein; though 
physically distant in sequence they may come into close spatial proximity in 
cellular settings117.  
1.3.4 Accessory binding site to CC2 
The concentration of positive charge in the CC1 cluster is thought to act in 
synergy with CC2 in a number of instances where PrPC interacts both with 
itself and other cellular factors. These include proteins involved in neural 
growth and neurogenesis, neural cell adhesion, neurosignalling, apoptosis 
and protein folding55, 107, 116-120. In the case of Aβ binding, the Aβ peptide is 
thought to bind PrPC primarily at CC2, with binding also influenced by 
CC1106. The KKRP stretch of sequence was shown to influence β-secretase 
activity on the amyloid precursor protein (APP): only the full length form of 
the protein, not CC1-deleted PrPC, was shown to inhibit APP cleavage at 
the cell surface121, 122. Earlier work reporting interactions between these 
proteins was carried out on recombinant proteins using biophysical 
approaches. Recent publications on cellular interactions between Aβ and 
PrP have accelerated the interest in this field61. Whether region 23-31 is 
important in mediating Aβ toxicity is yet to be established, but mouse 
models deleted for this region of PrP have been generated and could be 
tested to this end116. 
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1.3.5 Heparin binding site 
CC1 displays strong binding to highly sulphated glycosaminoglycans 
(GAGs), namely heparin103, 113, 123. GAGs are highly charged 
polysaccharides found on the surface of most extracellular matrix proteins. 
Several GAG binding domains have been identified in the N-terminal tail of 
PrPC, including CC1 with interactions at Lys 23, Lys24 and Lys27113. The 
other heparin binding domains on PrPC were found to lie in the OPR and 
CC2 region113. Pan et al. showed that the PrP-heparin interaction is lost in a 
PrPΔ23-25 deletion mutant103 whereas others suggest that this interaction is 
required for the successful incorporation of PrPSc into cells124. 
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1.3.6 Octapeptide repeat (OPR) region residues 51-90 
 
FIGURE I7: OPR 
Schematic of the prion protein with its various domains; N-SS: N-terminal signal 
sequence; CC1: charge cluster 1; OPR: octapeptide repeat region; CC2: charge 
cluster 2; PTM: putative transmembrane region; α1: helix 1; β1: strand 1; α2: helix 
2; α3: helix 3; SS-C: C-terminal signal sequence. Residues within each of the five 
OPRs are indicated by single letter amino acid. 
 
Often associated with an expansion of repeats, the octapeptide repeat 
(OPR) region is one of most heavily studied sections of the prion protein. 
Five repeats of a glycine-rich, eight-amino acid sequence is found within 
residues 51-91 (human numbering) in healthy individuals. Anywhere 
between one and nine additional octapeptide repeat insertions (OPRI) have 
been found in patients with Creutzfeldt-Jakob disease (CJD) and this 
insertion is thought to increase the risk of developing the disease with most 
cases showing earlier signs of disease onset compared to cases of sporadic 
or inherited prion disease. The average age of onset for people bearing one 
to four OPRI is 64, while this decreases dramatically to 38 for those with five 
or more OPRI51.  
Indeed PrPC with additional OPRs has been shown to have a strong 
propensity to aggregate and form amyloids125; increased OPR insertions 
directly impact the hydrophobic content of the sequence and this is thought 
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to promote disorder at the N-terminus126. Using circular dichroism 
spectroscopy Leliveld et al. were able to demonstrate that OPR expansion 
impacted the PrP folding landscape by upregulating certain misfolding 
pathways, rather than hampering production of the natively folded form of 
the prion protein127. Deletion mutagenesis studies in this region of the 
protein have been plentiful and most conclude that the OPR region can be 
disregarded in terms of generating PrPSc from PrPC128. Its significance in 
OPRI therefore remains abstruse; we may speculate that the extended 
conformation of the flexible N-terminal tail region alters physiological 
inter/intra-protein interactions that afford it a higher misfolding propensity, or 
that it alters the native function of neighbouring domains in the protein.  
The most remarkable feature of the OPRs is their copper binding and 
copper transport abilities37, 129; this is attributed to histidine side chains 
between the repeat regions that coordinate copper ions129. Copper binding 
to PrPC which occurs in a concentration-dependent manner is thought to 
both increase rate of protein endocytosis and provide neuroprotection 
against oxidative stress129. PrPC endocytosis upon copper binding has been 
shown in cells expressing wild-type PrP, as well as recombinant PrP (rPrP) 
with up to seven OPRI, but this is constrained in PrP with eight or more 
OPRI130. Interestingly, once the OPRI approach eight, copper binding 
affinity is ten-fold tighter. The prion protein is reported to have at least five 
copper binding sites, four of which lie in the OPR region and the fifth in 
histidine residues of the CC2 domain. Copper-binding activity of PrPC is 
reported to increase its aggregation tendency at lower than physiological 
temperatures, in a reversible manner130. Copper-bound PrPC adopts a 
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slightly different morphology to its unbound equivalents, as it brings CC2 in 
close proximity to α1 and the loop region preceding this helix. Additionally, 
α2 was purported to interact with the fifth repeat in the OPR region131. If 
both of these reported long-range interactions occur as reported by the 
authors are observed upon copper binding in the protein, it would exhibit a 
much more compacted state than the metal-free form of the protein and 
may bear some significance on the susceptibility of infection by PrPSc131. 
Suffice to say, the OPR region imparts no crucial feature for PrPSc 
propagation that could be demonstrated experimentally, but facilitates the 
process upon initiation of conversion131. 
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1.3.7 Charge cluster 2 (CC2) residues 90-111 
 
FIGURE I8: CC2 
Bar schematic of domains within moPrP. N-SS: N-terminal signal sequence; CC1: 
charge cluster 1; OPR: octapeptide repeat region; CC2: charge cluster 2; HC: 
conserved hydrophobic region; α1: helix 1; β1: strand 1; α2: helix 2; α3: helix 3; 
SS-C: C-terminal signal sequence. Charge cluster 2 (CC2) is defined as region 90-
111. Amino acids 95-110 within CC2 are reported to bind Aβ oligomers105, 132. 
Residues 98-108 on PrPC are believed to interact with PrPSc133. Residues 100-104 
when were found to be the minimal sequence that mediates conversion of the prion 
protein from PrPC to PrPSc134. 
 
This region is one of the most immunogenic parts of the protein, with many 
anti-prion antibodies raised against CC2: PrP-AA (105-109)135; 3F4 (109-
112); 6D11 (93-109)136 and ICSM35 (91-111)137. The high charge content of 
this region makes it amenable to a multitude of protein interactions, further 
aided by the flexibility of the N-terminal tail35, 138. CC2 is reported as the 
interaction site for Aβ oligomers107, 132, 139, is suggested to be involved in 
heparin binding interactions103, 113 and believed to mediate the rate of 
conversion to PrPSc, amongst other functions116. 
  
62 
 
1.3.8 CC2 and Aβ 
Both PrPC and Aβ are concentrated at synaptic boutons and bind with 
nanomolar affinity61, 139; a strong case for their interaction is the finding that 
PrP-knockout mice show full immunity to Alzheimer’s disease105. Moreover, 
several studies have shown that treatment with antibodies raised against 
the CC2 region of PrPC protect against several Aβ-induced deleterious 
effects, including synapse loss as well as memory and learning 
impairment61. High-affinity interactions between the two proteins have been 
published by many groups and been established reproducibly in biophysical 
settings132, 139; it is widely accepted that PrPC binds the oligomeric and not 
the monomeric form of Aβ.  Fewer instances of this interaction have been 
reported in a cellular framework: in COS-761 and SH-SY5Y cells108, and in 
cultured hippocampal neurons107. Aβ binds PrPC primarily at CC2, with 
accessory sites reported at CC1 and Helix1106, 132. Laurén et al., have 
mapped region 95-110 of PrPC as the prerequisite for Aβ binding, showing 
that anti-prion antibody 6D11 directly competes with Aβ for PrP105. Fluharty 
and colleagues have also shown that the flexible amino terminal region is 
both necessary and sufficient for binding early oligomeric intermediates 
during Aβ maturation into amyloid fibrils107.  
Many lines of evidence show that PrP interacts with Aβ primarily through its 
CC2 domain although this is not the only binding site105-108, 139. More 
recently, Kang et al. reproduced this finding, reporting PrPC region 93-119 
as the main Aβ binding domain using an ELISA-based method140; binding 
activity was also assigned to CC1 (residues 23-39)140. These two sites 
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interacted with PrPC independently in this study, but have been previously 
shown to act synergistically132. Reversal of the ELISA set-up as tested by 
Kang et al. involved anti-Aβ antibody binding to PrPC but the interaction site 
could not be delineated140. Interestingly, five out of forty-four 17-mer 
peptides corresponding to PrP sequence could not be generated due to 
their aggregation propensity; three of these correlate to the CC2 region, one 
at a loop region N-terminal to helix 1 and lastly a loop region between 
helices 2 and 3140. These regions may therefore interact with the rest of the 
PrPC molecule or other cellular factors to avoid spontaneous aggregation in 
healthy cells. CC1’s role as a secondary site may be ascribed to the 
polybasic residues KKRPK. Aside from the charge dependence of Aβ 
binding CC1 and CC2, it is also reliant on the length of sequence between 
these two regions106. 
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1.3.9 PrP-induced neurotoxicity 
Interactions between PrPC and Aβ go hand-in-hand with cell toxicity. They 
have been found to co-internalise, accumulate in endosomes and traffic to 
lysosomes in an LRP1-dependent pathway108. There is gathering evidence 
to suggest that Aβ-induced cytotoxicity is mediated by PrPC in Alzheimer’s 
disease107, 139. More debated however, is how exactly this toxicity is 
regulated: directly, indirectly, and through which molecular intermediates. 
PrPC is able to inhibit the enzyme β-secretase, which is responsible for APP 
cleavage N-terminal to the Aβ domain and thereby leads to amyloidogenic 
processing of APP141. It has been shown that PrP-Aβ binding triggers 
activation of Fyn kinase, which has in turn been shown to phosphorylate the 
NR2B subunits of NMDARs, resulting in calcium influx and subsequent 
cytotoxicity61, 108. Larson et al. also showed that active Fyn can 
phosphorylate tau; phosphorylated tau and Aβ being the two main toxic 
species in Alzheimer’s disease, points to PrP as the link between these 
disease-linked entities142. PrPC is purported to trap misfolded Aβ in an 
oligomeric form at CC2139 – it  is tempting to hypothesise a native cellular 
function for the high affinity interaction between these two proteins, as it 
cannot be completely attributed to charge interactions, especially as there is 
so much potential for misfolding and toxicity13. When examining Aβ 
oligomer-induced toxicity, the N1 fragment of PrPC (encompassing CC1 and 
CC2) is able to block this toxicity by binding to the assumed toxic fragment 
(residues 106-126)121. PrPC overexpression in N2a cells was shown to 
down-regulate tau protein via the Fyn pathway; an effect which can be 
regulated by Aβ oligomers143. Resenberger et al. also demonstrated binding 
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of PrP to various β-sheet conformations, including Aβ oligomers, and found 
that toxic signalling elicited by this initial binding  was mediated by N-
terminal residues60. 
1.3.10 Copper binding capacity linked to neuroprotective function  
PrP-copper interactions are well-established and occur at multiple sites on 
the protein37, 129. This binding is pH-dependent and at CC2 is regulated by 
imidazole rings at His95 and His110 and deprotonated amide groups 
forming five-, six, or seven-membered rings37. As mentioned, CC2 is a 
heparin binding site113 and interestingly, copper coordination enhances 
heparin binding to PrPC instead of competing for the same binding site123, 
124. Brown et al. depicted the native role of PrPC as a superoxide dismutase 
(SOD) that converts superoxide radicals to peroxide and oxygen; however 
this proposal is not without controversy37, 130. They argue that the amount of 
copper associated with PrPC depends on the concentration of the ions in the 
protein’s microenvironment; binding capacity tested in cell culture is 
reached at four copper ions per molecule of PrPC130. No SOD-like activity of 
the protein was observed when PrPC was singly occupied by copper, but 
this activity was present upon coordination of more copper – a phenomenon 
which can be inhibited by the presence of the neurotoxic PrP peptide 
fragment 106-126130.  
 
However, this was not seen by either the Aguzzi or Jackson groups who 
reported an absence of SOD-like activity of PrPC144, 145. What is universally 
agreed upon by prion researchers is that PrPC displays specific copper-
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binding activity; more debated is whether this binding regulates signal 
transduction, copper sensing and homeostasis, apoptosis, neurogenesis or 
a combination of these37. Some have even argued that copper coordination 
may influence prion conversion, owing to the copper binding site at His95 
proximal to the proteolytic cleavage site129. Although depleting cells of PrPC 
appears to have no discernible effects, it may be seen to lower the 
threshold of stress levels cells are able to tolerate131. Supporting this theory 
is the evidence that PrPSc added to cells inhibits copper binding to 
endogenous PrPC146, while cross-linking PrPC with monoclonal antibodies 
triggers rapid neuronal apoptosis133. 
1.3.11 Regulation of prion conversion  
PrPC expression is compulsory for PrPSc formation48. Rate of conversion is 
determined by primary sequence identity69, rate of PrPC turnover94 and lipid 
environment147 amongst other considerations; one such mediator is the 
availability of CC2 on PrPC for PrPSc116. The significance of lipids in PrPSc 
formation has been well-documented. There are well-known co-factors 
reported to aid formation the infectious agent64, 74, 120. Many approaches to 
study PrP use recombinant proteins in denaturing and refolding 
experiments; infectivity attributed to rPrP amyloid fibres is much reduced 
compared to PrPSc and this may be explained by the misfolded protein 
adopting slightly different conformations78. PrP interacts with liposomes via 
electrostatic binding interactions at positively charged residues on PrP and 
anionic lipid head groups with this association strengthened through 
hydrophobic side chains and lipid acyl chains: such interactions promote 
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higher β-sheet conformations of PrP and protect the globular C-terminal 
domain from proteolytic cleavage148. PrP binds lipids in both a GPI-
dependent and independent manner62, 149. To test where in the native PrPC 
sequence lipids are bound, Wang et al. carried out an iodixanol density 
gradient analysis of rPrP mutants with 1-palmitoyl-2-
oleoylphosphatidylglycerol (POPG) and found that not only does this entity 
enrich the population of infectious PrPSc formed, it does so by binding the 
CC2 and PTM regions of the protein64. CC2 deletions or point mutations at 
this region reduced electrostatic interactions but did not disrupt association 
of rPrP at the PTM region with anionic lipids; they did however, markedly 
reduce rPrP protease resistance suggesting a role of CC2 in positioning 
rPrP and supporting formation of protease-resistant conformers64. Mounting 
evidence highlight the CC2 region along with the PTM domain as critical 
regions at which conformational changes are observed during the PrPC-to-
PrPSc transition64. 
Following a minimal mutagenesis approach such as that undertaken in this 
study, Hara et al. were able to pinpoint a five-residue sequence that 
regulates conversion of moPrP: 100- KPSKP-104134. They adopted two 
methods to reach this conclusion; the first being exchange of moPrP 
residues in CC2 for equivalent residues in the chicken homolog to create 
chimeric proteinsand determine their propensity for PrPSc formation/their cell 
curing potential; secondly, generating alanine-point mutations to study the 
effect they would have on the conversion process, as assessed by a 
peptide inhibition assay134. Both methods incorporated use of a 3F4 epitope 
within the CC2 region itself (108-111)134. They reported a marked reduction 
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in the intensity of PrPSc accumulation in chronically infected cells expressing 
alanine replacement mutations K100A, S102A, K103A, P104A, which they 
termed ‘nonconvertible dead-end mutants’ and showed this to not be true 
for more N-terminal mutations134. They predict that this five-stretch segment 
forms an outward extended loop structure that arises from the core β-helical 
architecture134. They acknowledge that the primary binding interface 
between PrPC and PrPSc resides in the C-terminal portion of the protein, but 
that this segment may provide an auxiliary interaction site that accelerates 
the conversion134. 
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1.3.12 Putative transmembrane domain (PTM) residues 111-126 
 
FIGURE I9: PTM 
Bar schematic of domains within moPrP. N-SS: N-terminal signal sequence; CC1: 
charge cluster 1; OPR: octapeptide repeat region; CC2: charge cluster 2; HC: 
conserved hydrophobic region; α1: helix 1; β1: strand 1; α2: helix 2; α3: helix 3; 
SS-C: C-terminal signal sequence. Residues 111-126 of moPrP are indicated in 
single letter amino acid sequence. 
 
The middle section of the protein has a stretch of residues that many 
sequence prediction programmes predict to be a helical transmembrane 
segment. In fact, one such study which predicted this, used four algorithms 
to predict a transmembrane site, each of which use a unique way to analyse 
the presented sequence: (i) positive-inside rule (ii) greater conservation a 
stretch of amino acids relative to the rest of the protein (iii) artificial neural 
network that is taught on a transmembrane-protein database (iv) hidden 
Markov model to find the most-likely topology150. Work by Hegde et al., 
showed that this section can indeed be found associated with the 
membrane, in various topologies (Figure I2)63. PrPC is known to bind lipids 
independently of its GPI-anchor. Specific residues responsible for this 
interaction are yet to be identified, but overall binding has been attributed to 
hydrophobic interactions arising from the PTM domain of the protein, with 
CC1 and CC2 providing electrostatic interactions for charged phospholipid 
head groups64.  
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The prion-lipid interaction was shown to be abolished by removal of 
residues 111-131 leading to a reduction in the amount of lipid-induced 
ProteinaseK-resistant PrPSc formed64. When smaller deletions were made in 
this region (and stretching N-terminally into CC2), transgenic mice 
expressing these constructs displayed severe pathologies: ataxia, 
cerebellar loss and white matter disease.  This phenotype is quite different 
from that seen in typically Scrapie-sick mice and can be overcome by 
expression of the full-length native protein119.  
It is interesting to note that transgenic mice expressing CC2 deletions in 
concert with PTM deletions are resistant to prion infection, highlighting the 
possible role of these regions in prion conversion from PrPC to PrPSc76. 
Norstrom and Mastrianni reported the PTM region as not fundamental for 
PrP aggregation, but claimed its absolute requirement for de novo 
generation of the specific PrPSc conformation and association of PrPSc with 
PrPC88. This was tested in N2a cells and in a heterologous yeast expression 
system, with its association characteristics ascribed to the AGAAAAGA 
palindrome at residues 112-11988. Additionally, due to the flexibility afforded 
to this region, it is not restricted in its position; it can exist at least transiently, 
in a series of conformational forms ranging from structured α-helical, 
variable and partially denatured31. Partial denaturing or unfolding of the N-
terminal tail in PrPC facilitates conversion of the protein to alternative fold 
states including PrPSc19. Collating experimental evidence from PrPSc 
inhibition experiments using region-specific peptides, epitope blocking 
assays using antibodies and PrPC PTM deletion mutants, points to PrPSc 
binding PrPC at a site proximal to, but not exactly at the hydrophobic 
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centre77, 116, 119, 151. Nonetheless, PrPSc is unable to form (at a detectable 
level) when PrPC is devoid of some PTM residues, with these deletion 
mutants demonstrating dominant negative inhibition when expressed in 
constitutively infected N2a (ScN2a) cells119.  
The PTM deletion mutants in turn show lower aggregation propensities and 
are trafficked to the cell surface more efficiently than their full-length 
counterparts119. Moreover, pathogenic mutations within the PTM interfere 
with both the attachment of the C-terminal GPI-anchor and the folding 
dynamics of PrPC which in turn lead to increased formation of misfolded 
forms of the protein62. Chatterjee et al., report amyloid core formation 
resulting from the moPrP loop region between β1 and α1 with no input from 
the PTM region77. This conclusion was based on experiments involving 
short moPrP peptides that act as seeds for full-length recombinant moPrP77. 
However, it should be noted that in this study, PTM-spanning peptides were 
less thermodynamically soluble compared to the loop peptides and required 
high monomer concentrations for initiation of fibril formation, which may 
widen the margin of experimental error77.  
Unconventional topologies of PrPC at the ER lumen include CtmPrP and 
NtmPrP (Figure I2) and these have been studied extensively by the Hegde 
group63, 152, 153. The majority of PrPC once synthesised is fully secreted into 
the ER lumen, and termed SecPrP63. Intriguingly, mutations in PrPC that 
upregulate CtmPrP formation can lead to neurodegenerative disease in mice 
and in some heritable prion diseases152. Generation of this topological 
variant however is unlinked to PrPSc generation and thereby non-
transmissible63, 152. It still contributes to overall neurodegeneration by 
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influencing cell susceptibility upon PrPSc infection – this was tested by the 
Hegde laboratory using two PrP mutants with opposing roles: 
overproduction and down regulation of the transmembrane forms CtmPrP 
and NtmPrP152. They found that each of the topological forms formed from 
the nascent polypeptide chain prior to PTM synthesis; furthermore, 
disruption of the extreme N-terminal signal sequence (residues1-22) 
abolished generation of all topological forms152. Because of the irregular 
charge distribution pattern either side of PTM, the orientation predicted to 
be preferred by PTM (N-term cytoplasmic; C-terminus exoplasmic) negates 
that commanded by the signal sequence (translocation of the N-
terminus)152.  
In fact, improving the signal efficiency in transgenic mice reduced the level 
of CtmPrP and levels of cytosolic aggregates152. Essentially, it is the overall 
message delivered to the cell over these opposing pressures that 
determines the outcome of the PrP topology delivered152. So although the 
strength of the nascent signal sequence for initiating translocation 
suppresses CtmPrP formation, features of the PTM can modulate the degree 
of suppression152. Wang et al., have shown that CtmPrP elicits toxicity and it 
is speculated that this may be the trigger for neurodegeneration in some 
cases of prion disease154. How exactly toxic pathways are activated is not 
known, but a proposed mechanism is through CtmPrP accumulation, 
possibly within the proteasome, and subsequent cellular stress; this stress 
further accentuated by PrPSc accumulation.  
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1.3.13 Structured region C-terminal domain (126-230)  
 
FIGURE I10: STRUCTURED REGION 
Bar schematic of domains within moPrP. N-SS: N-terminal signal sequence; CC1: 
charge cluster 1; OPR: octapeptide repeat region; CC2: charge cluster 2; HC: 
conserved hydrophobic region; α1: helix 1; β1: strand 1; α2: helix 2; α3: helix 3; 
SS-C: C-terminal signal sequence. β-strands, loop regions and α-helices are 
shown in pink, grey and green respectively.  
 
The structured region of PrPC, also referred to as the globular domain, 
comprises three alpha helices and two beta sheets with a GPI-attachment 
at the extreme C-terminus (Figure I3). Residues Cys178 and Csy213 form a 
disulphide bond, connecting helices 2 and 3, contributing in some part to the 
overall stability of this region155. Some of the earliest experiments in prion 
biology employed a deletion mutagenesis approach to decipher critical 
regions in PrPC that led to PrPSc formation; from this it was concluded that 
the structured region of the molecule held the vital residues/ components for 
prion conversion to proceed93, 128. Present-day experiments support this 
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hypothesis, but also indicate that N-terminal regions of the protein and other 
cellular factors modulate the overall conversion efficiency31. The most 
striking change in PrPC upon conversion is the shift from a mainly α-helical 
content to β-sheet-rich conformation40. A fresh wave of research on prion 
protein stabilisation and its influence on conversion to PrPSc indicates that it 
is governed to a large extent by helices 2 and 3156-160. The β2-α2 loop 
region is thought be important for prion propagation with α1-α2 associations 
facilitating this effect161. Using seed-induced amyloid formation experiments 
with rPrP to identify residues in the makeup of PrPSc, Chatterjee et al. 
detected residues 127-143 but not 107-126 in an amyloid seeding assay, 
thus stating the more N-terminal peptide was not crucial for amyloid 
formation77. Backing this theory, a chimeric mouse-hamster PrP expressed 
in transgenic mice was able to support PrPSc formation in the absence of 
residues 23-88 and 141-176162.  
Yamaguchi et al. prepared peptides corresponding to various domains of 
moPrP and scored their amyloidogenic properties; α2 and α3 were found to 
be the major hydrophobic regions; α2 had a high intrinsic β-sheet propensity 
and readily formed amyloid-like fibrils163. Conversely, α3 peptides exhibited 
a preference for α-helix conformations – this was also true for the 
hydrophilic α1 peptides163. When these peptides were tested in the 
presence of full-length moPrP, α2 peptides induced formation of fibrils more 
readily than any other peptide fragment163. The authors reason that 
although the native fold of PrPC under physiological conditions prevents the 
molecule slipping into an amyloid state, the C-terminal region especially α2, 
has an inherent amyloidogenic capacity163.  
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Support for α2 as an amyloid-state facilitator comes from experiments 
where introducing a more rigid loop structure (as observed in cervids) into 
the moPrP sequence between β2 and α2 resulted in greater misfolding 
propensity compared to the native moPrP sequence164. Further 
mutagenesis experiments centred around α1 and α2 of moPrP implicate 
this region and the sequence C-terminal to it as being vital to PrP-PrP 
interaction165. The more rigid loop structure showed similar thermodynamic 
stability in both wild-type and mutant forms of moPrP; the authors deduced 
that increased prion protein conversion as observed in cervids arises not 
from loop rigidity, but from a boost in amyloidogenic potential due to 
changes in the native sequence at the β2-α2 expanse164. 
When comparing sequence identity between rabbit and hamster loop 
regions between β2 and α2 of PrPC Sweeting et al. showed that this 
segment comprises a helix cap motif that could influence β-state-misfolding 
propensities of the protein; this may be a determining factor for degree of 
prion susceptibility and relates to hydrogen-bonding interactions within the 
motif158.  
There are also a large number of point mutations in the vicinity of α2 and α3 
that are associated with inherited forms of prion disease51. Cappings are 
usually present in regions of the polypeptide chain immediately preceding or 
succeeding an α-helix and play an important role in stabilising helices by 
compensating for the absence of intrahelical hydrogen bonds between the 
first and last turns of the helix166. Looking more closely at helix capping in 
the α2 and α3 regions of moPrP, Iovino et al., used a molecular dynamics 
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simulation approach to selectively mutate α2 and α3 regions of moPrP. 
They found the wild-type sequence displayed stability throughout its trace 
whereas mutants showed varying degrees of stabilisation167. 
Apostol et al. described a novel motif for oligomer formation using a 
fragment from huPrP comprising regions α2 and α3 linked via the disulphide 
bond168. They report a hexameric assembly, as opposed to the 
characteristic steric zipper profile observed for amyloids with residues 
HDCVNI at α2 and EQMCIT at α3 forming this assembly40, 168. The overall 
structural configuration of one subunit was described as a hexamer made 
up of ‘three four-stranded antiparallel β-sheets arranged like the faces of a 
triangular prism’168. This assembly is presumably driven by hydrogen 
bonding between the β-sheets and burial of hydrophobic side chains168.  
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1 . 4  D i s e a s e - a s s o c i a t e d  m u t a t i o n s  i n  t h e  
p r i o n  p r o t e i n  
Human prion diseases can be divided into three main categories, 
distinguished by aetiology: sporadic, inherited and acquired51. This section 
will focus on mutations within the prion protein which either pose a risk or 
provide a protective function to the gene carrier. Population analysis studies 
have revealed a number of naturally occurring prion protein mutations which 
vary depending on the demographic sampled, and range from 
insertions/deletions (indels) to missense and nonsense mutations91. Indels 
usually arise around the OPR region due to the genetic instability of this site 
(residues 51-91, human numbering)51.  
Typically, the prion protein consists of five OPRs with an increase or 
decrease in number (in particular, a drop to three OPRs) associated with 
the inherited form of prion disease6. Nonsense mutations recorded for the 
prion protein comprise Y145X, Q160X, Y163X, and more recently, Y226X 
and Q227X6. It is stressed that this section is not an exhaustive compilation 
of all prion protein mutations identified to date, but paints an overall picture 
of the most common ones and the region of the protein in which they lie. 
1.4.1 Mutations in the flexible domain (residues 23-126) 
Mutations in this region are coupled to GSS-related amino acid 
replacements: P102L, P105L/S/T, G114V and A117V (human 
numbering)51. Mutations in various regions of the structured domain of PrP 
also give rise to the GSS phenotype and include G131V (C-terminal to β1), 
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V180I (within α2), F198S (N-terminal to α3) and D202N, Q212P and Q217R 
(all within α3)6, 51. The archetypal purified GSS amyloids formed by huPrP 
bearing the A117V mutation consists of 7kDa PrP peptides, whereas those 
containing F198S mutations tend to form 8kDa fragments169. Both 
configurations implicate a role for the N-terminus in formation of PrPSc, as 
the purified amyloid peptides from GSS patients corresponded to OPRs 
three and four in the case of F198S, and to OPR five and CC2 for the 
A117V mutation, as determined by sequence analysis of the ProteinaseK-
cleaved peptides169. The most prominent GSS-linked mutations are those at 
position 102 and 105 (human numbering)170. When Tremblay et al. 
synthesised a 55-residue peptide spanning the P102L mutation site (P101L 
in mice) they found that it refolded preferentially to a β-sheet structure171.  
Additionally, circular dichroism studies on wild-type moPrP versus P101L 
moPrP demonstrated attenuation of helical content in the mutant form171. 
The most compelling evidence for the importance of the N-terminal domain 
in prion diseases comes from the finding that the neurotoxicity elicited by 
PrP arises from peptides corresponding to amino acids 106-126 (CC2 
boundary and PTM region)172, 173. Forloni et al., showed that peptides 89-
106 are neurotoxic when the P102L mutation is present but not when 
P105L is expressed174. Furthermore, A117V mutations appear to reduce the 
capacity for helix formation in the ‘neurotoxic’ peptide174, 175.  Schiff et al., 
show that in a setting where either P105L or A117V PrP is co-expressed 
with the wild-type form, the cellular localisation of the wild-type protein is 
affected, often resulting in an increased amount of PrP with alternative 
membrane topology (Figure I2)176. Almost all known mutations that fall 
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within the PTM region of the protein correlate well with production of 
CtmPrP175. There is currently a lack of comprehensive analyses tracking the 
effect of minimal changes in the PTM on the overall protein and its 
propensity to propagate prions; this issue is addressed in the present study.  
1.4.2 Mutations in the globular structured domain (residues 126-231)  
Residues in the C-terminal structured domain of the prion protein form part 
of the amyloid core and are central to disease progression77, 89. This has 
been shown by numerous groups using a plethora of techniques: structure 
prediction and bioinformatics applications177, yeast-two-hybrid screening 
and studying yeast prions81, 178, recombinant and chimeric protein 
expression78, 87, structure determination65, 66, 179, various cell models of prion 
disease98, transgenic studies48, and reports from clinical studies detailing 
the molecular profiles of huPrP in patients bearing mutations at these sites6. 
R148H lies in α1 and is so far the only disease-associated mutation found 
to reside at this helix180. Krebs et al., demonstrated differential gel mobility 
of protease-resistant, wild-type PrP versus one with an R148 mutation181. 
This residue replacement is suspected to weaken one of the salt bridges 
formed during production of native PrPC and alters PrPSc in the R148 
protein in a manner that makes it indistinguishable from that seen in the 
sporadic CJD phenotype181.  
Intra-helix salt bridges are formed between two aspartic acid- arginine ion 
pairs at positions 144 and 148, and at residues 147 and 151179. When 
mutations were engineered at these sites to replace the native residues with 
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alanine in Syrian hamster PrP (ShaPrP), thermal and chemical denaturation 
experiments revealed that the mutants are not substantially destabilised, but 
appear to engage in a different unfolding pattern179. Cell-free conversion 
data however, showed a higher efficiency of protein conversion if the 
mutations were in place, thereby arguing a case the native intra-helix salt 
bridges stabilising α1 and preventing conversion to a misfolded moiety175, 
179. 
Nonsense mutations such as Y145X, Q160X, Y163X, and more recently, 
Y226X and Q227X put a premature stop to PrP translation and are often 
characterised by intense amyloid deposition of this anchorless protein182. 
Such events inevitably results in protein malfunction, or in this case 
increased propensity for misfolding due to lack of complete structure182.  
Using ssNMR and a CS-Rosetta averaging paradigm, Skora and 
Zweckstetter have modelled a left-handed β-helix for PrP expressing the 
Y145X mutation, comprised of three β-strands with contributions from 111-
HMAGA-115 (CC2-PTM region), 120-AVVG-123 (PTM region) and 128-
YMLGSAMSR-136 (spanning β1 of the structured domain)183. They suggest 
a mechanism whereby the third strand at P137 twists so as to extend the 
existing β-helix at 138-IIHF-141. The palindromic sequence 113-
AGAAAAGA-120 acts as a loop region connecting the two β-strands183.  
Prion protein with mutations D178N and E196K are thought to be more 
prone to aggregation in crowded cellular environments compared to their 
wild-type counterparts184.  Expression of D178N results in a lack of 
stabilising contacts for α1 with the remaining structured part of the molecule 
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and along with mutations V180I, T183A, F198S and E200K, is reported to 
show variable glycosylation patterns185.  
The V180I mutation is capable of conversion in vitro but does not display 
any evidence of such activity in patient brains. Transgenic mice expressing 
PrP lacking the first glycosylation site appeared to be resistant to prion 
infection while those lacking the second site were fully susceptible185. It is 
possible that the region between the loop and the first glycosylation site 
may be more prone to dominant negative inhibition due to steric hindrance.  
A H187R mutation results in the introduction of a positive charge group in 
an otherwise hydrophobic pocket and consequently a strong repulsive 
electrostatic interaction with R156, causing considerable local changes in 
PrPC folding186. The folded structure of PrPC, if mutated to H187R, causes 
the hydrophobic core to be solvent-accessible, exposing the previously 
buried F198 residue186, 187.  Some authors have alluded to this as a 
mechanism for increased misfolding propensity as the water-filled void 
lowers the activation energy for fibril formation by promoting protein 
stabilisation187. Hosszu et al. used NMR chemical shift and structural data to 
show that the principal effect of H187R on PrP structure is at α1 and α2 with 
little change to the remainder of the protein186. In particular, acidification 
(arginine replacement) shortens α1 C-terminally and creates disorder in α2 
with rearrangement of the salt-bridge reported as the prominent factor186. 
Many other known pathogenic mutations around this region of the protein 
also introduce a positive charge (E196K, F198S, T188R/K, E200K, D202N) 
while others introduce a bulkier side chain (V203I, R208H, V210I) or 
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constrict backbone rotation of the alpha carbon (Q212P)6, 19. The β2-α2 
linking residues were shown through prediction programmes to form a 
potential steric zipper (Class 2), as described by Eisenberg et al40. β1 and 
β2 have been purported to initiate seed formation towards a β-sheet-rich 
conformer, via strand elongation, driving α1 unfolding77. 
E211Q is located in the third α-helix of PrP65. Substitutions at this codon 
were found to affect protein stability as analysed by molecular dynamics 
and differential calorimetric experiments with rPrP188. The mutation affects 
the proteins cellular folding pathway and promotes aggregation by altering 
the native state of the protein189. Interestingly however, a more conservative 
mutation E211D, showed a higher propensity to form high molecular weight 
oligomers189. This mutation also promotes formation of a salt bridge 
between R208 of α3 and E146 of α1, which is not the case for the wild-type 
protein or even for E211Q189. Through this interaction, the E211D mutation 
is able to destabilise α1 by favouring its detachment from the α2-α3 
subdomain189. 
Q217R mutations are linked to GSS-type pathology and thought to undergo 
misfolding in a mechanism dissimilar to E211Q proteins190. Using molecular 
dynamics simulations, De Simone et al. have studied the role of surface and 
partially buried water molecules in PrP. They report that the Q217R 
substitution has the effect of immediately expelling water from an internal 
‘pocket’ as insertion of the bulkier side chain leaves no room for internal 
waters191. They also report the mutation’s effect on spatially neighbouring 
residue R220, as with the two arginine side chains repelling each other’s 
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positive charges and argue that Q217R mutations aberrantly affect the 
structured domain of PrP by displacing conserved waters. These waters 
play an important role in holding critical residues in their respective 
orientations, as Hydrogen-bond atoms interacting with adjacent water can 
lower the activation energy required to unfold191. 
P238R/S/T mutations are observed in familial cases of CJD and lie in the C-
terminal signal peptide portion of the protein. It was found that neither of 
these mutations affected addition of the GPI-anchor, but are still able to 
elicit cytotoxicity62, 149, 192. Suggested hypotheses included alteration of PrP 
processing preceding ER translocation which would alter PrP topology in 
the ER (Figure I2), or impairment of signal cleavage, resulting in abnormal 
ER retention or secretion of anchorless PrP149. Gu et al. demonstrated the 
role of this signal peptide as an efficient ER-targeting and GPI attachment 
signal for PrP, and that P232R and P232T mutations are associated with 
PrP occupying a Ctm topology at the ER membrane, which is thought to be 
neurotoxic193. 
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1 . 5  S t u d y  o f  e p i t o p e - t a g g e d  o r  l a b e l l e d  
p r i o n  p r o t e i n s  
Since there is still uncertainty about the exact physiological function of PrPC 
and how it is processed in vivo, a vast range of tagged PrP constructs have 
been generated over time to provide a better understanding of the cryptic 
benefit of ubiquitous prion protein expression194-197. The types of tags used 
to study PrP, the suitability of certain tags for particular experimental set-
ups, the position at which tags are inserted and the benefits and limitations 
of doing so, must all be taken into consideration as this may have a major 
impact on the aspect of protein processing under investigation198. 
1.5.1 Need for unique epitopes and tagged PrP constructs 
When studying the role of PrP, and its propensity to aggregate and form 
infectious particles, it is very difficult to distinguish de novo production of 
PrPSc from the original inocula used to infect the native protein. These 
complexities arise since: (i) PrPSc and PrPC share the same protein 
sequence and PrPSc must be added to cells expressing PrPC to study prion 
propagation; (ii) unless the infectious inoculum or the expressed PrPC has 
been labelled, applied PrPSc and newly formed PrPSc are indistinguishable. 
Some groups have reported that due to differences in the folded 
conformations of PrPC (more α-helical) and PrPSc (higher β-sheet content), 
different epitopes may be exposed in the two forms, that allows some 
degree of distinction82, 199; however, the caveat is that differential binding is 
only seen in a sub-population of fibrils formed82 . 
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In order to differentiate between these biochemically different forms, limited 
proteolysis experiments have often been the norm in characterising the 
different species, as PrPC unlike PrPSc is not resistant to ProteinaseK 
digestion. Nonetheless, this technique is not always feasible as it cleaves a 
significant portion of N-terminal residues200, 201 and alternative approaches 
must be employed to simultaneously track the activity of the two 
conformers. Further compounding the issue of distinguishing PrPC from 
PrPSc is the finding that the disease-associated conformer is not always 
present in the protease-resistant fraction and in some instances, shows 
higher infectivity in the soluble fractions202. Thus, an obvious approach to 
distinguish one form from the other would be to generate fusion constructs, 
fluorescent or affinity tags, so as to efficiently separate the two moieties.  
When analysed in protein overexpression cell systems, newly formed 
labelled PrPSc is readily separated from the un-tagged infectious inocula195, 
196. Total PrPSc can be calculated using standard measures and the amount 
of de novo protein determined based on expression of the reporter protein 
or presence of a unique epitope. Furthermore, detection of the tagged 
protein is substantially more sensitive than conventional methods using anti-
prion antibodies and allows for detailed intracellular trafficking 
experiments100, 198. Lastly, tagged constructs have been used in attempts to 
isolate and identify PrP-binding factors and PrP-interactors that may play a 
role in disease pathogenesis195. Given the tendency for prions to misfold35, 
considerable care is given to the type of tag chosen for insertion and indeed 
as to where in the sequence the tag or epitope be attached, so as to avoid 
generating a prion protein with: (i) increased misfolding propensity34; (ii) loss 
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of propagative capacity (iii) deficiencies in infectivity (iv) disruption of the 
native fold, and if the construct is expressed in cells susceptible to prions, 
(v) loss of the susceptibility phenotype, as either of these scenarios would 
hamper experimental analysis of cellular prion propagation.  
1.5.2 Positional insertion of tags within the PrP sequence 
The majority of the reported modifications to the prion protein sequence lie 
either at the extreme N- or C-terminus of the mature protein, or at various 
positions within the CC2 region140, 195, 203. In each case, special attention 
was given to conserve signal sequences as interfering with these regions 
leads to atypical protein sorting152. Large tags such as GFP are never used 
in the middle protein region such as at the PTM region of the prion protein 
or the α2-α3 structured region. In the instance of the PTM region, this is 
because the domain (as the name implies), carries a high hydrophobic 
content and the inserted tag/epitope would likely be inaccessible for 
detection purposes as it might be hidden within the protein core, or may 
generate misfolded forms204. Alternations within α2- α3 are predicted to 
significantly alter the native fold and thus tag insertions here may hamper 
native protein function or alter its cellular targeting205. Additionally, this 
helical region is left largely unchanged as it is considered to hold the 
infectious and propagative capacities of the protein206. The N-terminus 
appears to be the chief site for modification by tag or epitope insertion116, 140, 
203. This may be due to the flexibility afforded to this region which can 
accommodate change with little effect on the structured domain. Moreover, 
as N-terminal modifications tend to lie in proximity to charge regions that 
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have a greater likelihood of being solvent accessible, they are more likely to 
be detected203. A number of studies have been carried out assessing the 
ability of the protein to propagate and transmit a PrPSc phenotype to 
susceptible cell when the native sequence has been tagged195, 207. 
1.5.3 Biochemical nature of tags and their influence on prion 
propagation 
Charge interactions can play an influential part in the process of prion 
protein interactions and undeniably, in mediating stability of the native form 
over propagation of the misfolded conformer88, 114, 116, 117. For clear detection 
and purification of protein samples, it is sometimes necessary to use a 
multi-tag system whereby tagged constructs of the protein are generated 
and the protein of interest extracted from a milieu of other cellular factors in 
a two-step method. In this way, EGFP and FLAG tags have been useful in 
understanding the trafficking of the native protein pre- and post-infection 
with PrPSc. 
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FIGURE I11: TAGGED PRP CONSTRUCTS USED IN PRION RESEARCH  
Schematic of the prion protein showing segments of the protein as ascribed by structure or biochemical property. Shown above the 
sequence structure are a series of tagged constructs which have all been used individually or in tandem to dissect various roles of PrP. 
The tags are shown to be preferentially clustered at the N- or C-terminal ends of the sequence, followed by CC2 and the region around 
α1. N-SS: N-terminal signal sequence; CC1: charge cluster 1; OPR: octapeptide repeat region; CC2: charge cluster 2; PTM: Putative 
transmembrane region; α1: helix 1; β1: strand 1; α2: helix 2; α3: helix 3; SS-C: C-terminal signal sequence. Types of fusion proteins 
tested by various groups involved the use of: FLAG203, 208, GFP207-214, His204, 215-218, TC (tetracysteine)196, 197, 219, 220 , AP (alkaline 
phosphatase)221, 3F4222, 223, L42224, Myc100, 195, 225 and V5226 epitopes. Shown above the tags are the positions on the protein at which 
antibodies ICSM35 (CC2) and ICSM18 (α-helix 1), used in this study, bind moPrP. 
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Harris et al. used this method to identify intracellular sites of protein 
conversion227 and Lee et al. identified a modulatory role for copper ions on 
PrP internalisation using a GFP-tagged construct209. When expressed in 
transgenic mice, the fusion protein was shown to localise correctly and 
exhibit wild-type protein capacities, in its ability to rescue mice from toxicity 
elicited by PrP deletion mutant Δ32-134207. The fusion protein model was 
reported to be supportive of prion replication, but at a reduced efficiency208.  
More recently, Myc-tagged PrP was used to demonstrate rapid cell surface 
conversion of the protein following infection100. Tags such as polyhistidine 
are used mainly with recombinant PrP, their advantage being the specificity 
and ease of detection when processing the sample218. Poly-His-tagged PrP 
can be detected and captured using immobilised metal-affinity 
chromatography (IMAC) to isolate metal-binding peptides, based on the 
interaction between the negatively charged His residues and transition 
metal fixed on the matrix228. Purification can be carried out under denaturing 
conditions and the protein then renatured228. Unfortunately, the use of 
imidazoles can result in protein aggregates, especially in the instance of 
PrP and can encumber its physiological activity229. Supattapone et al. have 
characterised various poly-His affinity-tagged miniprions, reporting 
spontaneous formation of protease-resistant conformers that bore some 
resemblance to PrPSc204.  
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TABLE I2: TAGS AND EPITOPES USED TO AID AND COMPLEMENT DETECTION OF PRIONS 
A number of modifications to the native prion protein sequence make it easily 
distinguishable using anti-tag and epitope-specific antibodies. Listed in the table 
are a few common ones that have been used to track expression of PrP.  
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Tetracysteine (TC) tags, considerably smaller in size than most typical 
varieties, have been used in moPrP studies with native-like protein 
folding196, 220. TC motifs bind fluorescent biarsenical dyes (FlAsH) and allow 
specific detection of labelled PrP197. When inserted at the extreme N- or C-
terminus of the protein, TC-tagged PrP supported fibril formation whereas 
tags within the α2-α3 region inhibited conversion196. This method is 
amenable for live cell imaging and has been used by Taguchi et al. to 
internally label PrP at the unstructured region and identify sites of protein 
interaction197. It is possible that the presence of inherent cysteines and 
histidine-rich regions in PrP may result in non-specific binding interactions 
and in the case of PrP, the presence of the histidine tag could alter the 
copper binding activity of the protein and may alter the ratio of preferred 
conformers in solution129, 230. A more conservative change is the widely 
used 3F4 epitope on moPrP; moPrP does not have a 3F4 epitope, unlike its 
human and hamster counterparts. This difference is exploited and a 3F4 
epitope is inserted within the CC2 domain of moPrP194.   
By far the most conservative approach for investigating intermolecular 
interactions, and a popular technique, is alanine scanning mutagenesis53. 
Here, native amino are singly, doubly or triply replaced with alanine, to 
create a series of constructs for each region of interest in the mouse prion 
protein. This introduces minimal deviation from the native sequence 
compared to conventional tagging methods. It differs from deletion 
mutagenesis which may give stronger phenotypes, but also increased 
uncertainty as to the overall effect of the deletion on the folded native state 
of the protein. These alanine constructs can be considered to be the closest 
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representation of the native protein and abundantly useful in instances 
where protein function is probed, as small interferences such as single 
amino acid replacements can give rise to strong phenotypes if a critical area 
of the molecule is altered.  
93 
 
1 . 6  C u r r e n t  o p i n i o n s  i n  t h e  p r i o n  f i e l d  
a b o u t  r e g i o n s  t h a t  c o n f e r  p r i o n  
p r o p a g a t i o n  
Whether or not the flexible N-terminus of the prion protein plays a major role 
in infection and propagation of prions has often been a bone of contention, 
with some authors disregarding it altogether and others showing 
incriminating evidence for its role in producing the aberrant conformer. 
Methods used to deduce these conclusions, inclinations and hypotheses 
regarding the incriminating segment that partakes in PrPSc formation, vary 
between laboratories.  However, a general consensus has emerged in the 
prion field about regions of the protein that are responsible for the 
successful propagation of prions, and unanimous acceptance for the role of 
the structured region of PrPC in the conversion process. 
Typically, PrPC predominantly undergoes α-cleavage between 109 and 110 
under physiological conditions, to produce N1 (23-109) and C1 (110-230) 
fragments, as determined by radiosequencing huPrP (position 111 human 
numbering). PrPSc however, preferentially undergoes β-cleavage more N-
terminally, at around residue 90, generating N2 and C2 fragments. Partial 
digestion of PrPSc with ProteinaseK yields a protein fragment of 27-30kDa in 
size that is cleaved at the N-terminus, bordering residue Q90 and retains 
infectious properties; conversely, PrPC is digested completely. Various 
segments of the protein have been linked to diverse pathways such as 
induction of toxicity, neuroprotection, cell signalling, apoptosis, cell 
development and oxidative stress responses. The focal point in this section 
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is on regions of the protein that allow it to self-propagate and form the 
misfolded state.  
A double-deletion mutant of PrP (Δ23-88 and Δ141-176) devoid of α1 and 
the N-terminus except for CC2 was able to propagate PrPSc76, 231. Such a 
construct is termed a miniprion and defined as the minimal sequence of PrP 
that supports prion propagation76, 231. A study carried out using C-terminally 
His(6)-tagged chimeric construct that replaces residues 108 and 111 of 
moPrP with ShaPrP to generate a 3F4 epitope, was the first of its kind to 
demonstrate the miniprion phenomenon204, 231. The authors make a 
distinction however, regarding the ProteinaseK-resistant product formed 
from PrPSc versus the double-deletion mutant; the mutant misfolds relatively 
easily even in the absence of an infectious misfolded stimulus, whereas the 
full length protein requires PrPSc204. This conformational change may be 
attributed in some part, to positive charges in the affinity tag and suggests 
that positioning, spacing and charge of any tag in the native PrP sequence 
can have an impact on the molecules ability to propagate prions204. In 
another study where a synthetic peptide was generated to mimic the same 
double deletions in moPrP, it was shown that this sequence is able to 
induce nerve cell degeneration in primary cell cultures and glial cell 
activation in vitro76. Although the miniprion is a useful model to study 
aggregation kinetics of the peptide, it is by no means a direct comparison to 
PrPSc. Using this peptide, numerous studies have been carried out to infer 
and elucidate mechanisms by which PrPSc carries out its neurodegenerative 
function. This includes hypotheses to test the involvement of the PTM 
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domain232, regulation of membrane viscosity and intracellular calcium 
levels233, 234, SOD activity and copper coordination235.  
Some patients with prion disease present with mutation Y145X; peptides 
made to mimic this mutation give rise to a parallel in-register alignment of 
the β-sheet core183. Such evidence suggest a region stretching from CC2 
through to α1 plays an important role in PrPSc formation, with residues 112-
129 (PTM region) thought to be essential for generation of a productive 
‘PrPC-PrPSc complex’80, 118. Indeed peptides drawn from this region can form 
irregular coils, α-helices or β-sheets, in line with the conversion of the full-
length protein from α-helical to β-sheet75. Studies on the N-terminus of the 
protease-resistant core of PrPSc determined residue 90 as the start site for 
the infectious prion domain77, 183. For the most part, as vast as the evidence 
that links the N-terminus to PrPSc formation is, it has never been directly 
linked to maintaining the native structure of the globular region of PrPC nor 
is it solely responsible for conversion to PrPSc. This phenomenon is credited 
to the α2-α3 regions of the protein, without which a vast majority of prion 
amyloids would not exist. However, when deletions were made to the N-
terminal region of the protein, so as to eliminate entire OPR region, there 
was a marked difference in the amount of protease-resistant PrP detected 
in transgenic mice expressing these constructs128, 236.  
A peptide corresponding to the PTM region was shown to be able to induce 
neuronal toxicity in a manner comparable to that of the miniprion, and 
through electron microscopy, shown to generate pre-fibrillar structures 
under physiological conditions led to destabilisation of phospatidyl choline 
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membranes, as analysed by atomic force microscopy232. Together, these 
data allude to a mechanism of PrPC-independent cell death, at least when 
the PTM region is concerned. This region was considered highly toxic by 
the authors, as the peptide appeared to display an inability to cultivate 
protofibrils into mature fibrils, thereby giving rise to a protofibril-rich 
environment, which is considered conducive to neurodegeneration232.  
In terms of maintaining the stability of the native fold, the β2-α2-loop regions 
in tandem with the α2-α3 region, confer a high degree of structural 
organisation164, 237. Alterations made to the protein within these regions, and 
mutations residing here play an influencing role in destabilising PrPC160. 
Minimal mutations such as Q212P and V210I display similar globular 
architecture, but introduce novel local structural changes within the α2-α3 
inter-helical interfaces when analysed by solution NMR238. The majority of 
the mutations arising in the structured domain of the protein leave it 
vulnerable to solvent-exposed hydrophobic surfaces, promoting misfolding 
events. Legname has proposed that the β2-α2 loop and specifically the 
interactions of this loop with the extreme C-terminus determine the levels of 
hydrophobic region solvent exposure and thereby manipulate intermolecular 
contacts67, 238. This underscores the importance of α1 and its tertiary 
contacts on preserving PrPC stability. It is also possible to analyse data on 
the miniprion from the point of view of structured region expression as a 
stable part of the whole protein as opposed to focusing on the removal of 
the N-terminus. More evidence for the sure-fire involvement of the C-
terminal structural domain of the prion protein in the initiation of misfolding, 
fibrillation, infection and propagation of the misfolded conformer, comes 
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from more recent and more rigorous studies that wholly support previous 
findings stressing the significance of this region in prion propagation77, 239. 
Helix stability is highest for α1, followed by α3 and lastly α2240. Fibril 
formation is readily achievable for α2 segments of the protein under acidic 
conditions where the disulphide bond joining it to α3 is reduced and α2 
undergoes partial unfolding240. The local conformational changes were 
dependent on the delicate balance of hydrophobic and electrostatic 
interactions of α2 which in turn are influenced by the pH of the surrounding 
environment240. The authors argue that the existence of a variety of fibril 
types (reversible and non-reversible) may explain some of the diversity 
observed in prion strains240. In conclusion, the structured region of the prion 
protein is the principle proliferating agent in prion diseases that contributes 
to accumulation of aggregated material, which we label as amyloid as it 
leaves signature plaques and inclusions. The amino-terminal part of the 
protein, in particular charge regions and the inherent flexibility of this 
domain, act to alleviate or exacerbate the effects of the C-terminal domain, 
depending on the orientation of the nascent polypeptide, which is likely 
influenced by associations of the PTM region152, 153. 
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1 . 7  P r o j e c t  r a t i o n a l e  
The mouse neural crest-derived Neuro-2A (N2a) cell line is 
widely used in the field of neurology. Here, this cell line was 
subcloned in-house to be highly susceptible to infection by 
mouse RML prions. Expression of the endogenous prion 
protein (moPrP) was then silenced using shRNA against 
the 3’UTR of the protein and silencing maintained under 
antibiotic selection, giving rise to a knock-down cell line 
(KD). KD cells were reconstituted with either the full-length 
native sequence of the mouse prion protein (moPrPWT), or 
various mutants of the protein and analysed for their ability 
to propagate RML mouse prions in vitro. Comparison of 
mutant-expressing lines to wild-type expressors allowed us 
to discern regions within PrPC that play a modulatory role in 
prion propagation.  
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2 . 1  A l a n i n e  m u t a n t s  o f  t h e  m o u s e  p r i o n  
p r o t e i n   
2.1.1 Preparation of plasmid DNA  
Template DNA used in this study was pBluescriptSK+ plasmid DNA bearing 
the open reading frame (ORF) of the murine prion protein, provided by 
Emmanuel Asante, within the department. The ORF of the mouse prion 
protein was PCR-amplified with the addition of a 5’ SalI site and a 3’ XhoI 
site. This was then cloned into a pBluescriptSK+ vector by blunt-ended 
ligation at the SmaI site (CCCGGG) of the Multiple Cloning Site (MCS) of 
the vector (See Appendix). Plasmid DNA was prepared using the QIAGEN 
Plasmid Maxi (QIAGEN, Cat.No.12163) and Mini (QIAGEN, Cat.No.12125) 
kits. The protocols were followed as detailed by the manufacturer, using the 
provided reagents as instructed by the handbook for the relevant 
procedures. As large quantities of the template DNA 
pBluescriptSK+(containing the ORF of interest) and vector DNA (pLNCX2) 
were required, Maxi-preps of these were prepared. For all other mutants 
generated in this study, mini-prep DNA was sufficient to generate desired 
mutations in the final vector pLNCX2. 
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2.1.2 Primer design and site-directed mutagenesis  
Primers were designed as suggested by the Stratagene QuikChange® site-
directed mutagenesis kit (Stratagene, Cat.No.200523). Briefly, 18-45mer 
primers were designed to have at least 50% GC content where possible 
and maximal sequence homology (Eurofins MWG Operon; Unmodified 
DNA oligos); the intended mutations were created in the middle of each 
forward and reverse primer. The codon GCC was chosen to encode alanine 
due to codon bias in the mouse genome, as murine PrP was used in this 
study and future work would include mouse experiments.  
PCR parameters were as follows: melting temperature: 95°C for 30 sec; 
annealing temperature: 55°C for 1min; extension temperature: 68°C for 3 
min. These three steps were cycled 16 times for control samples and 18 
times for test samples. Strand extension was completed at 72°C for 5 min 
and reactions cooled to 4°C. In cases where it was difficult to attain 
amplification, particularly in GC-rich regions of the sequence, touch-down 
PCR worked better than standard PCR, starting with an annealing 
temperature of 65°C and lowering this by 1°C per cycle down to 55°C, and 
then completing the reaction with a further 10 cycles at this temperature. 
Where primers were designed for deletion mutagenesis, touch-up PCR was 
used when standard conditions did not generate the amplified product of 
interest: starting with an annealing temperature of 55°C and increasing this 
by 1°C per cycle up to 65°C, and then completing the reaction with a further 
10 cycles at this temperature. 10 ng of template DNA was used in each 
reaction, with mutagenic primers used at a concentration of 100ng/µl and 
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PhuUltra DNA polymerase at 2.5U/µl per reaction. Amplification of the 
samples was verified on 1% agarose gels. PCR products were DpnI-
digested (1μl per 50μl PCR reaction for 1h at 37˚C) prior to transformation 
to digest the parental (non-mutant) DNA strands. XL1-Blue super 
competent cells were used to transform the alanine mutants of moPrP in its 
parent pBluescriptSK+ vector. Note that reagents required for the 
mutagenesis steps including super competent cells are provided in the 
Stratagene QuikChange® site-directed mutagenesis kit (Stratagene, 
Cat.No.200523). All of the generated mutants were sequence-verified prior 
to sub-cloning into plasmid vector pLNCX2 using JS4 competent cells 
(made in-house). 
2.1.3 DNA sequencing 
Sequencing reactions were carried out in non-skirted 96-well plates.  1ul of 
mini-prep DNA (at a concentration of about 150ng/µl) was added to a well of 
a 96 well plate per sequencing reaction tested. 1x sequencing reaction 
contained 1μl Big Dye Mix (Applied Biosystems®, Cat.No.4337449), 5μl 
Better buffer (Microzone, Cat.No 3BB-5), 5μM of primer, 5M Betaine 
(Sigma-Aldrich®, Cat.No.B0300), 4.25μl PCR-grade water (Ambion®, 
Cat.No.AM9935). After reactions were added to all required wells, the 96-
well plate was centrifuged for 10 sec at 1650 x g to ensure sample was 
evenly distributed before PCR on a DNA Engine Tetrad® 2 Thermal Cycler 
(Bio-Rad, Cat.No. PTC-0240G) PCR conditions are outlined. Melting 
temperature: 95°C for 1 min; annealing temperature: 55°C for 1min; 
extension temperature: 68°C for 3 min. These three steps were cycled 20 
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times, and followed by a final melting and extension step for 5 min.  
Following amplification steps, 3.75µl 0.125M EDTA 
(Ethylenediaminetetraacetic acid; Sigma-Aldrich®, Cat.No.03609) is added 
to all wells, followed by 45µl 100% EtOH (Ethanol; Sigma-Aldrich®, 
Cat.No.459844) and a 15 min incubation at room temperature. The plate is 
then centrifuged for 30 minutes at 3000 x g, at 4˚C. Plates are inverted and 
centrifuged briefly at 185 x g to remove liquid from the pellet. 60μl of 70% 
EtOH is added the plate centrifuged for 15 min at 4˚C. The plate is inverted 
and centrifuged at 185 x g again. The plate is then left uncovered to allow 
final traces of EtOH to evaporate before running in the sequencer (Applied 
Biosystems 3730xl DNA Analyzer). Sequence data was analysed in 
Sequence Scanner v1.0 software. 
2.1.4 Plasmid DNA digest gel extraction and ligation 
The mouse prion protein ORF was excised from the pBluescriptSK+ vector 
using HindIII/XhoI (New England Biolabs (UK) Ltd, Cat.No. R0104T 
/Cat.No. R0146S) and gel extracted using a QIAquick Gel Extraction Kit 
(QIAGEN, Cat.No.28704) following the manufacturer’s instructions. 
pLNCX2 was linearised with HindIII/SalI (New England Biolabs, Cat.No. 
R0104T /Cat.No. R0138T). Ligations between the extracted DNA were 
carried out using USB high concentration T4 DNA ligase enzyme 
(Affymetrix, Cat.No. 70042X 500 UN) with a 5:1 vector-to-insert ratio at 
16°C overnight.  
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2.1.5 Preparation of transformation-competent JS4 cells 
Following preparation of a small overnight culture of JS4 cells, LB (Luria 
Broth; Sigma-Aldrich®, Cat.No. L3522-250G) was inoculated with the 
stationary phase JS4 culture at a dilution of 1:500. Cultures were grown at 
37°C until an A600 reading of 0.8 was achieved. The cells were then chilled 
on ice and harvested at 1,500 x g for 20 min at 4°C. Cell pellets were 
resuspended 1:10 in cold 0.1M CaCl2 (Calcium chloride; Sigma-Aldrich®, 
Cat.No.C1016) relative to starting volume, and harvested at 1,500 x g for 10 
min at 4°C. Cell pellets were then resuspended 1:100 in cold 0.1M 
CaCl2:glycerol (85:15) and aliquoted at 50µl into eppendorf tubes before 
quick-freezing in liquid nitrogen. Frozen cells were stored at -80°C. Prior to 
transformation, competent cells were thawed at 4°C and 0.95µl cold 0.1M 
CaCl2 was added to obtain a working concentration. 
2.1.6 Transformation of competent cells 
14ml FalconTM polypropylene tubes (BD Biosciences, Cat.No. 352059) were 
chilled on ice, and competent cells also thawed on ice. When using XL-1 
Blue cells, 50µl was aliquoted per reaction; for JS4 cells, 100µl was used 
per reaction. DNA of interest (1µl if PCR product; 10µl if ligation) was added 
to the chilled competent cells, gently mixed and incubated on ice for 30 min. 
Transformations were heat-pulsed for 45 sec at 42°C and placed on ice for 
2 min. 0.5ml LB pre-heated to 42°C was added to the samples and cells 
grown for 1 h at 37°C in a shaking incubator (220rotations per min). Cells 
were plated onto LB-agar plates (10g LB, 6g Agar (to give 1.5%; 
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(Invitrogen™, Cat.No. 30391-023) made up to 400ml with PCR-grade 
water; ampicillin (Gibco®, Cat.No.11593-027) added at a final concentration 
of 100μg/ml) and grown overnight at 37°C. The plates were checked for 
presence of colonies the following day and picked into 10ml LB media 
cultures for mini-prep DNA, or for PCR screening of the moPrP insert in 
pLNCX2. 
2.1.7 PCR screen for moPrP insert in pLNCX2 vector 
Bacterial colonies from a transformation of a ligation reaction between 
mutant moPrP ORF insert DNA and linearised pLNCX2 were picked to 
check for the presence of the insert. Each reaction for the PCR screen 
contained 100µM LNCX2 forward and 100µM LNCX2 reverse primers, 
10mM dNTPs, 50mM MgCl2, 1xPCR buffer, 0.05U/µl GoTaq
® DNA 
polymerase and the DNA of interest. Melting temperature was at 95°C; 
strands were annealed at 58°C, extended at 68°C and these three steps 
cycled 30 times for all samples. Strand extension was completed at 72°C 
and reactions cooled to 4°C. 
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2 . 2  E x p r e s s i n g  t h e  m o u s e  p r i o n  p r o t e i n  i n  
P K 1  c e l l s  
2.2.1 Transfection of Phoenix Eco-tropic cells 
moPrP_pLNCX2 mutants were introduced with the aid of FuGENE® 
transfection reagent (Roche, Cat.No.11814443001) into the Phoenix-Eco 
helper-free retrovirus producer line (Nolan lab, Stanford University). Phoenix 
cells were seeded in 10cm tissue culture dishes at 106 cells per 10ml of 
DMEM (Dulbecco's modiﬁed Eagle's medium;  Gibco®, Cat.No.11995065) 
supplemented with 2mM glutamine (InvitrogenTM Cat.No.25030024) and 
grown overnight at 37°C, 5 CO2. The transfection mix was prepared as 
100µl serum-free media plus 12µl FuGENE, which was incubated for 5 min 
before adding 5-10µg moPrP_pLNCX2 mutant DNA. Following 15min 
incubation with the DNA, the transfection mix was added drop-wise to 50-
60% confluent Phoenix cells. Fresh media was put on the cells the next day, 
24 h after which viral supernatent was collected, filtered through a 0.45µm 
filter and frozen at -80°C for later use in transductions. 
2.2.2 PK1 cell culture 
Murine PK1 neuroblastoma cells (D-Gen Ltd, UK) were cultured in Opti-
MEM (Gibco®, Cat.No.31985-070) containing 10% FCS (foetal bovine 
serum – gamma-irradiated; Life Technologies, Cat.No.10500, 
Lot.No.07Q1437K) and 1% PS (penicillin/streptomycin; Gibco®, 
Cat.No.15240-062). This media is referred to as OFCS. All cells were grown 
at 37°C, 5% CO2 and sub-cultured in OFCS when they reached confluency. 
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2.2.3 Dose-response curves 
In a 6-well plate, 5 concentrations of geneticin G418 and puromycin (Sigma-
Aldrich®, Cat.No.A1720 and P8833 respectively) were tested on KD cells 
grown to 40% confluency. Selection media (OFCS plus G418/puromycin) 
was replenished and cell death assessed by eye. 100% cell death was 
observed after 3 days for puromycin selection at 4µg/ml and 10 days for 
G418 selection at 200µg/ml.   
2.2.4 Transduction of PK1 and KD cells with retroviral supernatent 
2ml of filtered viral supernatent was added onto KD (50-60% confluent) in 
8ml OFCS. The polycation Polybrene (Sigma-Aldrich®, Cat.No.H9268) was 
added at a final concentration of 8µg/ml and cells grown overnight at 37°C, 
5% CO2. The following day, viral supernatent was replaced with full OFCS 
and cells grown to confluence at 37°C, 5% CO2 before addition of antibiotics 
(puromycin at 4µg/ml and G418 at 200µg/ml) for selection of clones. For 
PK1 cells without suppression of the endogenous prion protein, only G418 
selection was used at 300μg/ml to select pLNCX2-containing cells. 
2.2.5 Single cell cloning  
KD cells were plated at limiting dilutions prior to transfection with viral 
supernatent. This ensured that upon selection, individual clones could be 
picked from the plate, which would be genetically identical as they 
originated from a single successfully transduced cell. Clones were picked 
from a 10cm dish, transferred to individual wells of a 96-well plate and 
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expanded in selection media (puromycin at 4µg/ml and G418 at 200µg/ml) 
from thereon to establish stable cell lines expressing the mouse PrP 
mutants of interest. 
2.2.6 Scrapie Cell Assay (SCA) 
This assay was developed within the Prion Unit97 and allows for the 
detection of single cells that are positive for PrPSc.  
Briefly, cells are plated in replicate on 96-well plates, infected with a 
predetermined dose of infectious RML prions (diluted in the same cell 
culture media they were seeded in). Maintaining the format in which cells 
were seeded initially and the wells containing infectious inocula, the cells 
undergo six passages into new 96-well plates, with samples taken for 
ELISPOT analysis (in 96-well plates with a PVDF membrane attached) at 
the last three splits, to determine the proportion of RML-infected cells. 
All steps were undertaken in a class II microbiological safety cabinet in a 
containment level II laboratory used primarily for tissue culture involving 
infections with mouse RML prions. 
Sample cells: Following 7-10 days of antibiotic selection cell lines were 
seeded at 18,000 cells per well on a 96-well plate. RML mouse prions (10% 
homogenate) were added to the cells the following day at a dilution of 3x10-
5, which corresponds to 6309 tissue culture infectious units. Cells were 
grown at 37°C, 5% CO2 for the duration of the experiment (three weeks).  
SCA control cells: PK1 cells were seeded at 18,000 cells per well and 
infected with a range of concentrations of RML mouse prions This control 
was used to ensure the assay generated reproducible and expected results. 
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A double log plot of PrPSc-positive cells against tissue culture infectious 
units should result in a linear relationship (Figure R11). 
Splitting cells: cells were split 1:8 every 3 days and cell samples collected 
at splits 4, 5 and 6 for analysis of PrPSc accumulation via ELISPOT 
(enzyme-linked immunosorbent spot) assay. 
Dilution series: The 10% RML mouse prion homogenate was serially 
diluted to concentrations of 3x10-5, 1x10-5, 3x10-6, 1x10-6, 3x10-7 and 1x10-7, 
which corresponds to TCIU (tissue culture infectious units) of 6309, 1893, 
631, 189, 63.1, and 18.9, respectively.  
ELISPOT for SCA: At splits 4, 5 and 6, cells were counted and seeded at 
25,000 cells per well on activated ELISPOT plates (Enzyme-linked 
Immunospot Multiscreen Immobilon-P 96-well filtration plates, Millipore, 
Cat.No. MSHAN4550). The 0.45µm PVDF membrane at the bottom of the 
plate was activated using 70% EtOH. Plates were washed twice with 1xPBS 
(Gibco®, Cat.No.70013-073) before seeding cells and filtering through a 
vacuum manifold. Plates were dried at 50°C for 1 h or until all wells were 
dry. The cells were treated with 2.0-2.5 U/mg ProteinaseK (Roche) in 
1xPBS for 30 min (lysis) at 37°C, washed twice with 1xPBS and incubated 
with 2µM PMSF – a ProteinaseK inhibitor (Phenylmethanesulfonyl fluoride; 
Sigma-Aldrich®, P7626) for 10 min at RT. Treatment with GSCN 
(Guanidine thiocyanate; Sigma-Aldrich®, Cat.N o.G9277) for 20 min at RT 
followed as a decontamination procedure. Supernatant was discarded into 
NaOH (Sodium hydroxide; Sigma-Aldrich®, Cat.No.S8045) as waste and 
wells washed 7 times with 1xPBS. For the immuno-reaction, SuperBlock 
(Thermo Scientific; Cat.No.37545 ) was added to the washed wells for 1 h 
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at RT, followed by primary antibody ICSM18 (D-Gen Ltd, UK) at 1:6000 
dilution of a 3mg/ml stock in 1xTBST/1% non-fat milk powder for 1 h at RT. 
The supernatant was discarded into NaOH and wells washed 5 times with 
1xPBS. Anti-IgG1-AP (secondary antibody) was added at a 1:6000 dilution 
in 1xTBST/1% non-fat milk powder for 1 h at RT. The supernatant was 
discarded into NaOH and wells washed 5 times with 1xPBS. Plastic under-
drains were removed from the plates which were left to dry at RT under a 
hood. Colour development was carried out using an AP Conjugate 
Substrate Kit (Bio-Rad, Cat.No.170-6432) with a 30 min reaction time. 
Plates were washed twice with water, dried at RT under a hood and stored 
at -20°C in the dark (foil covered). 
Determination of PrPSc-positive cells: To count stained cells, the 
detection settings of the WellScan (Imaging Associates, Oxfordshire, UK) 
software were optimised for wells with PrPSc-positive cells and wells with 
non-infected cells. For single cells the object size of the detection module 
was set to 9 and the threshold (detection sensitivity) adjusted until all visible 
spots of the well were detected - the threshold is indirectly proportional to 
the sensitivity of detection. After all visible spots were detected, the 
classifier was reset and positive spots added to adjust the new parameters 
of the classifier. After training of the classifier had been completed, the 
shape factor was set to 0.4 to exclusively detect spherical objects. Wells 
with non-infected cells were scanned and if required, settings for a low 
background were optimised by varying threshold amounts. Recommended 
values for threshold are 25 to 30. 
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2.2.7 Harvesting cells; total protein extraction by freeze-thaw 
method 
Adherent PK1 cells were collected in ice-cold 1xPBS, and pelleted at 300 x 
g. The cell pellets were washed twice in ice-cold 1xPBS, resuspended in a 
small volume of PBS and frozen at -20°C. Lysates were prepared by 
resuspending the cell pellet in lysis buffer (150mM NaCl, 50mM Tris-HCl, 
pH 7.5, 0.5% Triton-X-100, 0.5% sodium deoxycholate, 1mM EDTA, 40U/ml 
benzonase). Cell debris was pelleted at 4°C, 7826 x g for 1 min and cell 
lysates collected in chilled eppendorf tubes. An aliquot of the lysate was 
collected for determining protein concentration via Bradford assay; lysates 
were then adjusted to 1mg/ml and stored at -20°C. 
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2.2.8 Western Blotting 
Protein concentration of cell lysates was determined via the Bradford 
method and 25µg of protein was loaded per well (diluted in 1xPBS), unless 
stated otherwise. Sample buffer containing β-mercaptoethanol was added 
to the lysates which were spun down in a micro-centrifuge at 100 x g for 1 
min. Samples were boiled at 100°C for 10 min, vortexed, centrifuged at 226 
x g and loaded onto 16% Novex® Tris-Glycine mini gels (Invitrogen, 
Cat.No.EC6495BOX). Working concentrations of the running buffer for the 
gel contained 25mM Tris, 192mM glycine and 1% w/v SDS pH 8.6. Gels 
were run at 200V for 80 min. Transfer of the proteins from the gel was 
performed on PVDF membranes with 1x blotting buffer containing 20mM 
Tris, 150mM glycine pH 8.5, and 20% v/v methanol. In all cases, transfer 
was carried out at 35V for 90 min. Following transfer, the membrane was 
blocked in 5% non-fat dry milk in 1xPBST for 1 h and washed 4 times in 
1xPBST. PrP was detected using ICSM18 at 1:10,000 . Primary antibody 
was applied for 1 h followed by 45 min of 1xPBST washes (2x 15 min 
washes; 3x 5 min washes). Secondary detection was carried out for 45 min, 
followed by 1 h of 1xPBST washes (buffer changed every 5 min) using 
goat-anti-mouse IgG-HRP (for ICSM18 primary antibody) or goat-anti-
mouse IgG-streptavidin-HRP (for ICSM35b primary antibody) at 1:10,000. 
Immunoblot was developed using ECL. 
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2.2.9 Immunofluorescence analysis of moPrP expression in PK1 
cells 
Sterile 22mm glass coverslips were coated with 1mg/ml Poly-L-Lysine 
(Sigma-Aldrich®, Cat.No.P1399) for 30 min, washed with 1xPBS under the 
hood and dried, prior to seeding cells at 20,000 cells per coverslip. Cells 
were grown in 5% CO2 at 37°C and fixed using 4% w/v PFA 
(paraformaldehyde, Sigma-Aldrich®, Cat.No.P6148 - pH 7.4, filtered 
through a 0.22µm filter) for 20 min at RT before immunofluorescence. Cells 
were washed 3 times with 1xPBS and subsequently incubated with primary 
antibody ICSM18 (D-Gen Ltd, UK) at a 1:7000 dilution for 1 h at RT, prior to 
3 further washes with 1xPBS.  AlexaFluor 488-conjugated goat anti-mouse 
(Molecular Probes®, Cat.No A-11001) was subsequently added at 1:1000 
for 1 h at RT. After three washes with 1xPBS, coverslips were mounted 
using ProLong® Gold Antifade Reagent (Life Technologies, 
Cat.No.P10144) containing DAPI for nuclear staining, and left to dry. They 
were stored in a cool dark place prior to imaging. 
2.2.10 Cell viability assay 
Cell viability was assessed using the CellTiter-Glo® Luminescent Cell 
Viability Assay (Promega, Cat.No.G7570). PK1 cells were seeded in flat-
bottomed plates at a density of 2.5 x 104 cells/well and exposed to various 
concentrations of G418 for 10 days. Antibiotic-containing media was 
subsequently removed from all wells and replaced with 84 μl/well CellTiter-
Glo® reagent, which was reconstituted following the manufacturer’s 
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instructions. Cells were lysed by shaking for 2 min and plates incubated for 
10 min at RT prior to recording luminescence (integration time = 100 ms). 
2.2.11 Dot blot of cellular PrP expression  
Cells were harvested, counted and subsequently centrifuged at 300 x g for 
4 min. The supernatant was discarded and the pellet resuspended in lysis. 
Nitrocellulose membrane and three filter papers were then soaked in lysis 
buffer and fitted to a dot blot manifold. The volume of lysate corresponding 
to the desired number of intact cells was applied to the top of the manifold 
and serial 1:2 dilutions of cells blotted down the membrane. Membranes 
were blocked in Odyssey Blocking Buffer (LI-COR Biosciences; consists of 
a non-mammalian blocking reagent and 0.1% NaN3 in PBS) for 1 h at RT, 
and PrP detected by incubating blots with 0.6 μg/ml ICSM18 for 1 h at RT. 
Bound ICSM18 was detected by incubating blots with 0.25 μg/ml goat anti-
mouse IRDye® 800CW Infrared Dye (LI-COR Biosciences, Cat.No.926-
32210) for 1 h at RT. Blots were washed twice with PBS, dried and 
visualised using an Odyssey infrared scanner. 
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3 . 1  G e n e r a t i o n  o f  a n  a l a n i n e - m u t a n t  m o u s e  
p r i o n  p r o t e i n  l i b r a r y  
3.1.1 Experimental strategy 
In order to test the contributions of individual residues of the 
cellular prion protein on the propagative potential of prions, 
we adopted a minimal mutagenesis approach. Various 
constructs of the mouse prion protein (moPrP) were 
generated, bearing alanine mutations: in the unstructured 
region (amino acids 23-111), the conserved hydrophobic 
region (amino acids 111-121) and the structured region 
(amino acids 121-230; Figure R1).  In the unstructured 
region, alanine was substituted for one, two or three amino 
acids at a time within the sequence encoding the mature 
protein. Replacing existing residues with alanine effectively 
worked as a method for substituting individual native side 
chains with simple methyl groups. This method of alanine 
scanning allowed the examination of contributions from 
individual side chains to the function of the protein53.  
Alanine replacements were also made within the hydrophobic core and 
structured regions of the protein to test the influences of these regions on 
prion propagation. In the conserved hydrophobic region, we generated 
additional mutations to leucine, isoleucine, valine, proline and glutamate to 
investigate the putative role of membrane association 63, 241 within this 
region on propagation.  
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FIGURE R1: PDB ENTRY 2LEJ, HUMAN PRION PROTEIN  
Mutations made in the moPrP mutant library are mapped onto prion protein PDB entry 2LEJ, modelled in PyMol (DeLano Scientific 
LLC). Note that human prion protein (huPrP) numbering shown here (2LEJ) differs from moPrP by +1, i.e. moPrP 84 is equivalent to 
huPrP 85. (A) Protein coloured by domain highlighting its main components. Note that residues 23-84 are missing from the structure. 
The unstructured flexible segment of the protein is highlighted in blue, the conserved hydrophobic domain in green and the globular 
structured domain in orange. (B) Regions coloured in yellow, orange and blue represent Ala, Gly and Pro residues, respectively, and 
highlight regions left largely unaltered so as to minimise structural changes; grey represents all residues other than Gly, Ala and Pro, 
most of which are mutated to alanine in this study. 
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Information on the solvent-exposed regions of the folded PrP structure is 
available from NMR and X-Ray Crystallography-derived structures67, 242. 
Using this information, surface residues of the protein were primarily 
targeted for mutagenesis to identify which face/side of the protein is 
important for propagation.  
Three spatially-proximal points on the protein surface were selected, and 
mutated to alanine. In this way, we ensured that cumulatively, most solvent-
exposed regions of the protein were mutated to determine their contribution 
to prion propagation. This study differs from the typical targeted approaches 
to study PrP function, in that the whole protein, and not selected domains, 
were analysed for their contributions to prion propagation. Furthermore, to 
our knowledge it is the first extensive, cell-based mutagenic screen of the 
prion protein that assesses the effect of minimal mutations on prion 
propagation without interference from the endogenous protein. We have 
amassed a library consisting of over one hundred mutant constructs of the 
mouse prion protein that can be used to probe many questions about 
cellular and aberrant functions of PrP. Here, the library was used to 
investigate regions of the protein that regulate prion propagation (Table R1). 
The mutations covered more than 55% of the overall protein (Figure R1). 
The remaining unaltered 45% represent regions with existing alanine, 
glycine and proline residues and the bulk of non-surface-exposed residues 
within the structured region of PrP (Figure R1). 
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TABLE R1: SUMMARY TABLE OF MOPRP MUTAGENIC CONSTRUCTS GENERATED IN PLASMID VECTOR PBLUESCRIPTSK+  
All mutations were created in pBluescriptSK+ by site-directed mutagenesis, and sequence-verified. 
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3.1.2 Site-directed mutagenesis of the mouse prion protein 
To generate the library of mutant constructs listed in Table 1, 
pBluescriptSK+ bearing the un-mutated, full-length moPrP open reading 
frame (ORF) was used as template DNA. This is equivalent to the 
endogenous protein and is therefore signified as the wild-type protein: 
moPrPWT. The small size of pBluescriptSK+ makes it an ideal template for 
mutagenesis (Figure R2).  
 
 
FIGURE R2: LINEAR MAP OF THE PLASMID VECTOR PBLUESCRIPTSK+ 
Linear map of the plasmid vector pBluescriptSK+ with moPrP ORF cloned at the 
SmaI site. Mutagenic primers were designed to anneal perfectly to the template 
sequence either side of the mutation site for both forward and reverse primers 
(panel 2). Primer pairs are indicated in black with non-annealing segments 
represented as loop regions bearing alanine codon GCC (sense) and CGG (anti-
sense) in red. They were typically designed to be 30-mers, with longer primers (40-
mers) designed for those more difficult to amplify (Appendix). 
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Mutations were introduced into the moPrP ORF using Stratagene®’s site-
directed mutagenesis kit. Complementary pairs of primers were designed 
per intended mutation to bind the same region of DNA on both sense and 
antisense strands for site-directed mutagenesis (Figure R2). Depending on 
the GC content within the sequence, annealing temperatures and cycle 
numbers varied for optimal amplification (Table R2).  
 
 
Step Process Temp  Time 
S
ta
n
d
a
rd
 P
C
R
 
1 Melting parental strands 95°C 30 sec 
2 Melting strands 95°C 30 sec 
3 Annealing  55°C 1 min 
4 Extending 68°C 3 min 
5 
Cycle steps (2-4) 16x for DNA 
template     
  /samples and 18x for controls     
6 Complete extension 72°C 5 min 
7 Cool reaction 4°C o/n 
 
TABLE R2: STANDARD PCR CONDITIONS FOR SITE-DIRECTED MUTAGENESIS 
Site-directed mutagenesis for all mutants generated was carried out using the 
appropriate mutagenic primer pairs and the PCR cycling conditions shown (o/n: 
overnight). For reactions that did not amplify well using this method, touch-down 
PCR was used.  
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Following successful amplification, as assessed by visualisation on 1% 
agarose gels (Figure R3 B), the PCR product was DpnI-digested to 
selectively cleave template DNA. The DpnI enzyme only cleaves 
methylated DNA strands, leaving newly synthesised, un-methylated, 
mutated DNA intact. DpnI-digested PCR product was then transformed into 
XL-1 Blue supercompetent cells, and colonies were picked to grow bacterial 
cultures. Plasmid minipreps were prepared and sequence-verified for the 
presence of the intended mutation, and also to confirm there were no errors 
within the ORF (Figure R4). Sequencing results were analysed using 
Sequence Scanner (v1.0). 
moPrP mutant DNAs correct for the intended mutation were digested with 
HindIII/XhoI and the excised insert ligated to pLNCX2, which was linearised 
with HindIII/SalI. The ligation reaction was transformed into competent JS4 
cells, a recA-derivative of MC1061243, and the resulting colonies screened 
by PCR for the presence of insert using pLNCX2-specific primers (Figure 
R3 E).  
Single digest of pBluescriptSK+ with either HindIII or XhoI yielded a single 
band indicative of linearised DNA. pBluescriptSK+ with moPrPWT ORF 
(Figure R2) also produced a single band when digested with HindIII. 
However, when digested with XhoI pBluescriptSK+ with moPrPWT ORF 
produced two bands, one migrating at approximately 3Kb and the other at 
about 850bp (Figure R3 A). Two fragments on the agarose gel indicated 
that the plasmid had been digested twice with XhoI, suggesting two cut 
sites. The additional XhoI site was introduced in pBluescriptSK+ when the 
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ORF of moPrPWT was cloned into this plasmid (Appendix). The sequence of 
moPrPWT cloned into pBluescriptSK+ is 815bp in length. When JS4 colonies 
were screened for the presence of moPrP insert in pLNCX2, bright bands 
were observed at 1Kb (Figure R3 E). This increase in size is the result of 
the screening primers binding the vector sequence approximately 150bp 
from the cloning sites, thereby incorporating the extra base pairs.  
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FIGURE R3: MUTAGENESIS OF MOPRP IN PBLUESCRIPTSK+ AND SUBSEQUENT CLONING INTO PLNCX2 
All gels shown here are 1% agarose gels with 5μl of Track It 1Kb ladder in lane 1 (A) Control digests: pBluescriptSK+ DNA bearing the 
mouse prion protein ORF is approximately 4Kb; nicked circle and supercoil versions of the plasmid were seen in the uncut DNA. 
Plasmid digested with HindIII displayed a singly cut band; digestion with XhoI gave two bands of 3Kb and 1Kb, with the smaller band 
running slightly lower when doubly digested. (B) 10μl of the PCR product was loaded to check for successful amplification. (C) Double 
digests: pBluescriptSK+ DNA bearing either moPrPWT ORF or moPrPAla ORF digested with HindIII/XhoI, giving bands at 3Kb and 
850bp. The last lane shows the final plasmid vector, pLNCX2, linearised with HindIII/SalI. (D) 10μl of gel extract obtained from 
purification of DNA from (C) was run to check for level of recovery. (E) PCR colony screening of JS4 colonies. Bright bands at 1Kb are 
indicative of the moPrP ORF being present. 
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FIGURE R4: SEQUENCING DATA CONFIRMING THE PRESENCE OF ALANINE MUTATIONS 
AT INDICATED SITES 
Small sections of sequencing are shown for the mutants of greatest interest. 
Segments corresponding to the mutated codons are highlighted in yellow within the 
sequence frame. All alanine replacements bear an XXX – to GCC change.  
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3.1.2 Expressing moPrPAla in mammalian cells 
This study required stable expression of moPrPWT, and engineered mutants 
of moPrP, in a cell line such as PK1 cells that can report prion propagation. 
PK1 cells are a derivative of mouse N2a neuroblastoma cells that are highly 
susceptible to RML prions. One of the most efficient ways of gene delivery 
in mammalian cells is through retroviruses244. Here we used Phoenix 
retroviral cells, an ecotropic packaging cell line originally created in the 
Nolan laboratory245, to package the retroviral vector plasmids containing 
moPrP into ecotropic viruses.  
The pLNCX2 vector was selected to introduce moPrP into mammalian cells 
on the basis that is a retroviral vector, which can be used to package the 
construct into ecotropic viruses by transient transfection. The plasmid vector 
is able to transiently express, or integrate and stably express, a transcript 
containing the viral packaging signal, a selectable marker and the gene of 
interest, which is cloned into the MCS under control of the CMV (Figure R5), 
which works very well in PK1 cells. The 5’ viral LTR drives expression of the 
neomycin resistance gene for G418 selection in mammalian cells. Phoenix 
retroviral cells are adherent cells that can be easily transfected. They 
contain the elements required to facilitate packaging, reverse transcription 
and integration. The Phoenix cells have the functions gag, pol and env 
stably integrated in them, which are required in trans to package the 
retroviral vector.  
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FIGURE R5: LINEAR SEQUENCE MAP FOR PLASMID VECTOR PLNCX2 
Linear sequence map for plasmid vector pLNCX2 showing presence of long 
terminal repeats (LTRs) in purple (derived from Moloney murine leukemia virus, 
MMLV); packaging element in green; resistance genes neomycin/kanamycin 
(NeoR/KanR) and ampicillin (AmpR) in yellow, cytomegalovirus (CMV) promoter in 
red. The multiple cloning site (MCS) lies between the CMV promoter and the 
3’UTR. Insertion of moPrP is shown as a black bar within the MCS.  
 
When pLNCX2 is introduced into Phoenix cells it has the packaging signal 
in cist on the RNA, which allows the construct to be inserted into the empty 
virus particles. The viral packaging signal (ψ) directs incorporation of vector 
RNA into viral particles, additional signals allow the reverse transcription, 
repeat regions at both ends of DNA allow for transfer, and partially inverted 
repeats at the ends of viral LTRs allow for integration246. Transfected 
Phoenix cells rapidly produce recombinant viral particles (between twenty-
four to forty-eight hours post-transfection) for the efficient infection of 
dividing cells. The viral particles are released into the cell media, which can 
be filtered and applied immediately onto target PK1 cells. Filtering through a 
0.45μm filter allows the virus particles to pass through whilst preventing any 
floating cells from contaminating the viral supernatent. Once PK1 cells were 
transduced, the culture was maintained in the presence of G418 until all 
cells in the non-transduced culture died out from antibiotic selection (10-14 
days; Figure R6).  
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FIGURE R6: DOSE-RESPONSE CURVE OF KD CELLS TO G418 ANTIBIOTIC 
KD cells were seeded on to a 96-well plate at a density of 25,000 cells/well. G418 
was added to the cell media at concentrations ranging from 0 to 2mg/ml and 
passaged for ten days. Luminescence for each well was determined using a cell 
viability assay and used to establish the optimum concentration for antibiotic 
selection. The panel below shows phase contrast images of the KD cells under 
G418 selection at 0, 50, 100, 200 and 400μg/ml. Magnification at x20.  
129 
 
The G418 added in the selection phase ensured that only cells that had the 
stably integrated provirus survived. Successfully transduced cultures were 
frozen down in bulk, with a new vial used per experiment. PK1 cells were 
frozen down at low passage numbers whenever possible since they have 
been observed to lose susceptibility to infectious prions if cultured long-term 
(unpublished data). PK1 cells are particularly susceptible to infection by a 
well-characterised, mouse-adapted prion strain known as Rocky Mountain 
Laboratory (RML)247.  
It is important to note that the method adopted here produced bulk cultures 
containing pools of mixed clones: multiple independent daughter cells were 
established from individual transductions. Each successful transduction 
initially generates single cell clones (SCCs). If they are not separated at this 
stage, multiple SCCs proliferate, creating a mixed population (referred to as 
a bulk culture) where all cells expressing moPrP with alanine replacements 
(moPrPAla) bear the same intended mutation, but may vary in some cellular 
aspects such as doubling time and expression level. This is due to random 
but preferred retroviral integration248.  
The bulk cultures represent an average of all successfully transduced 
SCCs.  All mutants created in this study were tested this way initially. Cells 
stably expressing moPrPAla were tested via a standard Scrapie Cell Assay 
(SCA)97, for their respective propagation profiles following RML infection.  
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3.1.3 Generating a PK1 cell line knocked-down for expression of 
moPrP 
PK1 cells, a derivative of N2a cells, are routinely used within the department 
for their high susceptibility to infection by RML prions. Expression of the 
endogenous Prnp gene in PK1 cells was silenced by shRNA targeting the 
3’UTR of Prnp. Eight shRNA were designed and cloned into pRetroSuper, 
and tested for their ability to reduce expression of endogenous PrP in PK1 
cells.  
Expression of the cellular form of the prion protein is necessary for that cell 
to be infected with, and propagate prions.  PK1 cells in which Prnp had 
been silenced were tested for their ability, or lack thereof, to propagate RML 
prions. shRNA8 yielded the highest level of silencing of endogenous PrP 
and was taken forward.  
Next, 100 SCCs of PK1 cells, into which shRNA8 had been stably 
transduced by puromycin selection, were isolated. These 100 SCCs were 
then individually reconstituted with moPrPWT; through SCA, the SCCs that 
presented the phenotype of silenced cells and were not susceptible to 
infection with RML, but regained susceptibility upon reconstitution with 
moPrPWT, were identified. Of these, SCCs that propagated RML to levels 
comparable with wild-type PK1 cells were expanded and SCC PK1-
10/si8#9 was found to meet these criteria.  
This represents a line of PK1 cells that are highly sensitive to RML prions 
(PK1 cells, single cell clone 10), but are silenced for expression of 
endogenous PrP protein (shRNA8 was most effective) and report near wild-
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type susceptibility to RML prions once reconstituted (#9) with moPrPWT. 
These moPrP knockdown cells are referred to as KD from hereon.    
KD cells were the main cell line used for this study as it allowed us to test 
the contributions of discrete mutations within moPrP on prion propagation, 
without interference from the endogenous protein. KD cells were found to 
have approximately 88% reduction in the level of PrP expression. (Figure 
R7). This residual level of protein expression did not support prion 
propagation. 
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FIGURE R7: MOPRP EXPRESSION IN PK1 AND KD CELLS 
PK1 and KD cells were lysed and seeded at four cell densities, ranging from 75K to 
9.4K cells per well, in a 96-well plate. moPrP expression was detected using 
ICSM18 antibody. Following standard dot blot procedure, expression levels were 
quantified based on absolute fluorescence as determined by Li-Cor Odyssey® 
Infrared Imaging System. (A) Fluorescence image from dot blot experiment 
showing PK1 and KD cells with four replicates per tested cell density; (B) Raw 
values for absolute fluorescence; (C) Bar chart for direct comparison of moPrP 
expression in PK1 cells versus KD cells. P-values for cells were calculated using 
an unpaired t-test with *** representing P- values ≤0.0001, ** ≤0.0005 and * ≤ 
0.005. Knockdown levels of moPrP were calculated to be approximately 88%. 
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3.1.4 Reconstitution of KD cells with alanine mutants of moPrP  
The silencing of endogenous PrP by targeting the 3’UTR of Prnp allowed for 
reconstitution of KD cells with moPrPWT without interference from shRNA8 
and/or the endogenous PrP protein.  
KD cells displayed similar growth and morphological characteristics to PK1 
cells, as did KD cells reconstituted with the full-length wild-type protein: 
KDmoPrPWT cells. This was also true for KD cells reconstituted with the 
moPrP deletion mutation Δ23-88: KDmoPrPΔ23-88 (Figure R8). These KD 
cells were previously made by Parineeta Arora, but are described in detail 
to document how they were established and why they are suitable for 
reconstitution with both moPrPWT and alanine mutants of PrP: moPrPAla. 
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FIGURE R8: IMMUNOFLUORESCENCE OF KD CELLS RECONSTITUTED WITH MOPRP CONSTRUCTS 
Panel showing confocal images of cells. moPrP expression is shown in green (ICSM18 antibody) and nuclear staining in blue (DAPI). PK1 cells 
showed surface labelling of the endogenous protein; KD cells exhibited very low levels of moPrP expression. KD cells reconstituted with either 
moPrPWT or an N-terminal deletion (Δ23-88), showed similar protein expression. Scale bar represents 20μm. Magnification at x40. 
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KD cultures, both transduced and non-transduced with virally packaged 
pLNCX2, were cultured in 4μg/ml puromycin to prevent the multiplying cells 
from losing the shRNA against Prnp 3’UTR that silences expression of the 
endogenous prion protein. This concentration was determined previously by 
Parineeta Arora in generating the KD cell line (unpublished data). Using this 
approach we generated KD cells expressing the moPrP mutants indicated 
in Table 1 (Figure R9). 
 
 
 
FIGURE R9: CELL LINE SCHEMATIC 
PrP is represented by green bars in this schematic. KD line was established 
through stable integration of a pRetroSuper construct expressing shRNA against 
the 3’UTR of Prnp; when shRNA8 is processed to siRNA8, expression of the 
endogenous protein is silenced. This KD line was used as the template to 
reconstitute expression of moPrPWT: KDmoPrPWT (packaged DNA shown in purple 
inside the virus particle), or to exclusively express mutant forms of moPrP. This 
includes deletion mutants of the protein such as moPrPΔ23-88 or alanine 
replacements: KDmoPrPAla.   
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3 . 2 K D  c e l l s  r e c o n s t i t u t e d  w i t h  m o P r P  
p r o p a g a t e  R M L  p r i o n s  i n  t h e  S c r a p i e  C e l l  
A s s a y  
3.2.1  Experimental strategy 
The Scrapie Cell Assay (SCA) is routinely used in the MRC 
Prion Unit as a quantitative method of assessing the ability 
of a cell line to propagate prion infection95. The cell lines 
used here were PK1 cells, KD cells and KD cells 
reconstituted with moPrPWT and its mutant forms. RML 
prions were applied to the cells seeded at a fixed density 
and their propensity to propagate prions was measured by 
the scrapie cell assay (SCA).  
RML prions are well-defined mouse-adapted prions derived from sheep 
infected with Scrapie by W. Hadlow at the Rocky Mountain Laboratories in 
Hamilton, Montana247. RML is suitable for prion studies in mouse cell lines 
and highly infectious to PK1 cells used in this study. It is prepared as a 10% 
brain homogenate from mice infected with these prions, and its potency 
measured in a limiting dilution assay (SCEPA); SCEPA is quicker than, but 
as sensitive as, mouse bioassays at determining infectious titre95, 97.  
It involves determining the number of prion-infected cells and calculating 
infectivity based on the proportion of ‘positive’ wells to ‘negative’ wells, P(0), 
from the total number infected, N(0). This is given by the Poisson equation 
that is: P(0) = N(0)/N = e
−m  where m denotes the mean number of infected 
cells per well95. Both SCA and SCEPA give an indication of a cell line’s 
ability to propagate prions.  There were a number of reasons why we 
adopted the SCA approach over SCEPA. Firstly, for both SCEPA and SCA 
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there is a user-defined threshold for what constitutes as propagation. 
However, in SCA these raw spot numbers can be graded so as to define 
the capacity of a cell line to propagate prions, as in this study, to full, 
reduced, severely limited and abrogated propagation. In SCEPA, there is 
only one threshold for a cell line being classified as positive or negative for 
propagation and comparisons between the propagative capacities are 
measured by the ratio of positive to negative wells. Since the propagation 
capacity of the moPrP alanine-mutant lines to propagate RML, was not pre-
determined, we did not want to bias the results in either direction and thus 
opted for data collection in the form of raw spot numbers – SCA. 
Additionally, SCEPA is generally a lengthier assay, with two additional cell 
passages equivalent to an extra week of experiments relative to SCA; SCA 
therefore provides a quicker turnaround time.  
3.2.2 Scrapie Cell Assay for reconstituted KD cells 
Each moPrPAla-expressing cell line was seeded at 18000 cells/well in 96-
well plates, typically with 8 repeats per line, and infected with RML 
homogenate at a 10-5 dilution (Figure R10). Duplicate plates were set up for 
non-infected cultures. All plates were split 1:8 twice a week, for six splits. At 
splits 4, 5, and 6, cell suspensions corresponding to 25000 cells per well are 
applied to pre-activated ELISPOT plates for detection of ProteinaseK-
resistant PrP. A serial dilution of the homogenate was always applied to 
PK1 cells as a positive control for the SCA, and a double log plot of the 
observed spot number against tissue culture infectious units (TCIU) was 
prepared (Figure R10). This should be linear to indicate that the assay has 
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worked. Wild-type PK1 cells and KDmoPrPWT cells consistently reported 
maximum spot numbers above 800 whereas spot numbers for non-infected 
samples were below 30. Note that at split 6, a plateau was reached for 
higher concentrations of RML, but linear for splits 4 and 5 (Figure R11). The 
combination of RML dilution used here (1x10-5) and sampling the cell 
population at splits 4, 5, and 6, allowed for a window of detection that was 
large enough to accommodate samples which propagate well and sensitive 
enough to pick up low signals from those that did not propagate as 
profusely. Furthermore, the standard SCA can detect propagation from 
background from split 3 onwards, as there is sufficient dilution of the applied 
inocula at this time point to call true positives from residual RML. Sampling 
the alanine-mutant moPrP cell lines at splits 4, 5 and 6 for propagation 
increases confidence in the data that the spots observed are generated 
from the reconstituted KD cells de novo. It is also important to note that the 
96-well layout of cells and subsequence applied infectious titres of RML 
prions is maintained throughout the assay. 
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FIGURE R10: SCRAPIE CELL ASSAY AND ELISPOT PLAN 
Schematic of screening alanine mutants of the mouse prion protein by SCA. All 
cells were seeded at 18000 cells/well. (A) Control plate in which RML was serially 
diluted down the plate from 3x10-5 to 1x10-7. Pink denotes infected wells and clear 
wells represent non-infected wells. KD and KDmoPrPWT were used as additional 
controls to PK1 cells. (B) An RML dilution of 1x10-5 was used to infect KDmoPrPAla 
cells; each column represents one cell line. (C) Cells were seeded following the 
same layout as in (B), but left non-infected. Cells were split 1:8 for six splits, but 
only at splits 4, 5, and 6 were sampled for ELISPOT. Revelation of ELISPOT plates 
following ProteinaseK treatment, GSCN denaturation, antibody incubation and 
colour development, was followed by reading the plates; Plate reader output was in 
the form of spot numbers per well. 
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FIGURE R11: SCRAPIE CELL ASSAY OUTPUT 
(A) Double log plot of spot number against tissue culture infectious units (TCIU). (B) Serial dilution of RML homogenate and calculated 
SCEPA data for TCIU. (C) SCA data from control cell lines PK1 (wild-type); KD (silenced for Prnp); pLNCX2 (vector only); moPrPWT 
(reconstituted KD cells); Δ23-88 (N-terminal truncation of moPrP). (D) Schematic of RML serial dilution in 96-well plate format for six 
concentrations shown in (B); (E) ELISPOT revelation of a positive well; (F) ELISPOT revelation of a negative well. 
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ELISPOTs were developed through a chromogenic assay, where an 
alkaline phosphatase (AP)-conjugated secondary antibody was added to 
wells treated with ProteinaseK and pre-incubated with anti-prion antibody 
ICSM18 (Figure R10). Increasing amounts of ProteinaseK-resistant PrP 
resulted in higher spot numbers, which were taken to represent the number 
of cells infected by RML. Infected cells that efficiently propagate prions 
showed a split-to-split increment in spot number. This however, is not an 
absolute requirement; depending on the days between splits (two or three) 
there may be slight variances such that Split 5 readouts are occasionally 
lower than Split 4. The best indication for efficient propagation is taken to be 
a value of about eight hundred spots achieved at split 6 (Figure R12). Note 
that the following conditions for SCA were used as standard in the following 
chapters: 
1) 10% RML homogenate as stock inoculum for all SCAs from which 
required dilutions are made in cell culture medium 
2) For general screening of propagation profiles, cells were infected with 
1893 TCIU of RML, which was applied as a 1x10-5 dilution of the 10% 
homogenate, based on SCEPA calculations. This concentration (1893 
TCIU) is referred to as a 1x10-5 dilution of RML homogenate from 
hereon. 
3) RML batches I8700 and I14051 were used in this study. TCIU are given 
(Figure R11) for I8700; I14051 displayed similar infectivity (data not 
shown).  
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FIGURE R12: GUIDE FOR RML PRION PROPAGATION READOUT 
Example of prion propagation profiles. SCA analysis of cells infected with RML: data shown for three consecutive splits (4, 5 and 6). 
KDmoPrPWT cells are knockdown (KD) cells reconstituted with the wild-type moPrP sequence and represent a positive control that can 
propagate prions efficiently - above 800 spots at split 6. KD and KD cells expressing the empty vector (pLNCX2) do not propagate 
prions and present spot numbers below 50. Samples 1, 2, 3 and 4 are shown as cells in which propagation relative to KDmoPrPWT is 
fully efficient, reduced, severely limited and abrogated, respectively. 
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3.2.3 moPrP deletion mutant Δ23-88 does not support prion 
propagation 
KDmoPrPWT propagated RML with a similar efficiency to PK1 cells (Figure 
R11). KD cells showed no propagation whatsoever; this demonstrated that 
susceptibility of KD cells to RML was fully restored upon reconstitution. KD 
cells expressing pLNCX2 represent cells transduced with the empty vector; 
lack of prion propagation in this line demonstrated that there was no 
contribution from the plasmid vector in terms of prion propagation, and that 
it was a suitable system for testing the effects of moPrPAla in KD cells.  
KD cells expressing of moPrP Δ23-88 lacked propagative capacity as the 
propagation profile for this construct mimics that of the negative control 
lines, that is, KD and KDpLNCX2 (Figure R11). This result was observed 
previously in our laboratory (Parineeta Arora, Personal communication) and 
was the basis for this study.  It has also been reported by others114, 134 and 
suggested that the octapeptide-inclusive N-terminal segment of PrP region 
23-88 regulates propagation of the prion protein37.  
Our initial aim was to investigate discrete regions within this domain, and 
then extend this study to the remainder of the protein, to delineate which 
amino acids within the prion protein are required for its efficient propagation. 
Note that for all SCA results shown in graphically, spot number is the total 
number of ProteinaseK-resistant PrP detected from 25,000 cells infected 
with RML prions. 
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3 . 3 P o l y b a s i c  r e g i o n  C C 1  a n d  r e s i d u e  4 1  
m e d i a t e  t h e  e f f i c i e n c y  o f  p r i o n  p r o p a g a t i o n  
3.3.1 Experimental strategy 
Bulk cultures of KDmoPrPAla cells were established and 
assayed on at least three independent SCAs to investigate 
their propagative potential following infection with RML 
prions. For cell lines that reported a reduced capacity for 
propagation compared to wild-type PK1 cells and KD 
reconstituted controls (KDmoPrPWT), protein expression 
levels were checked by Western blotting and cell surface 
expression of PrPC by immunofluorescence.  
3.3.2 Effects of charge cluster I (CC1) mutations on prion 
propagation  
KD cells were reconstituted with moPrP bearing minimal mutations 
(KDmoPrPAla), or the wild-type protein (KDmoPrPWT). It was shown that N-
terminal deletion Δ23-88 in moPrP does not support prion propagation 
(Figure R11). Here, alanine replacements were made along the 23-88 
sequence to determine which residues within this sequence, contribute to 
the ‘loss of propagation’ phenotype observed in mutant Δ23-88 when 
expressed in KD cells. 
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FIGURE R13: REGIONS OF INTEREST WITHIN MOPRP SEQUENCE 23-90 
Bar schematic of domains within moPrP. N-SS: N-terminal signal sequence; CC1: charge cluster 1; OPR: octapeptide repeat region (repeats are 
labelled 1-5); CC2: charge cluster 2; PTM: putative transmembrane region; α1: helix 1; β1: strand 1; α2: helix 2; α3: helix 3; SS-C: C-terminal 
signal sequence. Residues 23-90 of moPrP are indicated in single letter amino acid code. Charge cluster 1 is highlighted in red; YPGQ in orange 
as a YXXQ motif site; OPRs are shown in green. 
146 
 
Residue K23 is the most N-terminal amino acid in the moPrP sequence, 
following cleavage of the signal sequence (residues 1-22). K23 is followed 
by more positively charged amino acids, denoting region 23-31 of the 
protein as charge cluster 1 (CC1). A series of alanine mutations were 
created as point, double, or triple mutations to cover region 23-88 of the 
protein, to identify those that participate in reducing propagation, as 
observed in moPrP with deletion Δ23-88 (Figure R11).  
Alanine replacements K23A.K24A.R25A, P26A.K27A, that lie within CC1 
were created alongside neighbouring residues P28A, and 
W31A.N32A.T33A, to investigate their contributions to propagation.  KD 
cells reconstituted with these constructs were assayed for their propensity 
to propagate RML (Figure R14). SCA output is in the form of spot numbers 
where the number of spots is taken to be a measure of propagation; thus, 
high spot numbers represent high levels of propagation/efficient propagation 
(Section 3.2). It was found that KD cells reconstituted with triple mutation 
K23A.K24A.R25A propagated fewer prions compared to KD cells 
reconstituted with the wild-type protein (Figure R14). However, KD cells 
expressing moPrP mutation P26A.K27A, as well as neighbouring 
replacements P28A and W31A.N32A.T33A showed no deficiency in 
propagation (Figure R14). Thus, within CC1, only changes in sequence 
segment 23-25 had a modulatory effect on prion propagation.  
147 
 
 
 
 
FIGURE R14: SCA OF KDMOPRPALA CELLS; MOPRP MUTATIONS IN REGION 23-33 
SCA analysis of region 23-33 of moPrP revealed CC1 as a modulator of 
propagation. KD cells reconstituted with alanine-mutant forms of moPrP were 
compared to KDmoPrPWT cells for their propensity to propagate prions. Spot 
numbers for triple mutation K23A.K24A.R25A were significantly lower than 
KDmoPrPWT at all splits assayed in a one-way ANOVA with a Bonferroni correction 
for multiple comparisons. Significance is indicated by *** for P ≤0.0002 and ‡ for P 
≤0.0001. Significance only shown for split 6 for clarity. 
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Additionally, the lowered propagation phenotype observed in 
K23A.K24A.R25A maintained spot numbers below four hundred for all time 
points at which the cells were sampled: splits 4, 5 and 6 (Figure R12). 
Based on the SCA guide (Figure R12) this is indicative of reduced 
propagation relative to wild-type controls. 
All mutations in region 23-33 other than K23A.K24A.R25A, had no effect on 
reducing propagation, as spot numbers at three individual time points 
sampled, matched and surpassed those of KD cells expressing the wild-
type protein. The triple change to alanine reduced the propagation relative 
to wild-type PrP approximately five-fold; K23A.K24A.R25A reported spot 
numbers in the two hundreds, whereas moPrPWT-expressing cells that lack 
any mutation, gave spots approaching one-thousand (Figure R14).  
 
The observed lower propagation capacity was further probed by generating 
and testing point mutations within K23A.K24A.R25A, to assess which 
residue in particular within the continuous three amino acid stretch was 
central to reduced propagation (Figure R15). None of the point mutations 
generated in this region, (K23A, K24A or R25A) showed a deficit in 
propagating RML prions as each reported spot numbers equalling and 
surpassing those of KD cells reconstituted with the wild-type protein (Figure 
R14).  
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FIGURE R15: SCA OF KDMOPRPALA CELLS; MOPRP MUTATIONS IN REGION 23-25 
Propagation was markedly reduced for the triple alanine moPrP construct 
K23A.K24A.R25A, but not for individual mutations K23A, K24A or R25A, within this 
segment. Significance is indicated by *** for P ≤0.0002 and ‡ for P ≤0.0001. 
Significance only shown for split 6 for clarity; calculated in a one-way ANOVA with 
a Bonferroni correction for multiple comparisons. 
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3.3.3 CC1 amino acids K23.K24.R25 are important for efficient prion 
propagation  
Results from the triple mutation K23A.K24A.R25A in CC1 and subsequent 
experiments testing individual mutations K23A, K24A and K25A clearly 
indicated that K23.K24.R25 is a distinct cluster of positive charge within the 
prion protein that is important for propagation efficiency, as compromising 
the native sequence in this section led to sub-optimal propagation of prions.   
3.3.4 Q41 is identified as a novel modulator of prion propagation 
within region 36-88 of the mouse prion protein 
Region 36-88 of moPrP is largely composed of octapeptide repeats 1-5 that 
start at residue P51 and end at residue Q90 (Figure R13). A total of 
eighteen alanine-substituted moPrP constructs were created and expressed 
in KD cells to assay the contributions of residues within region 36-88 to 
prion propagation. Scrapie cell assay analysis of RML-infected KD cells 
reconstituted with alanine mutations in region 36-88 showed that 
surprisingly, the only substitution that had an effect on propagation was 
Q41A (Figure R14). All other mutations made in region 36-88, including 
those neighbouring Q41 at either termini, showed no loss of propagation 
(Figure R14). Single replacement at Q41 had a significantly lower 
propensity to propagate RML compared to KD cells reconstituted with 
moPrPWT (Figure R16).  
When analysed by SCA, KD cells reconstituted with moPrP bearing 
mutation Q41A gave spot numbers of one hundred, compared to one-
thousand for moPrPWT-expressing cells at the same split (Figure R16). This 
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is a ten-fold reduction in propagation, introduced by a single amino acid 
mutation in the prion protein. What is interesting and perhaps unexpected, 
is that no mutations made within the OPR regions reduced propagation as 
expansions in this region are known causes for familial prion disease51.  
Furthermore, OPRs are comprised of residues known to be involved in 
copper coordination37, 129 which in turn mediates cellular functions of PrPC 
such as endocytosis249. The five octapeptide repeat regions are defined by 
OPR1 (residues 52-58), OPR2 (residues 59-66), OPR3 (residues 67-74), 
OPR4 (residues 75-82) OPR5 (residues 83-90); their SCA profiles as tested 
in KDmoPrPAla cells challenged with RML prions demonstrated that these 
residues are not crucial for prion propagation (Figure R16). 
Mutations S36A.R37A.Y38A and S43A, which are N-terminal and C-
terminal to Q41 respectively, also had no inhibitory effect on prion 
propagation (Figure R16). The finding that all alanine replacements made 
and tested within region 36-88 of moPrP, except Q41A, exerted no 
limitations on the ability of cells expressing these mutations to propagate 
prions, defines Q41A as a discrete point of interest in the flexible N-terminal 
tail of the prion protein that can mediate propagation.  
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FIGURE R16: SCA OF KDMOPRPALA CELLS; MOPRP MUTATIONS IN REGION 41-88 
Reconstitution of KD cells with Q41A severely reduced the cells ability to propagate prions. Mutations either side of Q41A did not 
inhibit propagation. All other alanine replacements that were tested in region 34-88 did not reduce propagation, including region 52-88 
which is within the OPR segment of the protein. Significance is indicated by ‡ for P ≤0.0001; for clarity, this is only shown for split 6. 
Significance calculated in a one-way ANOVA with Bonferroni correction for multiple comparisons. Mutations that fall within OPRs 1-5 
are indicated below the graph.  
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3.3.5 Propagation efficiency of moPrP mutations K23A.K24A.R25A 
and Q41A can be improved with increased infectious dose 
Within regions 23-88 of the mouse prion protein, only K23A.K24A.R25A and 
Q41A of the alanine mutants generated, showed any effect on lowering 
prion propagation. For the triple mutation, the highest spot numbers 
achieved following infection with RML prions was three hundred spots, and 
for Q41A, one hundred. These two constructs represent two out of twenty-
six alanine-mutants of moPrP in region 23-88 that reduced propagation. 
 To test whether spot numbers of these N-terminal mutations had an upper 
limit of three hundred spots or one hundred spots for K23A.K24A.R25A and 
Q41, respectively, KD cells reconstituted with these mutations were infected 
with RML at a ten-fold higher concentration than before (Figures R14, R16): 
here, the infectious inoculum was applied at a dilution of 1x10-4 instead of 
the standard 1x10-5 used for SCA in this study (Figure R17). 
KD cells reconstituted with CC1 mutation K23A.K24A.R25A and single 
replacement Q41A appeared to reproducibly propagate RML at a level that 
was significantly less than KD cells reconstituted with the wild-type protein 
at both concentrations of RML (Figure R17). However, Q41A propagated 
RML prions at a lower capacity than K23A.K24A.R25A at both 
concentrations tested (Figure R17). 
154 
 
 
 
FIGURE R17: SCA OF KDMOPRPALA CELLS; MOPRP MUTATIONS IN REGION 23-25 OR 
RESIDUE 41 
KD cells reconstituted with moPrP mutations K23A.K24A.R25A, Q41A, and point 
mutations within segment 23-25, were tested for their propagation propensity at 
two concentrations of RML inocula via SCA. K23A.K24A.R25A- and Q41A-
expressing cell lines are highlighted in lighter pastels for easier comparison. All cell 
lines reported higher spot numbers at a ten-fold higher dose of RML. Significance 
is indicated by ‡ for P≤0.0001, *** for P≤0.0002, * for P≤0.005 ; for clarity, this is 
only shown for split 6. Significance calculated in a one-way ANOVA with Bonferroni 
correction for multiple comparisons. 
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At the higher dose, cells expressing Q41A propagated roughly five-fold less, 
and K23A.K24A.R25A approximately two-fold less, than wild-type-
expressing cells. Thus, increasing the concentration of infectious inocula 
resulted in improved propagative capacity for K23A.K24A.R25A and Q41A, 
but the presence of these mutations still has a limiting effect on propagation, 
as they did not achieve spot numbers comparable to KD cells reconstituted 
with the wild-type protein, or single replacements K23A, K24A and R25A 
(Figure R17). 
This result that moPrP mutation K23A.K24A.R25A within CC1 and point 
mutation Q41A lowered propagation at high doses of infectious inoculum, 
strengthens the notion that these two regions play an important role in prion 
propagation. This was further supported by the finding that none of the 
residues neighbouring these sites displayed deficiencies in propagation 
(Figures R14, R16). 
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3.3.6 Combination moPrP mutation K23A.K24A.R25A+Q41A does 
not have a cumulative effect on limiting prion propagation capacity 
Two regions were identified within the 23-88 segment of the mouse prion 
protein that propagated sub-optimally, when the native amino acids were 
substituted for alanine: K23A.K24A.R25A and Q41A (Figure R17).  Taken 
together with the finding that Δ23-88 did not support prion propagation 
(Figure R11), it would seem logical to suggest that the propagation limiting 
effects in Δ23-88 arise due to missing residues 23-25 and residue 41.  
Since neither of these mutations expressed separately in KD cells, had as 
much of an effect on propagation as Δ23-88, we generated a moPrP mutant 
bearing both changes, such that residues 23-25 as well as residue 41 was 
substituted by alanine in the same construct. The resultant construct was 
labelled K23A.K24A.R25A.Q41A. 
If expression of alanine mutations at both positions in moPrP sequence (23-
25 and 41) had an additive effect, it would suggest two independent 
pathways or mechanisms are affected in each mutant moPrP construct. If 
not, we could presume that there will be no greater limit on propagation 
observed by expressing both sets of mutations (23-25 and 41) compared to 
expression of these mutations individually (23-25 or 41) since the same 
pathway is compromised. 
To test this, pBluescriptSK+ DNA bearing the K23A.K24A.R25A mutation 
was used as template DNA for the site-directed mutagenesis PCR of Q41. 
This created a construct bearing both K23A.K24A.R25A and Q41A. Using 
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the techniques described in Chapter I for generating KDmoPrPAla cells, KD 
cells were reconstituted with this construct (K23A.K24A.R25A.Q41A). 
KD cells reconstituted with moPrP bearing mutations 
K23A.K24A.R25A.Q41A did not show evidence of K23A.K24A.R25A acting 
in synergy with Q41A when assayed for their propagation capacity by SCA 
(Figure R18). K23A.K24A.R25A and Q41A when expressed independently 
of each other displayed spot numbers between one hundred to three 
hundred, and when expressed as K23A.K24A.R25A.Q41A, gave spot 
numbers of about two hundred under standard SCA conditions of 1x10-5 
RML dilution (Figure R18). This increased to nine hundred, three hundred 
and seven hundred for K23A.K24A.R25A, Q41A and 
K23A.K24A.R25A.Q41A respectively, at a higher dose of inoculum (1x10-4 
RML dilution; Figure R18). 
Thus, expressed individually, each of these mutations showed limited 
propagation. Combined, they demonstrated an averaging of their respective 
propagation profiles (Figure R18).  
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FIGURE R18: SCA OF KDMOPRPALA CELLS; MOPRP MUTATIONS IN REGION 23-25 AND 
RESIDUE 41 
Cells bearing the triple alanine moPrP construct K23A.K24A.R25A displayed 
significantly reduced propagation compared to KDmoPrPWT cells. KD cells and KD 
cells reconstituted with moPrPΔ23-88 did not propagate RML at any time point 
tested. Combining mutations K23A.K24A.R25A and Q41A did not hinder 
propagation any more than Q41A alone. Spot numbers for K23A.K24A.R25A.41A 
fell between those of the individual mutations K23A.K24A.R25A and Q41A. 
Significance is denoted by * for P≤0.005 *** for P≤0.0002 and ‡ for P≤0.0001. 
Significance only shown for split 6 for clarity; calculated using a one-way ANOVA 
plus Bonferroni correction for multiple comparisons. 
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3.3.7 Lack of propagation in moPrP mutations K23A.K24A.R25A and 
Q41A is not due to lack of protein expression  
KD cells do not propagate prions as they do not express moPrP at a 
sufficient level to support propagation (Figure R11). The approach used 
here to test regions of PrP required for propagation, required reconstitution 
of KD cells in order to express the desired alanine mutation of moPrP. It 
could therefore be argued that the reason some reconstituted KD cells are 
unable to propagate RML prions fully may be down to lack of, or low-level 
prion protein expression. 
To demonstrate that the effects of mutations K23A.K24A.R25A and Q41A 
on propagation were due to modification of native residues at these sites 
and not simply inefficient expression, cells expressing these mutations were 
immunoblotted for protein expression, using α-moPrP antibody ICSM18 
(Figure R19). Since it has been shown that prion conversion occurs 
primarily at the cell surface100, mutant proteins were examined for cell 
surface expression by immunofluorescence. Cells were grown on glass 
coverslips and analysed for protein expression using the anti-PrP mouse 
monoclonal antibody ICSM18 for detection by immunofluorescence (Figure 
R20). 
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FIGURE R19: WESTERN BLOT OF KDMOPRPALA CELLS WITH MUTATIONS IN CC1 AND 
RESIDUE 41 
Expression of moPrP mutant constructs in KD cells. PK1 cells were taken as a 
positive control for expression of moPrP and KD the negative control.  
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FIGURE R20: IMMUNOFLUORESCENT ANALYSIS OF KDMOPRPALA CELLS; MUTATIONS IN CC1 AND RESIDUE 41 
Immunofluorescent analysis of KD cells, KDmoPrPWT cells and KD cells reconstituted with moPrP alanine mutants: K23A.K24A.R25A, Q41A and 
combined mutation K23A.K24A.R25A.Q41A. All moPrP-expressing cells displayed similar expression and distribution of the protein, which was 
detected at the cell surface. Magnification x40.  
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3.3.8 With the exception of K23A.K24A.R25A and Q41A where prion 
propagation is limited, all moPrP alanine replacements in the 
flexible region 23-88 of the protein propagate RML fully  
Deleting residues 23-88 from moPrP resulted in a protein that when 
expressed in cells, did not propagate RML prions as tested by SCA (Figure 
R11). Charge cluster 1 mutant K23A.K24A.R25A, and point mutation Q41A 
were found to propagate RML to a much lesser extent compared to cells 
expressing the full-length native protein (moPrPWT) and were the only 
mutations found to reduce prion propagation capacity in region 23-88 of 
moPrP.  
The reduction in propagation was not as stark as that observed for Δ23-88, 
which was akin to the negative control KD cells (Figure R18). Q41A was 
less able to propagate RML compared to K23A.K24A.R25A, despite it being 
a smaller change in the protein sequence (Figure R18). This suggested that 
it may have a stronger modulatory role on propagation than the more N-
terminal charge cluster at 23-25. Since the propagation efficiency of KD 
cells expressing the K23A.K24A.R25A mutant can be improved to half-
maximal potential compared to KDmoPrPWT cells, it may be that increasing 
the dose of inoculum compensates for the disruptions in propagation 
brought about by the triple mutation. Possible roles of these amino acids 
and how they may impact propagation are discussed. 
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FIGURE R21: SUMMARY OF FINDINGS; REGION 23-88 OF MOPRP 
Schematic of the prion protein sequence, as individual domains and structural elements within it. N-SS: N-terminal signal sequence; CC1: charge 
cluster 1; OPR: octapeptide repeat region; CC2: charge cluster 2; HC: conserved hydrophobic region; α1: helix 1; β1: strand 1; α2: helix 2; α3: 
helix 3; SS-C: C-terminal signal sequence. K23.K24.R25 in CC1 and Q41 replacements led to reduced prion propagation and are highlighted in 
pink (glycine and proline replacements were not tested with the exception of P26 and P28). Residues of the OPR region when replaced with 
alanine showed no loss of propagative capacity (green). However, deletion of residues 23-88 abrogated prion propagation (pink arrow).
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3.3.9 Role of CC1 residues K23.K24.R25 in prion propagation 
Although PrP is located in lipid rafts and tethered to the cell membrane by a 
GPI-anchor, aspects of cellular prion protein endocytosis have been 
ascribed to CC1 in a number of ways: (i) clathrin-mediated38, (ii) interaction 
with heparan sulphate proteoglycans113, (iii) glycosaminoglycan (GAG) 
interaction102. Additionally, region 23-33 has been found to be crucial for 
interactions with dynein family members to allow correct intracellular 
trafficking250. These actions involve modulation of cell surface expression 
and recycling of the cellular protein – processes that are also critical for 
successful prion infection and eventual propagation100, 115, 251. 
Region 23-30 which is inclusive of K23.K24.R25 is believed to contribute to 
the efficient folding of PrP to its native cellular conformation117 thereby 
contributing to protein stability. Furthermore, lysine residues within region 
23-30, specifically K23.K24.K27, are required for association of PrP with 
GAGs103. With both protein instability and GAG association believed to 
promote PrPSc formation123, it is possible that mutation K23A.K24A.R25A 
dampens this reported upregulation of PrPSc formation or indeed as 
evidence from our SCA data suggests, downregulates propagation of prions 
(Figure R17).  
CC1 represents the first of two charge clusters in the prion protein, thought 
to be involved in the protein’s endocytosis38, 58, 252. It has also been ascribed 
functions of neurotoxicity modulation60, zinc regulation253, interaction with 
tubulin to inhibit microtubule formation104, in addition to being a secondary 
binding site for Aβ oligomers106, 107. PrPC-mediated cytotoxicity of Aβ 
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oligomers is thought to be dependent on the transmembrane protein, 
LRP1108. LRP1 in turn, is required for the copper-mediated endocytosis of 
PrP249 and N-terminal region 23-107 of PrP binds the transmembrane 
protein with nanomolar affinity102. 
Since CC1 plays a modulatory role in a multiplicity of processes including 
recycling of the protein38, 252, it is possible that triple mutations in this region 
may disrupt native interactions which in turn inhibit this particular aspect of 
moPrP regulation. These mutations do not however, inhibit other forms of 
moPrP trafficking achieved through its GPI-anchor254. It is clear from SCA 
data that triple alanine mutations at CC1 residues K23.K24.R25 limit, but do 
not abolish prion propagation (Figure R17). Thus, the cellular pathway(s) 
involved in propagation have contributions from segments of the cellular 
protein other than CC1, that allow for moderate propagation. 
The finding that mutations at CC1 lead to a reduction in the amount of 
ProteinaseK-resistant prion protein detected after infection (Figure R15) are 
supported by data from Turnbaugh et al., who used RML inocula to test this 
hypothesis in vivo: mice expressing moPrPΔ23-31 displayed a much lower 
susceptibility to prion infection and accordingly, accumulated lower levels of 
PrPSc114. The same laboratory also showed that part of PrP-related toxicity 
is attributed to the 23-26 region of CC1 and is uncoupled from endocytosis 
activities119. Data presented here shows that propagation is not inhibited, 
but reduced, and that higher levels of propagation can be achieved with 
increased inocula (Figure R17). 
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Curiously, KD cells reconstituted with moPrP bearing single mutations 
within the same region of CC1 (K23A, K24A and R25A) propagated prions 
as well as full-length expressors (Figure R15). Ostapchenko et al., 
discovered through deletion mutagenesis of the 23-30 N-terminal segment 
of PrP that modifications to this region can affect overall fibril morphology117. 
This may explain why point mutations in CC1 (K23A, K24A and K25A) in 
our study had no detectable propagation deficiency, whereas a larger 
replacement K23A.K24A.R25A led to a reduced propagation phenotype 
(Figure R14). It does not however, explain why mutation P26A.K27A which 
is also in region 23-30 did not exhibit reduced propagation (Figure R14). 
The data presented suggest that CC1 has a regulatory role with which the 
efficiency of PrP propagation proceeds, and that it is controlled by multiple 
residues (Figure R15). Considering the negligible effect of the single 
mutants on propagation (Figure R15), a direct interaction of moPrP residues 
K23.K24.R25 with a factor that modulates propagation is unlikely: if 
K23.K24.R25 falls within part of a recognition motif or binding site, it is 
reasonable to assume that at least one of the single mutations would mirror 
the reduced propagation phenotype of the triple mutant; this is not the case 
(Figure R15). More probable, is that mutations at K23.K24.R25 lead to the 
loss of an accessory site, or of a weak interaction (if any), that aids 
propagation such that the conversion process is not forgone in its absence, 
but merely hindered.    
It is possible that the concentration of charge at residues 23-25 (KKR) 
contributes to propagation efficiency and that loss of charge from individual 
amino acids through point mutation is not sufficient to affect propagation, 
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but cumulatively, lowers propagation capacity. Indeed, expression of the 
cellular mouse prion protein lacking residues 23-31 has been shown to 
reduce susceptibility to prion infection and reduce the levels of PrPSc that 
accumulate following infection and propagation116. This reduced 
propagation was attributed to the deletion mutant on PrPC binding PrPSc 
with a lower affinity, thereby implicating segment 23-31 as a polybasic 
region that mediates propagation116.  
In this study, the initial experimental setup did not include mutating proline 
residues at positions 26 and 28 in moPrP. Thus, the possibility that these 
residues, encompassed within region 23-31 highlighted by Turnbaugh et 
al116, also lowered propagative potential when mutated to alanine could not 
be ruled out.  Following this result, KD cells expressing P26A.K27A, and 
P28A moPrP mutations were made to determine how residues 
neighbouring region 23-25 affected propagation. Our results suggest that a 
collection of residues at the N-terminus of PrP mediate some aspects of 
prion propagation, as their substitution led to diminished propagation activity 
(Figure R14). Since P26A.K27A and P28A propagated prions as well as 
moPrPWT, it can be inferred that residues P26, K27 and P28 do not play a 
significant role in limiting prion propagation, but K23, K24 and R25 taken 
collectively, do (Figures R14 and R15).  
It is important to note that the possibility of K23A.K24A.R25A combined with 
mutation K27A (as in K23A.K24A.R25A.K27A), further limiting propagation 
capacity has not been tested. If such a finding is established, then lysine 
residues within region 23-31 are key mediators of propagation in the 23-88 
region of moPrP. The data presented here supports the argument of 
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Turnbaugh et al., and further delineates the region of interest within the 
polybasic segment of PrP, to a minimal segment of the protein: 
K23.K24.R25 that together, governs the efficacy of prion propagation.   
 
3.3.10 PROPAGATION-SUPPORTING ALANINE MUTATIONS IN MOPRP 
Just as the data from SCA analysis of K23A.K24A.R25A emphasises the 
importance of maintaining sequence identity in this region to uphold 
maximum propagation capacity, SCA data from regions of the protein that 
can be altered without lowering propagation is important in delineating 
which segments of the protein are more amenable to change. These 
include amino acids 26-38 and 43-88 in moPrP. The two sequence 
segments are separated by residue Q41, where alanine replacement Q41A 
significantly reduced propagation (Figure R17). 
Mutations made in the more N-terminal segment 26-38 included moPrPAla 
constructs P26A.K27A, P28A, W31A.N32A.T33A and S36A.R37A.Y38A. 
Lack of propagation inhibition in these mutants demonstrates that this 
region of the protein is not absolutely required for successful propagation 
and that despite the high conservation in sequence54, the prion protein has 
a high tolerance for changes in the native sequence at these positions 
(Figures R14 and R16).  
The second segment of propagation-supporting KDmoPrPAla cells, bore 
changes in region 43-88 and cover the OPR region. The result that alanine 
replacements within this region support propagation is interesting, 
considering that insertion mutations within the OPRs are linked to 
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accumulation of aggregated protein and early onset prion disease130. It may 
be reasoned that in OPRI, the increased histidine and glutamine residues 
have effects on the overall copper coordinated by PrPC and its charge 
interactions; indeed such correlations have been reported130. If this were the 
case though, we would expect that eliminating some of these influences in 
alanine mutants Q52A, Q58A, H60A, Q66A, H68A, Q74A, H76A, Q82A or 
H84, may give an indication of reduced propagation, were such factors to 
influence the efficacy of prion propagation (Figure R16). Our data does not 
support this (Figure R16): instead, the single amino acid changes made in 
this region (residues 51-88) may be too small to significantly affect copper 
coordination individually; rather, longer stretches of mutations may be 
required to see a significant effect on prion propagation as that observed for 
deletion of segment 23-88 (Figure R11). That none of the mutations in 
OPR1-OPR5 lowered the capacity for RML propagation, taken with the 
result that deletion mutation Δ23-88 did not propagate prions, suggests that 
the increased length of the flexible N-terminal chain (as in OPRI) favours 
misfolding of PrPC into a more PrPSc-like formation, as opposed to the 
chemistry of the P(H/Q)GGG(−/G)WGQ sequence in the OPR region being 
the key contributing factor for propagation. It is possible that the flexibility 
afforded by glycine residues in this region may influence prion propagation, 
as shown by Yu et al., on yeast prion protein determinant, Ure2178. Overall, 
however, it appears as though the chain length offered by the N-terminal 
portion of moPrP has a greater effect on propagation propensity than the 
individual residues in the 43-88 region of the protein. 
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FIGURE R22: OCTAPEPTIDE REPEATS IN THE PRION PROTEIN   
The prion protein usually bears five octapeptide repeats (the first being a pseudo repeat), numbered 1-5 below the OPR label. These 
are represented as circles of equal size. Within the OPR sequence Gln (Q) and His (H) residues are highlighted as potential sites for 
charge interactions where the protein may associate with cellular components within its microenvironment. Each of the highlighted 
residues has been investigated through alanine substitution to assess its contributions on propagation of prions (Q52A, Q58A, H60A, 
Q66A, H68A, Q74A, H76A, Q82A, and H84A). None of these mutations resulted in a form of moPrP that was non-convertible and each 
was able to propagate RML to the same efficacy as cells expressing the wild-type protein. 
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3.3.11 Q41 is a novel regulator of prion propagation 
moPrP residue Q41 when replaced by alanine (Q41A) displayed a 
pronounced loss in its ability to propagate RML prions (Figure R16). This 
loss is greater than that seen in K23A.K24A.R25A (Figure R17), another 
alanine mutant in the flexible region 23-88, that displayed limited 
propagation. Interestingly, alanine replacements S43A and 
S36A.R37A.Y38A, that neighbour residue 41, displayed no deficiency in 
RML propagation (Figure R16). Furthermore, none of the KDmoPrPAla-
expressing cells in regions between CC1 and Q41 and between S43 and 
W88 were hindered in their ability to propagate RML prions (Figures R14 
and R16). This delineates both regions CC1 (KKR) and Q41 as specific 
sites of interest that regulate prion propagation, through mechanisms 
thought to be charge-linked, at least for CC1116 (Figure R15).  
Codon 41, to our knowledge, has at no time been assigned any function 
with regards to PrPC or PrPSc function. At most, it lies within epitope 
QGSPGGN (moPrP 41–47) that has recently been identified in one study as 
an epitope recognised in PrPSc, but not PrPC101. Q41 also lies within a 
YPGQ sequence pattern that bears the endocytosis motif YXXQ, a 
consensus sequence for designating recruitment and activation of Stat3 
(signal transducer and activator of transcription 3), through its SH2 (Src 
Homology 2) domain255. Stat3 belongs to a family of proteins that are 
analogous to transcription factors in their actions: they translocate from the 
cytoplasm to the nucleus upon activation by cellular factors to regulate gene 
function by binding DNA elements and up-regulating specific genes. Prnp 
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has been shown to regulate Nanog mRNA expression256; both Nanog and 
Stat3 are key markers for pluripotency257, with Nanog recently shown to 
amplify Stat3 activation to synergistically induce the naïve pluripotent 
program258. Although a direct interaction of PrP with Stat3 has not been 
shown, this cooperative interaction may be of importance if PrP associates 
with Stat3, as it may regulate expression of other as yet unidentified factors 
that influence prion propagation. If an association between PrP and Stat3 is 
found, it is likely to involve Q41.  
This is the first instance where Q41 has been linked to prion propagation. 
When both N-terminal mutations Q41A and K23A.K24A.R25A were 
expressed on the same construct as K23A.K24A.R25A.Q41, there was no 
further reduction in prion propagation compared to Q41A and 
K23A.K24A.R25A expressed independently, but an averaging of their 
respective propagation phenotypes (Figure R18). The results presented 
here highlight the importance of these two segments with regards 
propagation of the prion protein. They further imply that mutations at these 
two sites, K23.K24.R25 and Q41, may impact the same propagation 
pathway, as no additive effect is observed upon expression of the changes 
on the same construct (Figure R18). Finally, they show that these mutations 
are influenced by a rate-limiting or energy-barrier phenomenon, as 
observed from the dose-dependent improvement on RML propagation 
(Figure R18).  
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3.3.12 Q41 has a stronger control over prion propagation than 
K23.K24.R25 
Region 23-25 and residue Q41 were found to reduce propagation capacity 
when substituted for alanine as K23A.K24A.R25A and Q41A (Figure R17). 
It was shown that expressing K23A.K24A.R25A and Q41A on the same 
construct did not strengthen the inhibition exerted by K23A.K24A.R25A and 
Q41A independently (Figure R18). These two changes were isolated 
instances of alanine mutations in region 23-88 of moPrP negatively affecting 
prion propagation (Figures R14 and R16).  
The data presented here suggests that N-terminal fragments 26-40 and 42-
88 can be modified without having a negative impact on propagation, but 
changes made to region 23-25 and residue 41 limit the capacity for prion 
protein propagation, by at least two- and five-fold, respectively (Figure R18).  
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None Strong Very strong N/A 
 
TABLE R3: LIST OF MOPRP ALANINE MUTATIONS IN REGION 23-88 OF THE PROTEIN. 
All moPrP mutations expressed in KD cells propagated RML as well as the full-
length protein, and displayed no limitations on propagation. Exceptions to this 
general trend in region 23-88 include K23A.K24A.R25A, Q41A, and 
K23A.K24A.R25A.Q41A, which are indicated as having a strong lack of 
propagation when challenged with RML prions (lighter bar: strong inhibition of 
propagation). 
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3 . 4  C h a r g e  c l u s t e r  2  r e p l a c e m e n t s  r e d u c e  
p r i o n  p r o p a g a t i o n  
3.4.1 Experimental strategy 
The N-terminal deletion in moPrP Δ23-88 abrogated prion 
propagation (Figure R11). Minimal mutations were made 
within the 23-88 segment, which lies in the 23-111 flexible 
region of the protein (Figure R23), to determine which 
residues play a role in limiting propagation (Section 3.3). 
The mutagenesis approach used in this study was 
extended to the entire unstructured region of the protein 
(23-111).  
 
Alanine mutations were made from residue 90-111 in moPrP, to include: 
Q90A, T94A.H95A.N96A, Q97A.W98A, N99A.K100A, S102A.K103A, 
K105A.T106.N107A, L108A.K109A and H110A.V111A. This domain of the 
protein has a high concentration of charged residues and is known as the 
second charge cluster (CC2). 
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FIGURE R23: PDB ENTRY 2LEJ HUMAN PRP HIGHLIGHTS THE FLEXIBILITY OF N-
TERMINAL REGIONS 
The human prion protein is shown with CC2 region 90-111 in black; GSS-linked 
mutations which are within the CC2 region at positions P102 and P105 (human 
numbering) are shown in yellow and the remainder of the protein depicted in 
purple. The image was rendered in RasMol software and highlights the flexibility of 
the N-terminus as it is able to adopt all conformations shown. Image lines were 
smoothened in Photoshop.  
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3.4.2 Charge cluster 2 mutations significantly influence prion 
propagation 
KD cells reconstituted with the eight alanine replacements in moPrP (Q90A, 
T94A.H95A.N96A, Q97A.W98A, N99A.K100A, S102A.K103A, 
K105A.T106.N107A, L108A.K109A and H110A.V111A) were assayed for 
their ability to propagate RML prions alongside KD cells reconstituted with 
W88A and the moPrPWT by SCA (Figure R24). 
In stark contrast to W88A, mutation Q90A, and every alanine replacement 
C-terminal to this, exhibited very limited capacity to propagate prions at the 
three time points sampled (Figure R24). There was a sharp distinction 
between altering residues at position 88 and position 90 in moPrP and their 
effects on prion propagation (Figure R24). While KD cells reconstituted with 
moPrP W88A consistently exhibited spot numbers higher than eight 
hundred – full propagation, those reconstituted with any of the eight alanine 
replacements within CC2 gave spot numbers of less than one hundred – 
severely limited propagation (Figure R24). The highest spot count for a 
mutation within CC2 region was 90 spots for N99A.K100A at split 6 (Figure 
R24).  
The degree by which propagation was reduced in KD cells reconstituted 
with CC2 alanine mutants Q97A.W98A, S102A.K103A and H110A.V111A 
was almost as severe as that observed for KD cells reconstituted with Δ23-
88 (Figure R10) and non-reconstituted KD cells (Figure 24).  
178 
 
 
FIGURE R24: SCA OF KDMOPRPALA CELLS; MOPRP MUTATIONS IN REGION 90-111 
KD cells reconstituted with either moPrPWT or alanine mutants of the protein within 
region 88-111 were challenged with RML prions at a 1x10-5 dilution of infectious 
homogenate and their ability to propagate these prions assayed via SCA at three 
consecutive time points. All alanine substitutions made within region 90-111 
exhibited markedly reduced propagation profiles, compared to moPrPWT and single 
amino acid change W88A. Significance is indicated by ‡ for P ≤0.0001. 
Significance only shown for split 6 for clarity; calculated in a one-way ANOVA with 
a Bonferroni correction for multiple comparisons. 
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Compared to mutations made in more N-terminal domains, CC2 mutations 
have a stronger effect on limiting prion propagation than alanine 
substitutions at CC1 residues K23.K24.R25 or Q41 (Section 3.3). To test 
whether propagation of CC2 alanine mutants can be improved with an 
increase in infectious inoculum, as observed for K23.K24.R25 and Q41 
mutations (Figure R17), the dose of RML was increased ten-fold (Figure 
R25). Remarkably, and unlike the more N-terminal mutations K23.K24.R25 
and Q41, increasing the concentration of infectious inocula had very little 
effect on recovering the limited propagation of KD cells expressing CC2 
alanine mutations (Figure R25). All CC2 replacements tested gave spot 
numbers lower than one hundred, with the exception of mutation 
N99A.K100A which reported just over two hundred spots at split 6 (Figure 
R25). N99A.K100A represents the only mutation made in region CC2 that 
gave spot numbers in the two hundreds at RML dilutions of 1x10-4 (Figure 
R25). This is a two-fold increase in spot number, following a ten-fold 
increase in inocula – similar to the propagation profile observed for mutation 
Q41A (Figure R17). All mutations made in CC2 other than N99A.K100A 
resulted in spot numbers fewer than one hundred at RML dilutions of 1x10-4 
and 1x10-5 (Figures R24 and R25). Thus, all mutations within CC2 had a 
stronger influence on prion propagation than CC1 mutations 
K23A.K24A.R25A or Q41A, as tested by SCA in this study (Figures R17, 
R24, and R25). 
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FIGURE R25: SCA OF KDMOPRPALA CELLS; MOPRP MUTATIONS IN REGION 90-111, 
INCREASED RML 
KD cells reconstituted with either moPrPWT or alanine-mutant variants of the protein 
within region 88-111 of moPrP were challenged with RML prions at a 1x10-4 
dilution of infectious homogenate and their ability to propagate these prions 
assayed via SCA at three consecutive time points. This is a ten-fold higher dose of 
inocula compared to that used in Figure R20. All replacements C-terminal to and 
including Q90A, exhibited a significant reduction in their ability to propagate RML 
when compared to moPrPWT and W88A. Of the 90-111 region alanine mutations, 
N99A.K100A exhibited the highest propagation capacity. Significance is indicated 
by ‡ for P ≤0.0001. Significance only shown for split 6 for clarity; calculated in a 
one-way ANOVA with a Bonferroni correction for multiple comparisons. 
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3.4.3 Do CC2 mutations support prion propagation? 
Mutating CC2 residues to alanine resulted in cells that had severely 
compromised propagation (Figure R24). Additionally, the propagation 
phenotype was only improved slightly, by a ten-fold increase in inoculum; at 
the most it was doubled (Figure R25). All replacements within region 90-111 
inhibited prion propagation as tested under standard SCA conditions (Figure 
R24). Although spot numbers for the CC2 mutants tested were below one 
hundred, they were marginally above the negative control KD cells (un-
reconstituted). This would indicate that the spots observed are not residual 
inocula, but generated de novo, and the slight increase by split 6 is 
indicative of a propagative trend; however, such a significant reduction in 
propagation is within the range of severely limited propagation and 
complete abrogation of propagation (Figure R12). This finding could mean 
that: (i) a very small proportion of cells within these mixed populations can 
propagate unhindered; or (ii) the cells are capable of propagation, but on a 
much slower time-scale such that cell division out-competes prion 
replication. Thus, since spot numbers fall below one hundred they must be 
defined as mutations that abrogate prion propagation based on the template 
used for SCA output guidelines in this study (Figures R12). 
Furthermore, cell lines that propagate RML efficiently consistently give spot 
numbers above eight hundred by split 6 (Figure R12; Figure R25). By this 
criterion none of the alanine mutations within CC2 support full prion 
propagation. This includes single (Q90A), double (Q97A.W98A, 
N99A.K100A, S102A.K103A, L108A.K109A and H110A.V111A) and triple 
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substitutions (T94A.H95A.N96A and K105A.T106.N107A). This indicates 
that within the flexible tail of the protein (residues 23-111), there are three 
segments which limit propagation in increasing order of their position in 
sequence, such that CC2 mutations (region 90-111) restrict propagation to 
a greater extent than Q41, which in turn has a lower capacity to propagate 
prions than CC1 mutation K23A.K24A.R25A.  
3.4.4 Cells expressing CC2 mutations in moPrP are viable 
Deletion of region 105-125 in the mouse prion protein has been associated 
with neurotoxicity and neonatal lethality when expressed in vivo259. In 
cultured cells, this deletion confers hypersensitivity to the drug G418 and 
induced spontaneous ion channel activity172. Here, much more conservative 
changes were made to the protein, up to a maximum of three amino acid 
replacements. None of the moPrP alanine mutations in region 90-111 
resulted in toxicity when expressed in KD cells. Furthermore, none of the 
cells expressing these CC2 alanine mutations displayed any obvious 
morphological differences from their parental PK1 and KD cells (Figure 
R26).  
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FIGURE R26: KDMOPRPALA CELLS; MUTATIONS IN REGION 90-111, PHASE CONTRAST 
IMAGES 
Phase contrast images of control cells in the top panel: PK1 cells that express 
endogenous moPrP; KD cells are PK1 cells in which moPrP expression has been 
silenced. pLNCX2 represents KD cells transduced with the empty vector. All other 
cells shown are KD cells reconstituted with moPrP and mutants thereof, using the 
pLNCX2 vector. K23A.K24A.R25A, Q41A and their combined mutant 
K23A.K24A.R25A.Q41A, represent mutations in region 23-88 that reduce 
propagation. W88A is shown as an example of a mutant that propagates RML 
prions efficiently and has a similar morphology both to control cells and the CC2 
region replacements that limit propagation, shown in the bottom two panels. 
Magnification at x20.  
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3.4.5 Lack of propagation in moPrP mutations within the CC2 region 
is not due to lack of protein expression or cell-surface localisation 
Just as protein expression was verified for moPrP mutants 
K23A.K24A.R25A and Q41A, KD cells reconstituted with moPrP bearing 
alanine mutants within the CC2 region were analysed for prion protein 
expression by immunoblotting (Figure R27). All reconstituted lines 
expressed moPrP above KD levels (Figure R27). Furthermore, similar levels 
of protein expression as that seen in CC2 mutations were seen in mutation 
W88A; this level of expression was sufficient for RML propagation (Figures 
R19 and R27). 
Next we examined cell surface expression by immunofluorescence.  All 
cells expressing moPrP with substitutions in region 90-111 expressed 
moPrP at levels above that of KD cells and at levels comparable to PK1 
cells and KD cells reconstituted with moPrPWT (Figure R28). The level of 
protein expression between mutant lines was similar, both by 
immunoblotting and immunofluorescence analysis (Figures R27 and R28). 
Slight variances in expression level such are not unusual, due the 
heterogeneous nature of bulk cultures (Figures R27 and R28). 
Although KD cells reconstituted with mutations W88A and Q97A.W98A 
displayed lower levels of expression than PK1 and CC2 alanine mutations, 
they were still above KD levels (Figure R27). As for mutation N99A.K100A, 
which reported higher spot numbers in SCA that are indicative of better 
propagation, KD cells reconstituted with this construct did not have 
significantly higher expression levels than cells expressing moPrPWT or 
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other alanine mutations of moPrP within CC2 (Figure R27). Despite this 
difference, N99A.K100A is not a bona fide propagator, as it exhibits severe 
limitations on propagation (Figures R12, R24 and R25), indicating the whole 
stretch of residues within CC2 is important for efficient prion propagation 
and that residues either side of 99-100 have a stronger inhibition on 
propagation within CC2 than residues 99-100. Together, these experiments 
show that residues within the N-terminal domain of the mouse prion protein 
– specifically amino acids within region 90-111 – have a strong impact on 
prion propagation. The results presented argue that substitutions made in 
the CC2 region 90-111 limit propagation to a greater extent than those 
observed for more N-terminal residues K23A.K24A.R25A and Q41A 
(Section 3.3). Interestingly however, a larger modification N-terminal to 
position 90, namely Δ23-88, exhibited the same level of restriction on 
propagation as CC2 alanine-mutants (Figures R11 and R24). This deletion 
mutation consistently gave spot numbers below one hundred – a result 
comparable to KD cells and KD cells transduced with the empty vector 
(negative controls) and shown here, to KD cells reconstituted with moPrP 
bearing CC2 alanine mutations (Figure R24).  
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FIGURE R27: WESTERN BLOT OF KDMOPRPALA CELLS WITH MUTATIONS IN CC2  
Immunoblot of PK1, KD and KD cells reconstituted with moPrP bearing alanine 
mutations within region 88-111. 35μg of protein was loaded per well of a 16% Tris-
Glycine gel which was run for 90min at 200V; a biotinylated form of antibody 
ICSM35 (ICSM35b) was used to detect moPrP; goat anti-mouse Streptavidin 
conjugated to HRP was used as the secondary antibody, followed by ECL 
development. 3 min exposure. 
187 
 
188 
 
 
FIGURE R28: IMMUNOFLUORESCENCE IMAGES OF KDMOPRPALA CELLS WITH 
MUTATIONS IN CC2 
 
Immunofluorescence analysis of KD cells reconstituted with CC2 alanine mutants 
of moPrP. The top panel represents control cell lines: PK1 cells that express 
endogenous moPrP; KD cells in which expression of the endogenous protein is 
silenced; KD cells reconstituted with full-length moPrP and with moPrP deletion 
mutation Δ23-88.  The second and third panels show KD cells reconstituted with 
moPrP bearing minimal alanine mutations within the CC2 region. moPrPAla is 
detected in these cell lines at the cell surface, following the same localisation 
pattern as KDmoPrPWT on non-permeabilised cells. Blue: DAPI nuclear stain; 
green: moPrP. Magnification at x40. 
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3.4.6 Minimal mutations in prion protein CC2 significantly reduce 
prion propagation 
SCA analysis of N-terminal alanine mutants of the prion protein revealed a 
distinct segment that when altered, markedly reduced prion propagation 
capacity. This included point, double and triple mutations made within 
region 90-111 of moPrP. Charge cluster (CC2) region 90-111 on PrPC along 
with a smaller more N-terminal charge cluster (CC1) have been shown to 
interact with PrPSc133.  The data presented here shows that CC2 mutations 
strongly inhibit propagation – more so than CC1 or Q41 mutations (Section 
3.3). 
SCA data showed that KD cells expressing mutation W88A gave spot 
numbers in the thousands (Figure R24), comparable to propagation profiles 
of KD cells reconstituted with the wild-type protein; this is in stark contrast to 
cells expressing mutation Q90A, where spot numbers remained below one 
hundred for all splits (Figure R24). This suggests that depending on position 
in the sequence, PrP can tolerate small modifications without greatly 
diminishing the protein’s ability to convert PrP to a ProteinaseK-resistant 
form, following infection by RML prions. Every alanine replacement made C-
terminal to residue W88 exhibited a profoundly reduced ability to propagate 
prions, compared to those tested N-terminal to this site (Figures R14, R16 
and R24).  
The data shows that modifications within region 90-111 as small as single 
replacements (Q90A) and up to three replacements within the native 
sequence with alanine (K105A.T106A.N107A) severely diminish the ability 
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of cells expressing the modified protein (moPrP with minimal replacements 
in CC2) to efficiently propagate prions (Figure R24).  
Since all eight mutations made within CC2 segment 90-111 resulted in 
greatly reduced propagation at two concentrations of infectious inocula 
(Figures R24 and R25), we propose that this charge cluster represents an 
important region regarding native and aberrant PrP function. Whether the 
changes made led to a loss or gain of function phenotype, or whether it is 
linked to the binding of accessory proteins remains to be investigated. 
The second charge cluster (CC2) divides the OPRs from the conserved 
hydrophobic region of the protein (Figure R23). CC2 is purported to have a 
myriad of interaction partners: Aβ58, 105, 107, 139, metal ions37, 59, as well as 
undergoing self-association260. The interaction of CC2 with multiple partners 
may be attributed to the concentration of positive charge at this site. 
Additionally, the ease of interaction at CC2 could stem from the lack of 
steric restriction due to its glycine-rich, flexible N-terminal domain261. It is 
possible that the alanine mutations made within region 90-111 of moPrP 
disrupt interactions of this domain with native interactors or aberrant 
associations that the native CC2 sequence would engage in following RML 
infection; this could explain the severely reduced propagation observed for 
all mutations in this region (Figure R24). 
Earlier work on analysis of PrP function where deletion mutagenesis was 
employed to infer amino acid contributions produced conflicting results: 
transgenic mice overexpressing moPrP with deletions Δ32-80 or Δ32-93, 
developed disease, propagated prions and accumulated ProteinaseK-
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resistant prion protein, following inoculation with prions48. However, in the 
case of deletion mutation Δ32-93 longer incubation times were reported, but 
propagation and disease ensued, suggesting that segment 32-93 was not 
required for propagation48. When the deleted segment was widened to 
encompass residue 106 however (Δ32-106), no prion propagation was 
observed128.  
The toxicity elicited by PrP deletion mutants has been studied extensively in 
vivo and points to the removal of the flexible region, especially deletions in 
CC2 and HC domains, as the principal contributors to the elicited 
neurotoxicity115, 173. It is important to note that since a majority of the studies 
carried out in this region resulted in toxicity, previous efforts to study the 
individual contributions of amino acids within this segment was not always 
possible. Since then, many laboratories including ours have attempted to 
further characterise individual segments of the protein essential for the 
efficient propagation of prions, and found increasing evidence for a role of 
the N-terminus of PrP in prion propagation116, 134. Here, a range of viable 
cell lines expressing moPrPAla have been established, with which specific 
functions of CC2 can be investigated; the focus in this study being primarily 
prion propagation following RML infection.  
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FIGURE R29: HUMAN AND MOUSE PRION PROTEIN SEQUENCE; REGION CC2 
Panel A depicts the position and residues on prion protein structure PDB entry 2LEJ (huPrP) at which CC2 mutations to alanine were 
made in this study; these are outlined in green with side-chains shown as sticks on a grey protein backbone. As 2LEJ represents the 
human protein, the sequence composition varies from moPrP, which is the PrP isoform used in this study. Sequence differences 
between huPrP and moPrP are depicted in panel B, with the CC2 region (90-111 moPrP) in blue lettering. Sequence variation at CC2 
occurs at positions 96 (S/N), 109 (M/L) and 111 (M/V).  
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3.4.7 CC2 is a solvent-exposed region of the prion protein with 
multiple interactors  
CC2 is an important domain in the flexible region of the prion protein for a 
number of reasons: (i) point mutations within this region (P102 and P105; 
human numbering) are known to be associated with Gerstmann-Sträussler-
Scheinker (GSS) forms of prion diseases. (ii) it is a highly immunogenic 
segment in the protein exemplified by the number of antibodies to which this 
region is epitope-mapped. This includes anti-prion antibody ICSM35 used 
for immunoblotting in this study (Table R4). (iii) CC2 is cited in the literature 
as interacting with a range of proteins or peptides: Aβ105, LRP1102, 249, 
vitronectin262, 14-3-3263, self-association264 as well as participating in metal 
ion binding37. (iv) CC2 is also believed to regulate prion protein conversion 
through residues 100-104134. (v) Novitskaya et al., have shown using an 
immunoconformational assay, that segment 95-105 is a solvent exposed 
region82, which explains antibody access to this epitope137, 151 and reports of 
multiple protein interactions102, 105, 249, 262; this also correlates well with 
ProteinaseK-sensitivity of this region in PrPC201. The flexibility of CC2 
combined with the concentration of charge at this site makes it an effective 
interaction surface. This study supports the involvement of CC2 in prion 
propagation, as point, double and triple mutations to alanine in this region 
negatively and significantly lowered prion protein propagation (Figure R24).  
KD cells reconstituted with moPrPWT propagated RML efficiently at a 1x10-5 
dilution of homogenate (Figure R24), but in KD cells reconstituted with 
moPrP bearing CC2 alanine mutations, propagation was significantly 
reduced in comparison (Figure R24). All eight mutations made in this region 
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(Q90A, T94A.H95A.N96A, Q97A.W98A, N99A.K100A, S102A.K103A, 
K105A.T106.N107A, L108A.K109A and H110A.V111A) demonstrated a 
ten-fold lower response to RML propagation compared to the wild-type 
protein (Figure R24).  
Additionally, a ten-fold increase in the dose of infectious inocula did not 
improve the limited capacity of mutations within region 90-111 to propagate 
prions, with the exception of N99A.K100A (Figure R25). This mutation 
showed a two-fold increase in propagation when more inoculum was made 
available (Figure R24 and R25). Cells expressing CC2 alanine mutations 
displayed similar morphology (Figure R28) and protein expression levels 
compared to PK1 wild-type cells and KD cells reconstituted with the wild-
type protein (Figures R27 and R28). This suggests that the loss of 
propagation in these cells is due to the mutations in moPrP harboured 
within CC2 and not due to lack of protein expression. These data provide 
strong evidence for a modulatory role of the second charge cluster of PrP in 
prion propagation. A myriad of possible PrP-interactions may have been 
compromised when moPrP was expressed with alanine mutations in CC2 
region 90-111. Such disruption in native interactions could have contributed 
to the loss of propagation phenotype observed for these mutations when 
expressed in KD cells (Figures R24 and R25). 
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AB5058 78-97 Sanchez et al.
265 
12B2 89-93 Yull et al.
266 
6D11 93-109 Pankiewicz et al.
136 
P4 93-99 Harmeyer et al.
267 
12B2 93–97 Jeffrey et al.268 
POM3 95-100 Polymenidou et al.
151 
8G8 97-102 Féraudet et al.
269 
9A2 102-104 Yull et al.
266 
PrP-AA 106–110 Wei et al.135 
3F4 109-112 
Zomosa-Signoret et 
al.270 
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ICSM 35 93–105 
Khalili-Shirazi et al.137 
ICSM 37 96–105 
ICSM 42 96–105 
ICSM 54 96–105 
ICSM 61 96–105 
ICSM 62 96–105 
 
TABLE R4: ANTIBODIES AVAILABLE AGAINST PRP REGION CC2 
A vast array of antibodies available against the CC2 region of the protein are 
summarised here. The top half of the table shows antibodies generated from a 
range of immunogens, while the bottom half shows antibodies generated within the 
MRC Prion Unit using recombinant human PrP (with a high β-sheet content). 
ICSM35 used in this study, was generated using recombinant human PrP (high β-
sheet content) as the immunogen. 
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Since the effects of mutating region CC2 affected propagation so 
dramatically, the data suggests that the entire region is required for efficient 
propagation, and not just a segment within it. Additionally, if the requirement 
for CC2 in propagation was only partial, we would expect propagation to 
improve at least gradually if not drastically as seen for W88A versus Q90A, 
with mutations made further from a hypothetical ‘minimal site’. The only 
indication that differences in propagation existed within the CC2 region, was 
observed for N99A.K100A at a higher dose of inocula (Figure R24 and 
R25), indicating that these two residues are more tolerant of changes to the 
native sequence than amino acids either side of it. Despite the improvement 
in propagation seen for KD cells reconstituted with the N99A.K100A 
mutation in moPrP when infected with more inoculum (Figure R25), the 
ability of these cells to propagate RML was severely compromised 
compared to cells expressing the wild type protein (Figure R25). 
It could be hypothesised that a key step in the prion propagation pathway is 
modulated by segment 90-111 and that the drop in propagation observed 
for CC2 mutants in this study, is due to a single or combined effect of 
disruption in the prion propagation pathway. Such an event may be 
endocytosis of the cellular protein, which has previously been linked to 
charge clusters in the N-terminal region of the prion, either through GAG 
binding113, LRP1102, 108, 271 , or other interactions. Conversion of PrPC to 
PrPSc has been shown to occur at the plasma membrane both in cell 
culture100 and in vivo272. PrPSc reportedly forms string-like structures at the 
cell surface where it is retained for prolonged periods before eventual 
internalisation by unknown mechanisms251. Following conversion, PrPSc 
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must be internalised if propagation is to be maintained. This is established 
through accumulation of PrPSc in early and recycling endosomes for 
sustained infection273. The accumulation of PrPSc is believed to affect 
recycling of the cellular protein, a feature which may be perturbed in CC2 
alanine mutants of moPrP38. It could be argued that if cell surface 
conversion occurs, the need for endocytosis is negated for propagation. 
However, for the PrPSc to spread to neighbouring cells, internalisation and 
recycling of both PrPC and PrPSc are required273. CC1 alanine mutations in 
moPrP may alter the clathrin-mediated pathways for PrPC endocytosis, but 
not those mediated through copper association or GPI-dependent 
pathways254. This may explain why a reduction in propagation is observed 
for CC1 mutations, but also why it is not abrogated as other compensatory 
mechanisms may enable propagation with reduced efficiency (Section 3.3). 
Laurén et al. used deletion mutagenesis to outline region 95-105 of moPrP 
as the site of Aβ oligomer binding105. This finding has since been supported 
by biophysical characterisation of the binding epitope132. The significance of 
this binding has implications on how the two proteins regulate one another 
in terms of endocytosis274, neurotoxicity108 and synaptic plasticity105. PrPC 
has been shown to bind the metabotropic glutamate receptor 5 (mGluR5)61.  
The complex of Aβ oligomers with PrPC activates mGluR5-mediated 
calcium influx leading to compromised neuronal function61. It is interesting to 
consider that both prion disease and Alzheimer’s disease arise from protein 
misfolding events and yet Aβ oligomers associate with the cellular form of 
PrP. It is possible that the aberrant forms of these proteins activate similar 
toxicity-inducing pathways that culminate in neuronal cell death. Through 
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association of Aβ with PrP and vice versa, these proteins may regulate the 
amount of misfolded protein in the cytosol to protect the cell from, or 
exacerbate the effects of the amyloid cascade hypothesis12. In terms of 
PrP’s interaction with Aβ oligomers, it is known that a smaller segment (95-
105) within region 90-111 is involved in this association105. Since CC2 
residues 90-111 have also been shown to be implicated in the regulation of 
prion propagation in this study, it is possible that the native contacts in CC2 
amino acids are unavailable for association in the PrPSc state, which may 
explain findings of Aβ interaction with PrPC and none reported for its 
association with PrPSc. The range of mutations in PrPC generated in this 
study can be used for future applications to further probe the PrP-Aβ 
interaction and subsequent cellular outcomes. 
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3.4.8 Minimal segment required for efficient prion propagation 
extends beyond a five-amino acid sequence (100-NKPSK-104) 
Another group that undertook a mutagenic approach to identify regions 
required for prion conversion identified region 100-104 as the minimal 
segment responsible for the conversion of PrPC to PrPSc134. They carried 
out their investigation exclusively in N2a and chronically Scrapie-infected 
N2a cells. The authors reported no loss in propagation when moPrP 
sequence 95-98 was replaced by equivalent residues in the chicken 
homolog. However, they focused their study on region 92-107 of the protein 
on the premise that anti-prion antibodies raised against this region of the 
protein show differential binding activities for PrPC and PrPSc134.  
Furthermore, they proposed that their interest in this region also stemmed 
from the fact that it is a heterogeneous and flexible region of the protein 
found in the N-terminal end after ProteinaseK digestion of PrPSc275. 
Moreover, they stated that their data supports previous reports on moPrP 
region 89-103 and 105-114 as not being the major interface for the initial 
binding and propagation of PrPSc, but rather playing a role in the conversion 
event134.  
The finding that CC2 residues 100-104 in particular govern prion conversion 
is extremely relevant in the context of this study; it is also both in agreement 
and conflict with the data presented here: firstly, our data is in support of the 
hypothesis that region 100-104 is crucial for efficient prion propagation, but 
it also shows a strong case for the involvement of CC2 as a region that 
extends beyond 100-104 at both termini (region 90-111) to regulate 
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propagation (Figures R24 and R25). The disparity that arises between our 
data set and that of Hara et al. may be down to technical differences.  Hara 
et al. performed their investigation on a chimeric construct consisting of 
mouse PrP substituted for a chicken PrP sequence, tagged with a 3F4 
epitope134. Chicken residues replaced mouse PrP at sequence sections 95-
104. Our study in contrast, is based exclusively on moPrP, with minimal 
alanine replacements made throughout the protein in a more non-targeted 
approach.  
It is important to be mindful of the fact that Hara et al. tested the effects of 
their mutations in the presence of the endogenous protein whereas the SCA 
analysis performed in this study reports propagation of the expressed 
moPrPAla protein without the influences of the endogenous protein (Section 
3.2). Data presented here shows that prion protein region CC2 can mediate 
propagation at the highest dose of inocula applied (RML 1x10-4), as tested 
in eight CC2 mutations (Figures R24 and R25).  
What this finding highlights is that single, double and triple alanine 
replacements within region 90-111 are able to limit the degree of 
propagation following infection. It further delineates position 90 as a strong 
regulator of propagation in the flexible region of the protein – stronger than 
previously identified more N-terminal regions CC1 and Q41 (Section 3.3). 
Additionally, mutational effects were recorded in the absence of tagged 
constructs and with maximal sequence identity to increase sensitivity for 
detection of propagation; in this system, detection is further improved 
through the use of PK1 cells which are highly sensitive to infection with RML 
prions97. 
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3.4.9 Influences of the flexible amino-terminal region of the prion protein on 
propagation capacity 
The minimal mutagenesis approach adopted in this study has identified 
region 90-111 within the flexible N-terminal tail of the protein as having 
strong influences on propagation. Eight constructs of moPrP were 
generated, each bearing mutations to alanine within the CC2 sequence. KD 
cells reconstituted with any of the eight alanine moPrP constructs 
generated, showed significant changes in propagation of RML prions 
(Figures R24 and R25).  
In every instance of a CC2 alanine-mutation, prion propagation was 
severely compromised in cells expressing the mutated protein (Figure R24). 
Increasing the dose of infectious inocula did not restore the propagation of 
cells expressing the CC2 mutations in moPrP, to levels comparable with 
moPrPWT-expressing cells (Figure R25). That single, double and triple 
replacements within the flexible tail of the protein can have such a strong 
limiting effect on overall protein propagation is remarkable.  
The data further suggests that despite the C-terminal core being the 
essential component of the prion protein required for propagation88, 157, 160, 
161, 206, 276, the flexible N-terminal tail is a major player in the process that 
governs the efficiency with which propagation is achieved. The level of 
inhibition alanine mutations exerted on propagation capacity was stronger 
for mutations made more C-terminal to the signal sequence (residues 1-22); 
that is, CC2 mutations (region 90-111) exert stronger control over prion 
propagation than the more N-terminal residue Q41, which in turn has more 
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influence on propagation than CC1 amino acids K23.K24.R25 at the 
extreme N-terminus (Section 3.3).  
The significance of prion protein region CC2 is widely covered in the 
literature in the context of Aβ-linked neurotoxicity/neuroprotection107, 139, 
toxicity following PrPSc infection259 and in toxic PrP mutants115. Here, we 
show that minimal alanine substitutions (up to three amino acid 
replacements) in the 90-111 region of the protein do not give rise to toxic 
mutants and are well-expressed in KD cells (Figure R28). In terms of 
efficient prion propagation, CC2 is intolerant of changes, however minimal, 
to its native sequence: single replacement Q90A significantly reduced 
propagation compared to cells expressing the wild-type protein (Figure 
R24). Q90A defines the most N-terminal position in the flexible N-terminal 
tail of the protein that shows a ten-fold reduction in protein propagation, as 
W88A did not reduce propagation relative to moPrPWT-expressing cells 
(Figures R24 and R25). 
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TABLE R5: LIST OF MUTATIONS MADE WITHIN CC2 
List of mutations made within charge cluster 2 of the mouse prion protein. Native 
residues at these positions were changed to alanine and the modified protein 
expressed in KD cells to test the effect of the mutations on prion propagation. All 
cells expressing moPrP mutations within CC2 exhibited a very strong reduction in 
their ability to propagate RML prions in the scrapie cell assay. (N/A: not applicable). 
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3.4.10 Summary of mutations at moPrP region 90-111 (CC2) 
Single substitution Q90A, double replacements Q97A.W98A, N99A.K100A, 
S102A.K103A, L108A.K109A, H110.V111A and triple replacements 
T94A.H95A.N96A, K105A.T106A.N107A all markedly lowered the ability of 
KD cells expressing these mutations to propagate prions (Figure R21). This 
suggests that the entirety of CC2, region 90-111 inclusive, plays an 
important role in the efficiency with which prion propagation occurs. Notably, 
minimal perturbations in this segment of the protein, like Q90A, have a 
significant effect on the overall propagation pathway. This strengthens the 
evidence in favour of CC2 as having a strong controlling effect on 
propagation efficacy. 
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3 . 5  T a r g e t e d  m u t a t i o n s  i n  t h e  s t r u c t u r e d  
r e g i o n  n e g a t i v e l y  i m p a c t  p r i o n  p r o p a g a t i o n  
3.5.1 Experimental strategy 
The aim of this study was to identify regions within the prion 
protein that are important for the efficient propagation of 
prions. The prion protein has a long flexible N-terminal tail 
which constitutes roughly half the protein sequence. The 
other half of the protein is a C-terminal globular portion, for 
which structural information is available from X-ray 
crystallography and NMR data deposited in the protein data 
bank: http://www.pdb.org/pdb/home/home.do. Using the 
available structural information, targeted mutations were 
made within the structured region of moPrP at solvent-
exposed residues. Triple alanine substitutions were made, 
with the intention of altering a small portion of spatially 
proximal surface residues. Each of these moPrP constructs 
was then sequence verified in pBluescriptSK+ vector, 
moved into pLNCX2, and stably expressed in KD cells as 
described in Chapter I.  
They were then assayed for prion propagation by SCA. By targeting clusters 
of mutations at various sides of the protein surface, we investigated which 
‘face’ or ‘faces’ of the protein were crucial for prion propagation (Figure 
R27). In addition to the alanine substitutions at the protein surface, a few 
other amino acid replacements were made within the buried hydrophobic 
core of moPrP to destabilise the protein and promote unfolding. The effects 
of such modifications on prion propagation were then analysed by SCA.  
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FIGURE R30: TARGETED MUTAGENESIS OF THE STRUCTURED REGION OF MOPRP 
Solvent-exposed residues within the structured region of PrP were targeted for 
alanine mutagenesis. The sphere represents the globular, structured domain of 
PrP (residues 121-230). Triangles labelled 1-6 represent six moPrP constructs, 
each with three alanine substitutions (filled circles) that are spatially proximal. 
Using this approach, we tried to generate sufficient substitution mutants to cover 
multiple faces of the protein.  
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Surface mutations on moPrP can be categorised as those targeting: (i) α-
helices, (ii) loop regions and (iii) β-strands. Two destabilising mutations 
created in moPrP were M204A and double mutation C178A.C213A. The 
unfolding mutation M204Q.M205Q.V209Q.M212Q was designed to 
introduce charge residues within regions of the protein that are usually 
buried within the hydrophobic core, so as to disrupt native folding of the 
protein. All SCA experiments in this chapter were carried out using RML 
prions at a 1x10-5 dilution of 10% homogenate. 
 
3.5.2 Substitution of native residues for alanine between the first β-
sheet strand and the first α-helix of moPrP compromise prion 
propagation 
The globular domain of PrP has three α-helices and two β-strands. 
Mutations made within and bordering β1 and α1 include 
G123A.L124A.G125A, just N-terminal to the first strand of the anti-parallel 
β-sheet; M128A.Y162A.Q216A which affects residues at both β-strands and 
a neighbouring residue in the third helix; L129A.S131A.Q159A which 
targets amino acids at the first β-strand and those in the vicinity of β1 and 
β2; S134A.R135A.M153A includes two amino acids at the loop region 
between the first β-strand and α-helix, as well as a nearby amino acid within 
α1;  H139A.G141A.D146A mutations bear changes in the loop region N-
terminal to, and within, α1; D142A.W144A.E145A and 
R147A.R150A.E151A are exclusively α1 mutations within the moPrP 
sequence (Figure R32). 
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FIGURE R31: MOPRP STRUCTURED REGION; RESIDUES 123-151 
Bar schematic of domains within moPrP. N-SS: N-terminal signal sequence; CC1: charge cluster 1; OPR: octapeptide repeat region; CC2: charge 
cluster 2; HC: conserved hydrophobic region; α1: helix 1; β1: strand 1; α2: helix 2; α3: helix 3; SS-C: C-terminal signal sequence. Residues 126-
151 of moPrP are shown in single letter amino acid code; M/V polymorphisms known to influence susceptibility to prion disease are at position 128 
(red). PDB entry 2L39 of moPrP. 
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These mutations were generated as described in Chapter I and stably 
expressed in KD cells. Their propensity for propagating prions was analysed 
via SCA, using RML as the infectious inoculum (Section 3.2). None of the 
mutations tested fully propagated RML prions based on the SCA guide 
(Figure R12) when compared to cells expressing the wild-type protein; each 
mutation presented spot numbers below two hundred (Figure R33, R36 and 
R39).  
SCA analysis of KD cells reconstituted with moPrPWT consistently gave 
values approaching or above eight hundred spots at split 6 following RML 
infection. This is a good indication of efficient prion propagation (Figure 
R12). For the alanine mutants tested in region 123-159, the highest 
recorded average count was one hundred spots (Figure R33). This ten-fold 
reduction in the ability of KD cells reconstituted with these mutations to 
propagate prions highlights the importance of these solvent-exposed amino 
acids in prion propagation. Region 123-151 therefore represents a portion of 
the prion protein that when mutated, significantly reduces the ability of 
susceptible cells to propagate prions (Figure R33). 
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FIGURE R32: TARGETED SITES FOR MUTATIONS IN REGION 123-151 OF MOPRP  
Mutations targeted to the surface of the globular domain on moPrP are depicted on PDB entry 2L39, shown in full in the top left corner, 
showing two β-strands and three α-helices with a surface outline. Areas of the protein that were not targeted for mutagenesis are 
shown in light grey; where residues have been mutated, areas are shown in any colour other than grey. Following this entry are various 
positions on the protein where targeted mutations to alanine were made. Secondary structures bearing moPrP mutations are indicated 
above each image. Mutation sites are shown with coloured backbone carbons and side chains (line display) on an otherwise grey 
backbone. All images were created in PyMol. 
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Low levels of expression of the cellular prion protein are known to abrogate 
prion propagation; indeed transgenic mice devoid of PrP are not susceptible 
to infection by prions48. The moPrP surface mutations generated in this 
study expressed well in KD cells, thereby ruling out lack of protein 
expression as a factor for limited propagation (Figures R34, R37 and R41). 
One exception where the standard anti-PrP antibody ICSM18 could not be 
used for immunoblotting and immunofluorescence applications was for 
mutation R147A.R150A.E151A, since the antibody epitope is destroyed137. 
In this instance, anti-PrP antibody ICSM35 was used to detect the protein 
(Figure R37), as its epitope lies within CC2 region 93-105137. 
From this data, a triple mutation of sequentially proximal residues 
G123A.L124A.G125A abrogated propagation (Figure R33). All the other 
mutations tested in this section also exhibited severe limitations on 
propagation (Figure R33). R147A.R150A.E151A also appears to abrogate 
propagation, but the effect on propagation of this mutation could not be 
verified in the current SCA setup, as the mutation destroys the binding site 
for ICSM18 which is used in the standard SCA setup and alternative anti-
prion antibody ICSM35 could not be adapted for SCA as ELISPOT 
processing steps such as ProteinaseK digestion which cleaves PrP within 
the ICSM35 epitope site do not allow for sensitive detection (data not 
shown). 
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FIGURE R33: SCA OF KDMOPRPALA CELLS; MOPRP MUTATIONS IN REGION 123-151 
KD cells reconstituted with either moPrPWT or alanine mutant variants of the protein 
within region 123-159 of moPrP were challenged with RML prions at a 1x10-5 
dilution of infectious homogenate and their ability to propagate these prions 
assayed via SCA for at least three consecutive passages. All replacements within 
this region exhibited a significant reduction in their ability to propagate RML when 
compared to moPrPWT. Significance is indicated by ‡ for P ≤0.0001. Significance 
only shown for split 6 for clarity; calculated in a one-way ANOVA with a Bonferroni 
correction for multiple comparisons. 
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FIGURE R34: IMMUNOFLUORESCENT ANALYSIS OF KDMOPRPALA CELLS WITH MUTATIONS IN STRUCTURED REGION 123-151 
Immunofluorescence analysis of KD cells reconstituted with structured region (123-151) mutants of moPrP. The top panel represents 
cells probed for moPrP using ICSM18 antibody. The lower panel shows moPrPWT and KD cells stained with ICSM35. KD and moPrPWT 
represent negative and positive control lines, respectively. moPrP mutant R147A.R150A.E151A was not detected by ICSM18, as the 
antibody epitope is in this region; it was however, recognised by another anti-moPrP antibody, ICSM35 whose epitope is more N-
terminal (residues 93-105). All reconstituted KD lines expressed moPrP on the cell surface. DAPI nuclear stain; green: moPrP. 
Magnification at x40. 
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3.5.3 Alanine mutations made between the first and third α-helices 
of moPrP display strong inhibition of prion propagation 
The second series of mutations on solvent-exposed regions of the prion 
protein included: Y148A.T198A.D201A where replacements were made in 
the first α-helix and the N-terminal cap of the third helix; 
R155A.K193A.E195A where R155 of α-helix 1 comes into close proximity 
with charge residues in the loop region between α-helices 2 and 3; 
R163A.Y168A.H176A with two loop region mutations between the first and 
second β-sheets, and one at α-helix 2; S169A.N170A.Y224A alters native 
residues in the loop region between β-sheet 2 and α-helix 2 as well as an α-
helix 3 residue (Figures R31 and R32). F174A.V179A.I183A constitutes 
replacements exclusively in α-helix 2, V188A.T191A.T192A targets amino 
acids at the C-terminal cap of α-helix 3 and the following loop region; 
K203A.E206A.R207A, as well as E210A.Q211A.Y225A and 
K219A.E220A.Q222A, bear mutations at various positions along α-helix 3 
(Figures R31 and R32). When assayed for their ability to propagate prions, 
these mutations appeared to be markedly limited in their propagative 
capacity (Figure R36). While KD cells reconstituted with the wild-type 
protein reported spot numbers in the thousands, KD cells reconstituted with 
these mutants yielded spot numbers of two hundred or fewer (Figure R36). 
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FIGURE R35: TARGETED SITES FOR MUTATIONS IN REGION 148-230 OF MOPRP 
Mutations targeted to the surface of the globular domain on moPrP are depicted on PDB entry 2L39, shown in full in the top left corner, 
showing two β-strands and three α-helices with a surface outline. Areas of the protein that were not targeted for mutagenesis are 
shown in light grey; where residues have been mutated, areas are shown in any colour other than grey. Following this entry are various 
positions on the protein where targeted mutations to alanine were made. Secondary structures bearing moPrP mutations are indicated 
above each image. Mutation sites are shown with coloured backbone carbons and side chains (line display) on an otherwise grey 
backbone. All images were created in PyMol.  
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FIGURE R36: SCA OF KDMOPRPALA CELLS; MOPRP MUTATIONS IN REGION 148-230 
KD cells reconstituted with either moPrPWT or alanine mutant variants of the protein 
within region 148-230 of moPrP were challenged with RML prions at a 1x10-5 
dilution of infectious homogenate and their ability to propagate these prions 
assayed via SCA at three consecutive time points. All KD cells expressing moPrP 
replacements within this region exhibited a significant reduction in their ability to 
propagate RML when compared to those expressing moPrPWT. Significance is 
indicated by ‡ for P ≤0.0001. Significance only shown for split 6 for clarity; 
calculated in a one-way ANOVA with a Bonferroni correction for multiple 
comparisons. 
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Mutations in region 148-225 of moPrP resulted in a reduced ability of cells 
expressing these constructs to propagate RML. KD cells expressing these 
mutations demonstrated a ten-fold reduction in their ability to propagate 
prions compared to moPrPWT.  
This is similar to the limitation on propagation exerted by alanine mutations 
within region 121-155 of moPrP at solvent-exposed regions (Figures R33 
and R36).Neither set of surface mutations produced/yielded over 200 
hundred spots at the final split, compared to the one-thousand spots 
obtained for KD cells expressing non-mutated moPrPWT (Figures R33 and 
R36). Such values for propagation of RML prions are comparable to those 
reported for CC2 region 90-111 of the mouse prion protein (Section 3.4).  
Spot numbers higher than background (KD cells; 50-spot threshold) were 
observed for some of the moPrP surface region mutations between splits 4-
6. This includes values nearing on average one hundred spots for 
M128A.Y162A.Q216A, L129A.S131A.Q159A, D142A.W144A.E145A 
(Figure R33), R163A.Y168A.H176A, S169A.N170A.Y224A, 
F174A.V179A.I183A, K203A.E206A.R207A and E210A.Q211A.Y225A 
(Figure R36). This level of propagation in KDmoPrPAla cells with structured 
region mutations was ten times less than that of KD cells expressing the 
wild-type protein (Figures R33 and R36) and not due to a lack of cell-
surface protein expression (Figure R34 and R37).  
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It is apparent from SCA analysis of moPrP surface region mutants, that 
propagation capacity is severely compromised by every change made 
within this 123-230 globular domain of the protein. However, some triple 
mutations showed a complete abrogation of propagation whereas others 
appeared to permit a low level of propagation (Figures R33 and R36).  
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FIGURE R37: IMMUNOFLUORESCENT ANALYSIS OF KDMOPRPALA CELLS WITH MUTATIONS IN STRUCTURED REGION 148-230  
Immunofluorescence images of KD cells reconstituted with structured region (148-230) mutants of moPrP. The cells were probed for 
moPrP expression using ICSM18 antibody. Expression detected in KD cells reconstituted with moPrP bearing mutations 
R163A.Y168A.H176A, S169A.N170A.Y224A and E210A.Q211A.Y225A was stronger than that for other mutations. Importantly, 
despite the difference in moPrP accumulation in these cells, all reconstituted KD cells expressed moPrPAla. DAPI nuclear stain; green: 
moPrP. Magnification at x40. 
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3.5.4 Mutations made within the core hydrophobic region of moPrP 
to destabilise the protein lower its capacity for propagating prions 
Three mutants C178A.C213A, M204A and M204Q.M205Q.V209Q.M212Q 
were made at non-surface regions of the protein. They targeted hidden 
residues in the hydrophobic core of the protein and were designed to 
destabilise the protein. The third α-helix of the prion protein has a 
hydrophobic face formed predominantly of methionine and valine residues, 
with the former known to contribute to protein folding and stability156, 277-279. 
In addition to substituting methionines, the effect of protein stability on prion 
propagation was also tested by replacement of cysteine residues that form 
the disulfide bridge between α-helices 2 and 3.  RML prions were used to 
challenge cells expressing these mutations in the KDmoPrPAla cell system 
(Section 3.2). All destabilising mutations described here are located on α-
helix 3 of moPrP, and in the case of disrupting the disulfide bond 
(C178.C213), also on α-helix 2 (Figure R38).  
All mutations made to destabilise the protein or promote unfolding (M204A, 
C187A.C213A and M204Q.M205Q.V209Q.M212Q), showed a considerably 
reduced capacity for RML propagation (Figure R39). KD cells reconstituted 
with wild-type protein gave spot numbers of over one-thousand by split 6, in 
sharp contrast to spot numbers averaging one hundred at most, for 
destabilising mutations at the same split (Figure R39).  
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FIGURE R38: TARGETED SITES FOR MUTATIONS IN CORE HYDROPHOBIC RESIDUES OF MOPRP 
Mutations targeting core hydrophobic residues in moPrP are depicted on PDB entry 2L39, showing two β-strands and three 
α-helices with a surface outline (first image). The protein is coloured grey; positions at which destabilising mutations were 
created are coloured in red, black and yellow. Destabilising mutations are shown in the images zoomed at α-helix 3 in 
2L39. Position 204 where the native methionine was mutated to alanine is shown in red with its side chain projecting from 
the protein backbone. Another mutation within α-helix 3 was created where core hydrophobic residues shown in black, 
were replaced with the amino acid glutamine; this quadruple mutation was predicted to cause the protein to unfold. The last 
image shows the disulfide bond between α-helices 2 and 3, which was destroyed by mutation C178A.C213A. Secondary 
structures bearing moPrP mutations are indicated above each image. Mutation sites are shown with coloured backbone 
carbons and side chains (line display) on an otherwise grey backbone. All images were created in PyMol.  
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It is interesting to note that moPrP-destabilising mutation M204A and 
unfolding mutation M204Q.M205Q.V209Q.M212Q exhibited spot numbers 
approaching three hundred at split 4 (for M204Q.M205Q.V209Q.M212Q 
this was true also for split 5), but then dropped to less than two hundred 
spots for the last split (Figure R39). If split 4 was to be considered solely, 
then propagation in these two moPrP mutants is not remarkably different 
from their wild-type counterpart. At split 6 however, due to high spot 
numbers achieved from true propagation in the moPrPWT-expressing cells, 
the difference between spot numbers is significantly less in the mutant-
expressing lines (Figure R39). Since results at split 6 are used to determine 
the propagation efficiency, destabilising and unfolding mutations in moPrP 
severely limit the propagation of prions (Figure R12). Lowering of spot 
numbers between passages, especially when spot count falls below two 
hundred for any split, is not indicative of full propagation. It could therefore 
be argued that the spots observed here may be due to protein aggregation 
as opposed to propagation. This is in fact, what is observed for KD cells 
reconstituted with moPrP bearing the mutation M204A at splits 5 and 6, but 
not for M204Q.M205Q.V209Q.M212Q at any split (Figure R39). This may 
be a case of the cells being susceptible to RML infection and initial 
propagation, but failed maintenance of prion propagation as described by 
Vorberg et al280. When comparing the RML-infected versus non-infected 
samples, spot numbers for KD cells reconstituted with moPrPWT and 
M204Q.M205Q.V209Q.M212Q were significantly different at all three 
passages at which cells were sampled for ELISPOT processing (Figure 40). 
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FIGURE R39: SCA OF KDMOPRP CELLS; MUTATIONS IN CORE HYDROPHOBIC REGIONS 
OF MOPRP 
KD cells reconstituted with either moPrPWT, alanine-substituted moPrP (M204A 
and C187A.C213A) or glutamine-substituted moPrP 
(M204Q.M205Q.V209Q.M212Q) were challenged with RML prions at a 1x10-5 
dilution of infectious homogenate. Their ability to propagate these prions was 
assayed via SCA for at least three consecutive time points: split 4, 5 and 6. All 
replacements made exhibited a significant reduction in their ability to propagate 
RML when compared to moPrPWT. Significance is indicated by **** for P ≤0.0001. 
Significance only shown for split 6 for clarity; calculated in a one-way ANOVA with 
a Bonferroni correction for multiple comparisons.   
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All non-infected control plates were run in the same SCA as the RML-
infected plates as is standard SCA procedure and processed for ELISPOT 
in the same way. None of the non-infected samples gave spot numbers 
above one hundred for any split (Figure R40). The number of spots 
obtained for non-infected samples in SCA is usually in the order of zero to 
fifty. This is the background ‘noise’ within the system and also represents 
the range of spot numbers recorded for KD cells, both in RML-infected and 
non-infected conditions (Figure R34).  
The highest background value recorded from the samples presented here 
was 55 (averaged across six replicate wells). This is slightly higher than 
background values for non-infected KD cells reconstituted with the wild-type 
protein, but negligible (Figure R40). Nevertheless, spot numbers below two 
hundred represent severe inhibition of propagation and under four hundred, 
are reduced in their capacity to propagate prions based on the SCA guide 
used in this study (Figure R12). This indicated that cells expressing 
mutation M204A, a destabilising mutation, or the unfolding mutation 
M204Q.M205Q.V209Q.M212Q, are severely inhibited in their ability to 
propagate prions, relative to moPrPWT (Figure R39). Many studies have 
indicated that increasing protein stability in the cellular prion protein makes it 
more resistant to prion infection and vice versa. Thus, it could be expected 
that cells expressing the destabilising and unfolding mutations introduced 
here (M204A M204Q.M205Q.V209Q.M212Q) would have propagation 
profiles higher than, or equalling that of moPrPWT; this is not the case 
(Figure R40). SCA data for these mutations was further analysed to 
determine whether the nature of these mutations made the cells expressing 
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them more likely to form ProteinaseK-resistant material in the absence of 
RML-homogenate (Figure R40). Since the M204A-expressing cells showed 
spot numbers above two hundred at split 4, it suggests that this mutation 
allows for reduced propagation, but cannot maintain it for more than a few 
splits. There is also evidence of this for cells expressing the quadruple Gln 
mutation (Figure R39). Whether or not infectivity is retained in these cells 
following infection remains to be investigated. 
For mutation C178A.C213A, spot numbers increased at the last split, from 
thirty to one hundred (Figure R39). Despite the trend of increasing spot 
number with subsequent passages, the spot count was below the eight 
hundred threshold to be considered efficient propagation, below the four 
hundred mark that represents reduced or inefficient propagation and fell 
within the range of fifty to two hundred, where propagation was taken to be 
severely inhibited (Figure R12).  
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FIGURE R40: SCA ANALYSIS OF RML-INFECTED VERSUS NON-INFECTED KDMOPRP 
CELLS WITH MUTATIONS MADE IN THE CORE HYDROPHOBIC RESIDUES OF THE PROTEIN 
Comparison of SCA data collected from RML-infected samples versus non-
infected samples. Shown above are representative data from three consecutive 
passages of cells that were either infected with RML or not infected with any prions 
(NI: non-infected). For KD cells reconstituted with moPrPWT, or 
M204Q.M205Q.V209Q.M212Q, RML-infected samples gave significantly different 
values compared to their non-infected counterparts. For KD cells reconstituted with 
M204A however, the difference between infected and non-infected samples was 
only significant at split 4. A grey line at 100 spots demonstrates that none of the 
non-infected samples had values above this; still, the mutations reported higher 
background (non-infected samples) values than those collected for the wild-type 
protein. Significance is indicated by *** for P ≤0.001. Significance is only shown for 
split 6 for clarity; calculated in a one-way ANOVA with a Bonferroni correction for 
multiple comparisons.     
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Overall, SCA analysis showed that introducing destabilising changes into 
the folded structure of the prion protein considerably lowered the ability of 
cells expressing these mutant forms of moPrP to propagate prions (Figure 
R39). Still, cells expressing mutation M204Q.M205Q.V209Q.M212Q were 
able to propagate prions for two splits – more than M204A. This indicates 
that propagation occurs in cells expressing the modified proteins, but cannot 
be maintained for multiple passages. Thus, alanine replacements made 
within core hydrophobic residues of the protein exert propagation-limiting 
effects on cells expressing them such that: (i) cells can propagate RML 
prions initially, but at a reduced rate compared to moPrPWT; (ii) propagation 
reduced from split 4 to split 6; (iii) propagation cannot be maintained for six 
passages post-infection. 
KD cells reconstituted with moPrP mutations M204A, C187A.C213A and 
M204Q.M205Q.V209Q.M212Q were seeded on coverslips and probed for 
prion protein expression using ICSM18. In all instances, protein expression 
was detected at the cell surface (Figures R34, R37 and R41). Thus, 
limitations on propagation for these mutants were not due to lack of 
expression. A complete analysis of mutations generated in the structured 
region of the prion protein could not be tested at an additional 1x10-4 dilution 
of homogenate due to time constraints. For comparison, some of the SCA 
data available at both doses of RML prions is shown (Figure R42). This 
corroborates findings within this chapter that show all changes made in this 
region severely reduced propagation. 
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FIGURE R41: IMMUNOFLUORESCENCE IMAGES OF KDMOPRP CELLS WITH MUTATIONS IN CORE HYDROPHOBIC REGIONS OF THE PROTEIN 
Immunofluorescence images of KD cells reconstituted with mutants of moPrP designed to destabilise the protein. Cells were probed for moPrP 
expression using ICSM18 antibody. All reconstituted KD cells expressed moPrP. The last three images represent control cell lines where moPrPWT 
is a positive control showing expression of the wild-type protein, KDpLNCX2-only represents KD cells transduced with empty vector (negative 
control) and moPrPWT Secondary only shows the background signal (noise) when the primary antibody (ICSM18) is omitted. DAPI nuclear stain; 
green: moPrP. Magnification at x40. 
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FIGURE R42: SCA ANALYSIS OF KDMOPRPALA CELLS WITH MUTATIONS IN THE 
STRUCTURED REGION TESTING TWO DOSES OF RML INOCULA  
Comparison of SCA data collected from RML-infected samples at two doses of 
inocula versus non-infected samples. Shown above are representative data from 
three consecutive passages of cells. This demonstrates that samples tested at a 
ten-fold higher dose of infectious inocula displayed a very modest increase in 
response to RML as spot numbers remained below two hundred. Significance is 
indicated by ‡ for P ≤0.001. Significance is only shown for split 6 for clarity; 
calculated in a one-way ANOVA with a Bonferroni correction for multiple 
comparisons.  
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TABLE R6: LIST OF MUTATIONS MADE WITHIN THE STRUCTURED REGION OF MOPRP 
List of mutations made within the structured region (SR) of the mouse prion 
protein. Native residues at these positions were changed to alanine or glutamine 
(Q) and the modified protein expressed in KD cells to test the effect of the 
mutations on prion propagation. All cells expressing moPrP mutations within the 
structured region exhibited a very strong reduction in their ability to propagate RML 
prions in the scrapie cell assay. (N/A: not applicable). 
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3.5.5 Integrity of the structured region 123-230 of the prion protein 
is necessary for efficient prion propagation  
A series of moPrP mutations were generated in the structured 123-230 
region of the mouse prion protein and expressed in cells susceptible to RML 
prions, to test the effect of these mutations on prion propagation. Mutations 
were designed based on two criteria: (i) targeting solvent-exposed regions 
of the protein to determine whether a particular face of the folded protein 
was integral to propagation and if so, which one; (ii) whether destabilising 
the protein by altering core hydrophobic residues facilitates or limits 
propagation. 
It was found that mutations between the first β-sheet strand and the first α-
helix of moPrP limited the ability of cells expressing these mutations to 
propagate RML. Propagation as measured by spot numbers in SCA 
showed at least a ten-fold reduction for moPrP bearing alanine mutations 
within this region compared to the wild-type protein (Figure R33). When 
similar analyses were performed for alanine mutations between the first and 
third α-helices of moPrP, it was found that most triple alanine replacements 
at solvent exposed sites within this region of the protein lowered the ability 
of cells expressing these constructs to propagate prions at least ten-fold 
with respect to moPrPWT (Figure R36). Essentially, propagation was 
severely reduced in both instances, and by the same amount for both sets 
of mutations in the structured region of the protein. 
Of note, mutations G123A.L124A.G125A, S134A.R135A.M153A and 
H139A.G141A.D146A, had the strongest inhibitory effect on propagation 
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within regions 121-153 of the protein (Figure R33). These represent 
changes made just N-terminal to β1 and the loop region between β1 and α1 
(Figure R32). From region 148 – 225 of moPrP, Y148A.T198A.D201A, 
R155A.K193A.E195A and V188A.T191A.T192A showed the strongest 
inhibition of propagation (Figure R36). These represent changes made to 
surface residues at α1 and the loop region between α2 and α3 (Figure 
R35).  
When alanine mutations were made within core hydrophobic regions of the 
protein, prion propagation was severely limited in cells expressing the 
modified protein (Figure R39). Interestingly, spot numbers of two hundred 
were readily achieved for both M204A and M204Q.M205Q.V209A.M212Q 
at split 4, but not for C178A.C213A (Figure R39). Additionally, spot numbers 
for M204A and M204Q.M205Q.V209A.M212Q fell at split 6, whereas for 
C178A.C213A, they increased at the last split. For single replacement 
M204A but not for M204Q.M205Q.V209A.M212Q, spot numbers observed 
for splits 5 and 6 were comparable to background levels where the cells 
expressing this mutation in moPrP had not been infected with RML prions 
(Figure R40). Thus, both C178A.C213A and the quadruple mutation 
M204Q.M205Q.V209A.M212Q, may be able to propagate prions at a low 
level but in the case of M204, the spots observed were not significantly 
different to background levels and thus, not indicative of true propagation 
(Figure R40). For M204A and M204Q.M205Q.V209A.M212Q, the higher 
spot numbers observed may be indicative of higher misfolding propensity in 
the protein as reported by Hirschberger et al.277 Both methods of altering 
prion protein stability used here – altering core hydrophobic residues and 
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disrupting the disulfide bond – are linked to conformational rearrangement 
of α-helix 1155, 277. Data from the single mutation M204A and the quadruple 
change to Gln at M204.M205.V209.M212 suggest that although both 
changes reduce the ability of cells expressing these mutations to propagate 
RML prions relative to moPrPWT, the larger change in the unfolding mutation 
is more amenable to propagation than a smaller destabilising mutation 
(Figure R39).  
The reduction in propagation observed for all cells expressing moPrPAla 
here was not due to lack of prion protein expression, but due to the mutation 
introduced in the protein (Figures R33, R36, and R39). There have been a 
number of studies probing the replicative interface for PrPC-PrPSc binding 
and conversion, each giving evidence for involvement of different regions of 
PrP: from α-helix 188, 179, 205 and neighbouring residues205, to the loop region 
between α-helices 2 and 3157, to specific methionine156, 159, 279 or tyrosine 
residues; all of which were determined by vastly different experimental 
approaches.  
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3.5.6 Effects of alanine mutations in α-helix 1 on prion propagation 
Abalos et al. identified region 136-140 as residues involved in the specific 
binding interaction between PrPC and PrPSc118; this followed earlier work by 
Moroncini et al., who used motif-grafted antibodies to characterise two 
PrPC-PrPSc interaction sites: one at N-terminal residues 89-112 and the 
other at 136-158, within the structured domain of the protein199. The latter 
segment spans α-helix 1 and a few residues either side of the helix. 
Norstrom et al. used chronically Scrapie-infected cells to show that only 
charged residues within α-helix 1 region had a controlling effect on prion 
propagation88. Other studies suggest that specific aspartate residues at 
positions 143 and 146 within this region govern this interaction179, with 
regions N-terminal to α-helix 1 deemed unimportant for PrPC-PrPSc 
interaction205. Our data supports the general argument that mutations made 
within and surrounding α-helix 1 have a distinct negative effect on prion 
propagation (Figures R33). Data presented here also suggests that 
propagation is mediated by residues other than charged moieties or α-helix 
1 residues, as α1 mutation D142A.W144A.E145A showed higher spot 
numbers for all three splits compared to loop region mutation 
G123A.L124A.G125A which is N-terminal to both α-helix 1 and β-sheet1, 
and not highly charged (Figure R33). It is important to note however, that in 
either instance, spot numbers were below the threshold considered to be 
efficient propagation (Figure R12). Thus although all mutations in this region 
severely inhibited propagation, not all can be labelled as ‘abrogating’ 
propagation as some were above fifty at split 6, the cut-off for background 
spots obtained with KD cells (Figure R12). 
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3.5.7 Loop regions determine prion propagation propensity 
Structural comparisons of the prion protein in its cellular and disease-
associated state showed that residues 132-167, which span β1-α1-β2, 
relocate away from the α2-α3 core206 during prion protein conversion165, 281. 
This may explain why changes to alanine within the β1-α1-β2 region of the 
protein had a significant effect on prion propagation (Figures R33 and R36). 
Additionally, the β2-α2 loop has been shown to influence the outcome of 
prion propagation in terms of susceptibility to prion infection – transgenic 
mice expressing a triple amino acid substitution within the β2-α2 loop region 
Y168G.S170N. N173T were resistant to two strains of mouse prions160.  
A well-known fact in the prion field, with regards to disease transmission is 
that some species such as bank voles, elk and deer are considerably more 
susceptible to prions than others, such as rabbit70. The higher tolerance in 
rabbit PrP is believed to be due to a more ‘rigid-loop’ structure in the rabbit 
sequence, with contributions from hydrogen-bonding interactions within the 
helix cap motif at this site158. Mutations made in this study which 
encompass region β2-α2 include S169A.N170A.Y224A (underlined 
mutations S169A and N170A fall within β2-α2, but Y224A is in α-helix 3), 
which showed considerably lower propagation but did not completely 
abrogate prion propagation as spot numbers were above fifty (background 
threshold; Figure R36). However, other loop region mutations made in the 
structured region (G123A.L124A.G125A, S134A.R135A.M153A and 
H139A.G141A.D146A, R155A.K193A.E195A and V188A.T191A.T192A) 
exhibited some of the strongest inhibition, abrogating prion propagation and 
236 
 
reporting spot numbers under fifty when analysed via SCA (Figures R33 
and R36). Helices α2 and α3 represent regions of the prion protein where a 
large number of pathogenic mutations are clustered51, and have been 
proposed to be major sites for initiating prion propagation157.  
Salamat et al., investigated the effects of altering the sequence with the α2-
α3 loop region; peptide insertions in the loop region between α-helices 2 
and 3 were found to have no effect on limiting prion propagation, leading the 
authors to conclude integrity of the α2-α3 segment is not required for 
propagation282. Findings from alanine mutagenesis presented here are 
contrary to this statement as minimal changes in areas within and 
surrounding α-helices 2 and 3, severely limited propagation (Figure R36). In 
particular, triple mutation at the C-terminal end of α-helix 2, 
V188A.T191A.T192A, displayed abrogation of propagation, akin to negative 
control KD cells (Figure R36). Our data therefore supports the finding that 
loop region mutations significantly affect the outcome of prion propagation. 
However, mutations within the α2-α3 loop were found to have a stronger 
effect than those within the β2-α2 loop (Figure R33 and R36). 
3.5.8 Protein stability as a determinant of prion propagation 
The disease-associated PrP conformer PrPSc is characterised by its high β-
sheet content and lower solubility with a high resistance to chemical 
denaturation44, 283, 284. Smirnovas et al. showed that the prion protein 
undergoes major refolding during the conversion from soluble native PrPC to 
insoluble PrPSc79. The refolding is hypothesised to originate from amino acid 
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region 80-90 (depending on prion strain) to the C-terminus79. Higher stability 
in the prion protein is believed to be correlated with a lower misfolding 
propensity and lower susceptibility to prion infection242. This follows the 
reasoning that if the protein exists in a more stable state, it is less likely to 
form non-native bonds that would encourage misfolding. Here, we 
generated mutations aimed at lowering native protein stability, either 
through modification of core hydrophobic residues or removal of the 
disulfide bond between α-helices 2 and 3. Following the reasoning for 
higher stability correlating with reduced misfolding propensity, it could be 
predicted that lowering stability would have the opposite effect and that 
higher propagation could be expected for PrP bearing destabilising 
mutations.  
The SCA results obtained for prion propagation of moPrP bearing 
destabilising mutations showed that substituting methionine for alanine at 
position M204, or altering the charge at residues M204M205V209M212 by 
glutamine substitutions resulted in considerably reduced protein 
propagation (Figure R39). Interestingly for these mutations, there was a 
higher level of misfolding that led to detection of ProteinaseK-resistant 
material in the absence of prion infection (Figure R40). Upon RML prion 
infection however, low levels of propagation were observed for cell lines 
expressing both M204A and M204A.M205A.V209A.M212A, but significantly 
less than cells expressing the wild-type protein (Figure R39). Younan and 
colleagues undertook protein unfolding experiments and identified surface 
residues M205, V209, and M212 as key sites that were perturbed in the 
protein upon inducing oxidative stress279. The authors suggest a general 
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misfolding pathway for the protein, where methionine oxidation, which could 
be brought about by cellular oxidative stress, represents an early event in 
prion disease279. This finding is supported by Elmallah et al., using huPrP 
121-230 to show formation of monomeric molten-globule entities which are 
reportedly similar in their properties to misfolding intermediates observed for 
PrP57. 
If methionine oxidation facilitates misfolding to a PrP conformer closer to 
PrPSc, this may support the SCA findings reported here that cells expressing 
moPrP bearing the substitutions M204A.M205A.V209A.M212A are 
inefficient at propagating prions. It is possible that substitution of the 
exposed methionine residues to alanine protects the protein from the effects 
of oxidative stress on methionine, which could contribute to PrPSc formation 
and accumulation, defined as prion propagation. 
In an alternative approach to lower the stability of moPrP, KD cells were 
reconstituted with the moPrP construct bearing mutations C178A.C213A 
which destroys the disulfide bridge between α2 and α3; this resulted in very 
limited propagation (Figure R39). Cells expressing this mutation did not 
show accumulation of ProteinaseK-resistant material in the absence of RML 
homogenate as analysed by SCA, unlike M204A and 
M204A.M205A.V209A.M212A-expressing cells (Figure R40). This suggests 
that although lowering protein stability makes it more likely to misfold, this 
does correlate with efficient prion propagation as the destabilising mutations 
exhibited reduced propagation relative to moPrPWT (Figure R39). 
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3.5.9 The miniprion and its implication in PrP domains required for 
efficient prion propagation 
A mouse prion protein construct with two large deletions, Δ23-88 and Δ141-
176, assumes a protease-resistant conformation when expressed in cells 
that are chronically infected with Scrapie prions. This construct was termed 
‘miniprion’ or PrP106 (consisting of 106 residues)204. Limitations of this 
construct, as addressed by the authors, lay in the incorporation of a His(6)-
tag which was predicted to aid the formation of protease-resistant 
fragments204. This is still considered to be the minimal segment of the prion 
protein capable of sustaining prion propagation76, 204; indeed recent 
research on elucidating prion protein regions required for infection, 
conversion propagation and toxicity continue to employ deletion 
mutagenesis techniques285. We propose that modifications made to the 
cellular protein in this study are extremely slight, so as to reduce the amount 
of perturbations introduced. With this minimal approach, we were able to 
report significant differences in the response of these proteins to infectious 
prions (Figures R33, R36 and R39). Deletion Δ23-88 in the miniprion 
corresponds to a large portion of the flexible N-terminus, retention of CC2, 
and domains C-terminal to it up to the second deletion Δ141-176, which 
represents removal of α1-β2 and β2-α2 loop region, whilst retaining most of 
α2 and α3 in its entirety. It could be argued based on this model that 
residues that comprise α1-β2 are not required for prion propagation, nor are 
the loop regions between α1 and β2, and between β2 and α2. Although the 
data presented here does not show that propagation is nullified upon 
mutagenesis of α1-β2 residues, it shows that mutations in these regions 
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severely compromise the ability of cells expressing the modified protein to 
propagate prions (Figures R33 and R36). 
3.5.10 Summary 
Overall, nineteen constructs were generated in the structured region of the 
mouse prion protein, largely at solvent-exposed regions, to identify surfaces 
of the protein that are required for efficient propagation. Of these, sixteen 
constructs comprised triple alanine mutations at solvent-exposed regions, 
all of which hindered prion propagation. This was regardless of native 
position or biochemical property of the modified residue within the globular 
structured domain of the protein (Figures R33, R36 and R39). Three 
mutations made to alter the stability of the protein also displayed reduced 
propagation (Figure R40). Since all the prion protein mutations were 
expressed in KD cells, there are negligible contributions towards 
propagation of the endogenous protein (Section 3.2). Propagation is not 
completely blocked by the presence of these mutations, but its efficiency is 
severely impacted (Figure R12). Thus, the data collected from SCA analysis 
suggests that the integrity of the structured domain of PrP, 121-230 in 
moPrP, is essential for efficient prion propagation. 
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3 . 6  D o m i n a n t - n e g a t i v e  i n h i b i t i o n  o f  p r i o n  
p r o p a g a t i o n  b y  m u t a t i o n s  i n  C C 2   
3.6.1 Experimental strategy  
For the unstructured region 23-111 of the prion protein, bulk 
cultures of KDmoPrPAla cells were established and assayed 
on at least three independent SCAs to investigate their 
propagative potential following infection with RML prions 
(Section 3.3 and Section 3.4). It was found that within this 
segment of the protein, three distinct regions, when 
mutated to alanine, severely limited prion propagation. 
These were CC1, residue Q41 and CC2 of moPrP. Here, 
repeat infections of KD cells with virally packaged moPrPAla 
constructs were carried out; single-cell clones (SSCs) of the 
transduced cells were generated and assayed for their 
ability to propagate prions by SCA. 
SSCs were established for each moPrP mutant construct of interest and re-
tested for their propagative potential in independent SCAs in order to verify 
earlier findings from bulk cultures (Section 3.3 and 3.4). A ten-fold increase 
in the standard RML concentration from 1x10-5 dilution of homogenate to  
1x10-4 was seen to improve the propagation profile for some, but not all 
cells expressing moPrPAla in SCA experiments (Section 3.3 and 3.4). For 
prion infection of SCCs therefore, the higher dose of inocula was selected to 
ensure a saturated system, such that any increase in the cells’ ability to 
propagate RML would be easily detected. KDmoPrPAla cells tested included 
those with CC1 mutation K23A.K24A.K25A, point mutation Q41A and six of 
the eight mutations within CC2.  
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FIGURE R43: CC1, Q41 AND CC2 ARE IDENTIFIED AS MODULATORS OF PRION 
PROPAGATION   
Residues 23-111 of moPrP. Bar schematic of domains within moPrP. N-SS: N-
terminal signal sequence; CC1: charge cluster 1; OPR: octapeptide repeat region; 
CC2: charge cluster 2; PTM: putative transmembrane region; α1: helix 1; β1: 
strand 1; α2: helix 2; α3: helix 3; SS-C: C-terminal signal sequence. Region 23-88 
is defined by double-headed arrow; when deleted from the wild-type protein, 
results in abrogation of prion propagation. Sequence segments of moPrP shown in 
pink represent regions of the protein that when substituted for alanine, led to a 
significantly reduced ability in cells expressing these mutations to propagate RML 
prions. 
3.6.2 Single-cells clones versus bulk cultures 
To verify the stark differences observed for prion propagation when different 
regions of the N-terminus were mutated, new bulk cultures were established 
as biological replicates and from these, single-cell clones generated (Figure 
R44). KD cells stably transduced with pLNCX2 bearing the mutated moPrP 
ORF were plated at limiting dilutions and isolated cell clusters were picked 
from the plate and expanded separately to establish SCCs. The advantage 
of SCCs over bulk cultures is that all cells arise from one cell and should 
therefore be identical in characteristics such as growth and protein 
expression. Protein expression levels for the KD cells reconstituted with 
moPrPAla constructs and expanded as single-cell clones were found to be 
comparable to endogenous levels in PK1 cells by Western blotting and 
immunofluorescence (Figures R19 and R27; Figures R20 and R28). 
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FIGURE R44: SINGLE CELL CLONING 
KD cells were transduced with viral supernatent containing particles in which pLNCX2_moPrP was packaged and plated at limiting 
dilutions. Each moPrP ORF was sequence-verified for insertion of alanine mutations at targeted positions within CC1, at Q41 and 
within CC2, prior to cloning into pLNCX2 and transducing Phoenix cells to package the construct (Chapter I). This represents a bulk 
culture. Isolated cell clusters were isolated from the bulk culture plate and expanded separately to establish SCCs; eight SCCs were 
picked from each bulk culture; six of the eight SCCs that grew well under G418 selection were probed for moPrP expression; three of 
the six SCCs that had the greatest protein expression were taken forward to SCA to test their response to RML infection and 
propagation. 
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FIGURE R45: IMMUNOFLUORESCENCE IMAGES OF SINGLE CELL CLONES 
Immunofluorescence was carried out on SCCs picked from bulk cultures plated at 
limiting dilutions. ICSM18 was used to detect moPrP in KD cells reconstituted with 
moPrP bearing various alanine mutations within the N-terminal region 23-111; 
DAPI was used as a nuclear stain. Each row represents SCCs of the indicated 
alanine replacement; letters (a-f) denote the individual SCC populations picked and 
expanded for each bulk culture. Clones (a-c) represent SCCs that displayed the 
highest protein expression and best growth profile; some clones (d-f) had higher 
expression levels but grew slowly compared to the parental  PK1 or KDmoPrPWT 
cells; these cells were excluded from the SCA on SCCs. Clones (a-c) were taken 
forward to SCA to test their ability to propagate RML prions. Top panel: PK1 cells 
show endogenous levels of moPrP. KD cells demonstrate the degree of silencing 
and moPrPWT cells the level of moPrP expression achieved after reconstituting KD 
cells. Magnification at x40. 
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3.6.3 Clonal cell populations for alanine replacements in CC1, Q41 
and CC2 of the mouse prion protein 
Bulk cultures and SCCs of KD cells reconstituted with moPrP mutations 
K23A.K24A.R25A, Q41A, T94A.H95A.N96A, Q97A.W98A, N99A.K100A, 
K105A.T106.N107A, L108A.K109A and H110A.V111A were infected with 
RML at the highest dose of inocula for PK1 cells: 1x10-4 and analysed for 
their ability to propagate RML prions (Figure R46). Newly established bulk 
cultures displayed similar propagation profiles to those tested previously 
(Section 3.3 and 3.4), supporting the finding that CC1 mutation 
K23A.K24A.R25A in PrP lowers the ability of cells to propagate prions. 
Propagation was further limited when a mutation was made at position Q41. 
The most severe limitations on propagation however, were observed for 
mutations within the CC2 domain of the protein (Figure R46). 
Interestingly, single-cell clones of K23A.K24A.R25A and Q41A that 
displayed strong protein expression (clone b; Figure R45) compared to their 
sister SCCs harbouring the same mutation, displayed no inhibition of RML 
propagation in SCA when infected with the homogenate at a dilution of 
1x10-4, reporting spot numbers comparable to cells expressing the wild-type 
protein (Figure R46). This is in contrast to the bulk cultures from which they 
were established. It may be that the clones isolated represented one 
extreme of clonal variation that exists in bulk cultures, simply because it was 
not representative of the average bulk culture, or of other clonal lines 
expressing the same mutation. KD cells reconstituted with moPrP bearing 
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CC2 alanine mutations showed a consistent profile of reduced RML 
propagation for every bulk culture and SCC tested (Figure R46).  
 
All cell lines tested (both bulk cultures and SCCs) showed split-to-split 
increases in spot number indicative of propagation, with the exception of 
L108A.K109A and H110A.V111A where spot numbers reduced with 
progressive splits, or remained unchanged (Figure R46). For KD cells 
reconstituted with K23A.K24A.R25A, the bulk culture gave spot numbers 
approaching six hundred at split 6, compared to twelve hundred for KD cells 
reconstituted with moPrPWT (Figure R46). Of the three SCCs tested for this 
mutation, two (clones a and c) displayed similar spot numbers ranging 
between three- to four hundred spots for split 6; the third SCC however 
(clone b), gave fifteen hundred for the same split (Figure R46). For Q41A, 
the bulk culture displayed the lowest spot number of approximately one 
hundred counts compared to three hundred (clone a), seven hundred (clone 
c) and sixteen hundred (clone b) for SCCs established from this culture. KD 
cells reconstituted with CC2 mutations showed similar spot numbers for 
bulk cultures and SCCs. Each KDmoPrPAla line expressing CC2 mutations 
gave spot numbers around two hundred or below for split 6 (Figure R46).  
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FIGURE R46: SCA ANALYSIS OF SINGLE CELL CLONES IN REGION 23-111 
KD cell lines reconstituted with moPrPAla that exhibited ‘inhibitory’ phenotypes upon infection with RML (Section 3.3 and 3.4) were 
expressed as bulk cultures (mutation indicated in full) and SCCs (represented as clones a, b and c after each indicated mutation). 
Significance is indicated by ‡ for P ≤0.0001, *** for P ≤0.0002, * for P ≤0.005; for clarity, this is only shown for split 6. Significance 
calculated in a one-way ANOVA with Bonferroni correction for multiple comparisons. 
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The alanine mutations on moPrP tested here show that when cells were 
selected for more uniform protein expression by single cell cloning, those 
bearing the CC1 mutation K23A.K24A.R25A and Q41A were able to reach 
levels of propagation that were similar to moPrPWT such that no limitation on 
propagation was observed. However, cells expressing alanine mutations in 
CC2 maintained a severe reduction in propagation, despite testing SCCs 
that were selected for higher levels of moPrP protein expression (Figure 
R45). This is in line with the finding that CC2 mutations exert a stronger 
control over prion propagation than CC1 or Q41 mutations (Section 3.3 and 
3.4). For K23A.K24A.R25A and Q41A, clones a, b, c were re-tested 
alongside clones d, e and f (Figure R38) at three dilutions of the RML 
homogenate (1x10-5, 1x10-6 and 1x10-7) to assess whether clone b for 
K23A.K24A.R25A and Q41A displayed high levels of propagation at all 
doses of RML, and whether similar propagation profiles would be observed 
for other as yet untested clones (d-e). It was found that clone b for both 
K23A.K24A.R25A- and Q41A-expressing cells, maintained higher spot 
numbers than their sister clones and bulk cultures at split 6 for every dose 
of RML tested (Figure R47). However, although K23A.K24A.R25A clone b 
gave spot numbers around one-thousand, Q41A clone b gave counts of 
around five hundred for RML infection at 1x10-5 dilution of homogenate 
(Figure R47). The range of SCCs tested demonstrates the variability in bulk 
cultures, but still supports the finding that K23A.K24A.R25A and Q41A 
reduce propagation. 
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FIGURE R47: SCA ANALYSIS OF SINGLE CELL CLONES IN CC1 AND Q41 AT THREE DOSES OF INFECTIOUS INOCULA 
SCA of bulk cultures and SCCs (a-f) of moPrP alanine mutations K23A.K24A.R25A and Q41A at three doses of RML infection. 
Significance is denoted by * for P≤0.005; ** for P≤0.0025; *** for P≤0.0002 and ‡ forP≤0.0001. Significance only shown for split 6 for 
clarity; calculated using a one-way ANOVA plus Bonferroni correction for multiple comparisons. 
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3.6.4 Experimental strategy II 
From the results of SCA of clonal cell populations 
expressing moPrP CC1, Q41 and CC2 alanine mutations 
(Figure R46), it was evident that the flexible amino terminal 
region has a strong effect on prion propagation. The 
limitation on propagation exerted by these mutations could 
be for a number of reasons: (i) RML prions were not able to 
effectively infect KD cells reconstituted with these 
mutations; (ii) RML prions can infect KD cells reconstituted 
with N-terminal alanine mutations, but the reconstituted 
cells were subsequently unable to release their infectivity to 
surrounding cell populations, thereby limiting propagation; 
(iii) reconstituted KD cells were susceptible to infection by 
RML prions and can successfully release infectivity once 
infected, but the presence of alanine mutations at N-
terminal regions inhibited formation of de novo prions; (iv) 
formation of de novo prions that allows successive 
propagation was achieved in the reconstituted KD system 
following RML infection, but the mutations exert a ‘curing 
effect’ on already formed prions, thereby reducing the total 
amount detected. A series of experiments were set up to 
address each of these possibilities (Figure R48).  
Firstly, to test the hypothesis that the reconstituted KD cells were 
successfully infected by RML prions but unable to release their infectivity, 
KDmoPrPAla cells with CC1, Q41 and a number of CC2 alanine mutations 
were infected with RML under standard SCA conditions. The cells were 
grown for five splits and harvested at split 6. Lysates were then made by 
ribolysis of the infected samples. Lysates of individual KDmoPrPAla cells 
were subsequently used as infectious inocula for SCA analysis of PK1 cells. 
In this setup, PK1 cells acted as reporters of infectivity in the applied 
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lysates. If the KDmoPrPAla cells were successfully infected but hampered in 
their ability to release infectivity, collecting the cells at the last split of SCA 
would allow for maximal accumulation of prions, and ribolysis of the 
samples would release infectivity such that it is easily available to 
surrounding cell populations.  
Secondly, KD cells reconstituted with moPrP bearing alanine mutations 
K23A.K24A.R25A, Q41A and a select number of CC2 alanine mutations 
were expressed on PK1 cells in which expression of the endogenous 
protein was not silenced. Since PK1 cells express moPrPWT endogenously 
and propagate RML prions efficiently, expression of alanine-mutant moPrP 
in these cells allowed for direct analysis of the effects of moPrPAla on prion 
propagation of moPrPWT. This allowed us to test whether expression of 
moPrPAla could exert limitations on the propagation of endogenous 
moPrPWT – i.e. a dominant negative inhibition of propagation. Lastly, a few 
moPrP constructs with alanine mutations in CC2 were expressed on 
chronically RML-infected PK1 (iPK1) cells to determine if they would ‘cure’ 
prion infection; this was assayed by the number of ProteinaseK-resistant 
spots in the absence and presence of moPrPAla mutants. 
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FIGURE R48: EXPRESSION OF MOPRPALA IN KD, PK1 AND IPK1 CELLS 
Schematic of experimental strategy; the ORF of moPrP bearing various alanine 
mutations was cloned into pLNCX2 and expressed in three different cell lines (1: 
KD cell in which suppression of the endogenous protein is silenced. Thus only the 
alanine-substituted protein is expressed; 2: PK1 cells in which both moPrPWT and 
moPrPAla were expressed; 3: iPK1 cells where the disease-associated form 
(moPrPWT(Sc)) and cellular moPrPAla proteins were expressed. The subsequent 
steps follow the layout of experiments described in experimental strategy II. 
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3.6.5 Lysates of RML-infected KD cells reconstituted with moPrP 
bearing alanine mutations in CC1, Q41 and CC2 retain infectivity 
and lead to prion propagation in PK1 cells 
KDmoPrPAla cells expressing K23A.K24A.R25A and Q41A were infected 
with RML homogenate (1x10-5) and passaged up to split 6, where they were 
harvested and ribolysed to make cell lysates at 1 million cells/ml in sterile 
1xPBS.  
To test whether the lysates retained infectivity post-RML infection, the 
ribolysed cells were applied to PK1 cells, and the PK1 cells tested for their 
ability to propagate RML in a modified SCA where the infectious inocula 
was not RML homogenate, but infected ribolysed KDmoPrPAla cells. PK1 
cells were seeded in 96-well plates at 18,000 cells per well and the cell 
lysate added to the PK1 cells. 100μl of cell lysate was added to the seeded 
cells in 200μl of cell culture media. As per SCA protocol, PK1 cells were 
passaged for 6 splits, with spot numbers analysed at splits 4, 5 and 6. 
Remarkably, the response of PK1 cells to the lysate applied mirrored the 
propagation profile of reconstituted KD cells when infected with RML 
homogenate. That is to say, the efficiency with which KD cells reconstituted 
with moPrP bearing various alanine mutations in the N-terminus propagated 
RML prions was reflected in the ability of cell lysates collected from these 
cells to infect PK1 cells (Figures R14, R16, R24 and R49).  
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FIGURE R49: PK1 CELLS INFECTED WITH LYSATE FROM PRION-INFECTED KDMOPRPALA 
CELLS 
Response of PK1 cells to infection with lysates of RML-infected KD cells 
reconstituted with: the wild-type mouse prion protein (moPrPWT), empty vector 
control (pLNCX2), or various moPrP constructs bearing point, double or triple 
alanine mutations (moPrPAla). Significance is denoted by * for P≤0.005; ** for 
P≤0.0025; *** for P≤0.0002 and ‡ for P≤0.0001. Significance only shown for split 6 
for clarity; calculated using a one-way ANOVA plus Bonferroni correction for 
multiple comparisons. 
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KDmoPrPWT cells and PK1 cells propagate RML efficiently, with spot 
numbers above eight hundred by split 6 when infected at a 1x10-5 dilution of 
homogenate (Figure R12). PK1 cells which were infected with cell lysate 
collected from RML-infected KDmoPrPWT cells gave spot numbers of six 
hundred at split 6; this is the highest spot number obtained for PK1 cells 
with cell lysate infections (Figure R49).  
Lysates collected from RML-infected KD cells reconstituted with S43A were 
also tested for their response on PK1 cells and used as a positive control in 
addition to KDmoPrPWT as this mutation did not retard RML propagation 
(Figure R16). Infection of PK1 cells with KDmoPrPS43A lysate gave five 
hundred spots at split 6 and was not significantly different from propagation 
of PK1 cells achieved with moPrPWT lysate infection (Figure R49).  For PK1 
infections with lysates from KD cells expressing mutations 
K23A.K24A.R25A and Q41A, spot numbers below three hundred and two 
hundred, respectively, were obtained (Figure R49).  
For infections with lysates from KD cells expressing moPrP alanine 
mutations in CC2 regions, spot numbers of less than one hundred were 
observed at all splits (Figure R49). In fact, for infections with lysates from 
KDmoPrPQ97A.W98A and KDmoPrPL108A.K109A, PK1 cells reported similar spot 
numbers to infections with lysate from KD cells expressing the empty 
pLNCX2 vector (Figure R49).  Therefore, lysates collected from RML-
infected KD cells reconstituted with moPrP bearing alanine mutations in 
CC2, at Q41 and at K23.K24.R25 were less infectious to PK1 cells than 
lysates from RML-infected KD cells reconstituted with the wild-type protein 
or that bearing mutation S43A (Figure R49). Additionally, lysates collected 
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from RML-infected KD cells expressing moPrP mutations K23A.K24A.R25A 
were more infectious to PK1 cells than those with the single mutation Q41A, 
which in turn was more infectious than any tested CC2 alanine mutation 
(Figure R49). 
3.6.6 Expression of moPrP constructs bearing alanine mutations in 
PK1 cells  
PK1 cells express the mouse prion protein endogenously. We used the 
available library of moPrP constructs bearing single, double, or triple alanine 
replacements to express these minimally mutated forms in PK1 cells such 
that expression of both moPrPWT and moPrPAla proteins was achieved in the 
same cell line. These were established as described in Section 3.2 to test 
the hypothesis that alanine mutations in the flexible N-terminal region of the 
mouse prion protein can exert an inhibitory effect on the formation of prions 
not only on the protein bearing the minimal alanine mutations, but also on 
the wild-type protein.  
PK1moPrPAla cells were infected with RML prions in a standard SCA (1x10-5 
dilution of infectious inoculum) and analysed for their ability to propagate 
these prions (Figure R50). PK1 cells were transduced with virally packaged 
moPrP constructs bearing moPrPWT, the N-terminal deletion mutant Δ23-88, 
CC1 mutation K23A.K24A.R25A, and CC2 mutations Q90A, 
T94A.H95A.N96A, Q97A.W98A, N99A.K100A, L108A.K109A and 
H110.V111A. 
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Neither deletion mutation Δ23-88, nor CC1 mutation K23A.K24A.R25A 
inhibited prion propagation when PK1 cells expressing these mutations 
were infected with RML prions, in contrast to all CC2 mutations tested which 
reduced propagation to at least half of that achieved for PK1moPrPWT cells 
(Figure R50). PK1moPrPWT, PK1moPrPΔ23-88 and PK1moPrPK23A.K24A.R25A all 
gave around eighteen hundred spots at split 6 (Figure R50). 
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FIGURE R50: SCA OF PK1MOPRPALA CELLS 
PK1 cells were transduced with various moPrP constructs bearing alanine 
mutations cloned as point, double or triple replacements in the N-terminal regions 
23-111 of the protein. PK1 cells expressing these alanine mutations on moPrP 
were assayed for their ability to propagate RML prions by SCA. Significance is 
denoted by * for P≤0.005; ** for P≤0.0025; *** for P≤0.0002. Significance only 
shown for split 6 for clarity; calculated using a one-way ANOVA plus Bonferroni 
correction for multiple comparisons. 
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Inhibition of propagation was equal for CC2 mutations Q97A.W98A, 
N99A.K100A, L108A.K109A, and H110.V111A with spot numbers of six- to 
eight hundred at split 6, compared to eighteen hundred for PK1 expressing 
moPrPWT. PK1 cells expressing moPrP mutations Q90A and 
T94A.H95A.N96A reported lower spot numbers of three- and five hundred, 
respectively, at split 6 (Figure R50). Thus, a graded reduction in 
propagation, rather than poisoning of RML propagation was observed in 
PK1moPrPAla cells that express mutations in the CC2 region 90-111. This 
may be due to the association/dissociation of CC2 in the native form of the 
protein with a particular cellular factor or factors, an interaction that is 
competitively inhibited in the presence of alanine-mutant forms of moPrP, 
which has previously been shown to be a poor propagator (Section 3.4). 
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3.6.7 Expression of moPrP constructs bearing alanine mutations in 
chronically RML-infected PK1 (iPK1) cells 
iPK1 cells are described as chronically infected cells as they produce 
ProteinaseK-resistant moPrP. They are typically used for cell curing assays 
to test the potency of various pharmacophores286. Here, they were 
transduced with virally packaged moPrP constructs bearing point, double or 
triple mutations in the flexible N-terminal region; this was to test whether 
expression of moPrPAla in these cells, would lead to a reduction in the 
amount of ProteinaseK-resistant material – a test for ‘curing’.  
iPK1moPrPAla cells were established in the same way PK1moPrPAla and 
KDmoPrPAla cells were made (Chapter I). It was found that none of the 
moPrP constructs, regardless of the mutation expressed, cured iPK1 cells 
of prion infection as the levels of ProteinaseK-resistant material did not 
decrease after expression of moPrPAla in these cells (Figure R51). 
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FIGURE R51: EXPRESSION OF MOPRPALA DOES NOT RESCUE IPK1 CELLS FROM PRION 
INFECTION 
(A) iPK1 cells were transduced either with empty vector pLNCX2, or moPrP 
bearing various point, double or triple mutations within region 23-111 of the protein. 
Following antibiotic selection of transduced iPK1 cells, levels of ProteinaseK-
resistant material were measured by ELISPOT. (B) Expression of moPrP in 
transduced iPK1 cells was tested alongside non-transduced cells to compare 
protein distribution; there were no apparent or statistically significant differences 
noted between samples expressing CC1 or CC2 alanine mutations and non-
transduced iPK1 cells. IF: immunofluorescence; PC: phase contrast. 
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3.6.8 N-terminal mutations in moPrP at charge cluster regions 
protect cells from prion infection  
Experiments were carried out to express moPrPAla with mutations targeted 
at charge clusters within the flexible N-terminal domain of the protein in KD, 
PK1 and iPK1 cells. They were then analysed for their ability to propagate 
RML prions by SCA.  
KDmoPrPAla cells showed significantly limited propagation when alanine 
replacements K23A.K24A.R25A, Q41A, and various alanine mutations 
within CC2 region 90-111 were tested for RML prion propagation (Figures 
R46 and R47). To test whether this reduction in propagation was due to the 
inability of cells expressing the moPrP mutations to be infected by RML, or 
to release infectivity to surrounding populations of cells, RML-infected 
KDmoPrPAla cells were ribolysed and lysates subsequently added to PK1 
cells (Figure R49). It was found that KDmoPrPAla cells were susceptible to 
RML infection to varying degrees and that the level of infection achieved 
depended on the region mutated, with alanine mutations at CC1, Q41 and 
CC2 lowering susceptibility to infection in increasing order (Figure R46). If 
the KDmoPrPAla cells were successfully infected by RML but unable to 
release their infectivity, ribolysing the cells would overcome this barrier. 
However, when RML-infected KDmoPrPAla cell lysates were tested for their 
infectivity on PK1 cells by SCA (Figure R49), only KDmoPrPWT and 
KDmoPrPS43A exhibited high levels of infectivity, suggesting that RML prions 
were successfully produced and accumulated in these cells following RML 
infection. This was followed by progressively lower infectivity for 
K23A.K24A.R25A, Q41A and alanine mutations in CC2, respectively 
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(Figure R49). The low level, but ever-present detection of ProteinaseK-
resistant spots observed at split 6 for PK1 cells infected with cell lysates of 
KDmoPrPAla cells with CC1, Q41 and CC2 mutations (Figure R49) supports 
data on RML infection of KDmoPrPAla cells (Figure R46): CC1, Q41 and 
CC2 alanine mutations do not abrogate propagation, but considerably 
lowered the ability of cells expressing these mutations to propagate prions. 
This suggests that the presence of alanine mutations at these specific sites 
in the protein renders cells expressing them less susceptible to prion 
infection, rather than interfering with propagation/replication of prions, based 
on the low–level infectivity displayed by RML-infected KDmoPrPWT cells as 
tested on PK1 cells (Figure R49). That is, when KDmoPrPAla cells were 
infected with RML, passaged for six splits at 1:8 to dilute out the initial 
inoculum and allow for propagation and accumulation of de novo prions, 
harvested and subsequently ribolysed, they displayed incredibly low 
infectivity within their respective cell lysates when applied to RML-
susceptible PK1 cells compared to KDmoPrPWT cells treated in the same 
way (Figure R49). This suggested a low titre of infectivity was present within 
the RML-infected KDmoPrPAla cells (Figure R46).  
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3.6.9 Dominant-negative inhibition of prion propagation by residues 
within CC2  
Further analysis of alanine mutations within region 23-111 probed the 
question of whether they could exert a lowered propagation phenotype in 
the presence of the wild-type protein. To test this, constructs bearing 
moPrPAla were expressed in PK1 cells. The resultant cell line PK1moPrPAla, 
expressed both moPrPWT and moPrPAla and was challenged with RML 
prions to assess its ability to propagate these prions. It was found that 
following RML infection of PK1moPrPAla cells, only alanine mutations in 
CC2, but not CC1, lowered the level of propagation observed (Figure R49). 
Furthermore, an N-terminal deletion which encompasses CC1, Q41 and 
OPR regions of the protein but not CC2 is known to abrogate RML prion 
propagation when expressed in KD cells (KDmoPrPΔ23-88) – this mutation 
Δ23-88, had no inhibitory effect on prion propagation when expressed in 
PK1 cells, as PK1moPrPΔ23-88 cells propagated with the same efficacy as 
PK1moPrPWT cells (Figure R42). This suggests that CC2, but not CC1 or 
Q41 alanine replacements exert dominant-negative inhibition of propagation 
by lowering the native ability of PK1 cells to propagate RML (Figure R42).  
It also shows that small changes between one and three alanine 
replacements in CC2 have a stronger control over prion propagation than a 
large deletion (Δ23-88) N-terminal to CC2 region 90-111 (Figure R42). 
Together, this strengthens the case for CC2, with residue Q90 as the most 
N-terminal point within it, as a significant charge cluster within the flexible 
tail of the protein that modulates propagation. It further demonstrates that 
mild alterations within CC2 can inhibit de novo prion formation in trans by 
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limiting the ability of the PK1 cells expressing the wild-type prion protein to 
propagate RML prions. Since these mutations when expressed as 
KDmoPrPAla rendered the cells less infectious to other RML-susceptible 
cells (Figure R49) we could speculate the moPrPAla protein can lower 
infectivity of RML when applied to moPrPWT as in PK1 cells (Figure R50) 
perhaps by sequestering some factor required for efficient propagation.   
It is interesting to consider however, that Δ23-88, like CC2 alanine 
mutations, abolished prion propagation in KD cells, but unlike CC2 alanine 
mutations did not exert an inhibitory effect in PK1 cells (Figure R50). This is 
an important finding as CC1 mutation K23A.K24A.R25A and point mutation 
Q41 were the only mutations identified within region 23-88 that when 
expressed in KD cells, reduced the ability of these cells to propagate prions 
relative to KD cells reconstituted with the wild-type protein. However, when 
both these changes were expressed on the same construct as 
K23A.K24A.R25.Q41A, the reduction in propagation was not as severe as 
Δ23-88. We could infer then, that deletion of segment 23-88 may impinge 
on the positioning and ultimately the activity of the CC2 region; this would 
explain why prion propagation is similarly reduced for KD cells reconstituted 
with Δ23-88 and CC2 alanine mutations.  
The graded pattern of spot number reduction when moPrPAla is expressed 
in PK1 cells is characteristic of competitive inhibition where moPrPAla 
competes for the same moiety as moPrPWT; a moiety that facilitates 
propagation. This may be in the form of a true binding interaction or a 
transient interaction either with PrPSc, or another cellular factor; this 
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association encourages the initiation of propagation, or its maintenance 
following successful initiation post-infection.  
This would also account for the finding that CC2 alanine mutations, but not 
deletion Δ23-88 exhibit dominant negative inhibition of prion propagation, as 
small amino acid replacements, unlike deletion Δ23-88 are not likely to alter 
the positioning of CC2, but may affect its native activity within its cellular 
environment, i.e. interaction with a propagation facilitator.  
In the context of region CC2 being critically involved in a cellular association 
that facilitates initiation of propagation, we would expect: (i) KDmoPrPAla 
cells with CC2 mutations to have significantly reduced propagation as it 
would never be established efficiently; (ii) the presence of moPrPAla CC2 
alanine mutant forms in PK1 cells to deplete the available pool of the 
propagation-facilitating-factor, making its interaction with moPrPWT less 
likely and thus, reduce the efficiency with which moPrPWT can propagate 
RML prions. These are both results confirmed by SCA analysis.  
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3.6.10 Alanine replacements in CC2 inhibit de novo formation of 
prions, but cannot reverse the fate of existing prions 
Since alanine mutations in CC2 were able to limit prion propagation in 
KDmoPrPAla cells (Figure R46) and inhibit prion propagation by the wild-type 
protein in PK1moPrPAla cells (Figure R50), we investigated whether they 
could cure chronically RML-infected cells of prion infection (Figure R51). 
When CC2 alanine mutations were expressed on chronically infected cells 
as iPK1moPrPAla, none of them reduced the level of ProteinaseK-resistant 
spots relative to iPK1 or iPK1_pLNCX2 cells (Figure R51). Hence, they 
were not able to reverse the propagation phenotype by curing iPK1 cells of 
RML infection (Figure R51). In conclusion, charge cluster 2 region of the 
prion protein mediates the efficacy of prion propagation by regulating the 
susceptibility of cells to prion infection (Figures R46 and R49). There is a 
probable interaction of CC2 with a cellular factor that promotes initial 
propagation, but not maintenance of propagation. Additionally, CC2 
mutations can regulate in trans the efficiency with which surrounding 
populations propagate prions (dominant-negative inhibition of prion 
propagation), probably by competing for binding to the facilitating factor, but 
cannot reverse the formation of prions once they have been established. 
This could be because promotion of initial propagation by binding to the 
facilitating factor is made redundant in chronically RML-infected cells. 
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FIGURE R52: PROPOSED MECHANISM OF INHIBITION OF PRION PROPAGATION BY MOPRPALA MUTATIONS IN CC1, Q41 AND CC2 REGIONS OF 
THE PROTEIN 
Prion propagation is made more efficient by association of PrPC to a propagation facilitator (pink) with its primary interaction (1˚) 
domain in CC2, and accessory sites or secondary interactions (2˚) at CC1 residues K23.K24.R25 and Q41. Bar schematic of moPrP, 
highlighting residues 23-111 within the protein. N-SS: N-terminal signal sequence; CC1: charge cluster 1; OPR: octapeptide repeat 
region; CC2: charge cluster 2; PTM: putative transmembrane region; α1: helix 1; β1: strand 1; α2: helix 2; α3: helix 3; SS-C: C-terminal 
signal sequence. Region 23-88 is defined by double-headed arrow. Sequence segments of moPrP shown in pink represent regions of 
the protein that when mutated (alanine replacement or deletion of 23-88), led to a reduced ability of cells expressing the mutated 
protein to propagate RML prions. 
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3.6.11 Features of charge cluster regions within PrP that may 
contribute to regulation of prion propagation. 
A number of studies have focused on the roles of N-terminal PrP residues 
and their various contributions to prion infection, propagation and toxicity. 
This flexible region of the protein is believed to promote propagation 
through its inherent disorder138; dissociation of fibrillar forms to generate 
more surfaces for conversion87; regulation of α-cleavage in the cellular 
protein49 and charge associations or repulsions that are involved in direct or 
indirect PrPSc binding101, 115, 117, 134. 
Region 23-31 at the extreme N-terminus of PrPC has been shown to bind 
directly to PrPSc116, with Δ23-31 reported to be defective in endocytosis116. 
The influence of this region on PrPSc formation is in line with the data 
presented here where KD cells reconstituted with moPrP bearing mutation 
K23A.K24A.R25A displayed a significant reduction in their ability to 
propagate RML prions (Figure R47).  
There is very little evidence in the literature for the involvement of residue 
Q41 in prion propagation. Q41 comprises part of the YXXQ (YPGQ) 
consensus sequence motif for the recruitment and activation of Stat3255. 
Association of PrP with Stat3 has only been shown in terms of prion 
regulation of pluripotency in embryonic stem cells256. This however, is 
unlikely as mutations in surrounding residues such as Y38 in mutation 
S36A.R37A.Y38A or S43A did not exhibit any reduction in propagation) 
(Figure R14 and R16). Although the mechanisms by which Q41A interferes 
with propagation in KD cells reconstituted with moPrPQ41A are not known, 
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the effect observed here is clear (Figure R47).  A study by Ushiki-Kaku et al. 
alluded to the involvement of Q41 as part of a novel epitope present in 
PrPSc but not PrPC: QGSPGGN (moPrP 41–47)101. Their study involved 
peptide array analysis of sera from PrP-null mice injected with Scrapie 
homogenate and a screen for differential binding between infected and non-
infected samples to uncover disparities in protein conformation and exposed 
residues in the cellular and aberrant protein forms. This data supports our 
finding that Q41 is a critical site that can mediate prion propagation, as 
KDmoPrPQ41A cells propagate RML prions with markedly reduced 
efficiencies relative to KDmoPrPWT cells (Figure R47). 
Loss of prion propagation in deletion mutation Δ23-88, but the subsequent 
inability of this mutation to inhibit formation of de novo prions in infected 
PK1 cells may be explained by phenomenon of intrinsically disordered 
regions29, 36. The intrinsic flexibility of the N-terminal 23-111 domain of the 
protein may contribute to misfolding propensity, thereby encouraging prion 
propagation following infection. Removal of this region may then in turn, 
stabilise the native fold of PrPC, making it less likely to misfold into PrPSc 
upon RML infection. Alternatively, the effects observed for Δ23-88 may be a 
reflection on the displacement of CC2 residues made by this deletion, which 
have been shown to have a strong controlling effect on prion propagation 
(Figures R24, R25, R46, R49 and R50). 
Qi et al. suggest that the flexible N-terminal region bears key histidine 
residues that when protonated under mildly acidic conditions contribute to 
fibril dissociation, a necessary event in prion propagation87. They showed 
that fibrils formed from recombinant protein when placed in a mild acidic 
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environment such as that in late endosomal compartments, undergo 
dissociation both laterally and axially87.  
Oliviera-Martins et al. and Hara et al. highlighted the role of CC2 residues 
100-104 in α-cleavage49 and prion conversion134 of the protein, respectively. 
In the first instance, lack of α-cleavage is stated as a shared characteristic 
of PrPSc and toxic PrPC mutants; the authors infer that the α-cleavage 
tolerance of PrP with K109I.H110I mutations, which is also toxic in 
transgenic mice, points to the importance of region CC2 in regulating prion 
protein cleavage and may have consequential roles in disease 
pathogenesis49. McDonald et al. present a revised report on the α-cleavage 
of PrP, suggesting that in the presence of copper, the protein is processed 
by ADAM family proteins between A119↓V120 and G227↓R228, in addition 
to the canonical K109↓H110 cleavage50. Although this shifts α-cleavage 
outside the CC2 region, this region is still required for alternative ADAM-
mediated cleavage, as copper coordination primarily occurs at histidine 
residues within OPR and CC2 segments of the protein129. 
Hara et al. used 3F4-epitope-tagged constructs to show the inability of 
moPrP mutants K100A, S102A, K103A and P104A to form ProteinaseK-
resistant protein134. This is consistent with our findings that CC2 mutations 
significantly lower prion propagation with spot numbers in the range of fifty 
to one hundred which falls in the range of severe limitation to, and 
abrogation of, prion propagation (Figure R47). Hara et al. also emphasise 
that CC2 alanine mutations within epitope 100-104 ‘eliminated the 
endogenous PrPSc’ in chronically infected cells – this is in contrast to the 
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findings presented here, where CC2 alanine mutations do not have any 
effect on lowering ProteinaseK-resistant PrP in chronically infected cells 
(Figure R51) where RML-infection is already established, but exert 
dominant-negative inhibition on the de novo prion formation (Figure R50).  
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TABLE R7: LIST OF MUTATIONS MADE WITHIN THE UNSTRUCTURED REGION OF THE 
MOUSE PRION PROTEIN. 
N/A: not applicable. Colour intensity signifies the extent to which expression of the 
moPrP mutation limits propagation in the indicated cell line. 
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3.6.12 Mutational analysis of the flexible N-terminal tail of moPrP 
reveals three distinct regions that exert varying control over prion 
propagation 
moPrP was expressed as the wild-type protein, or with point, double or triple 
mutations within region 23-111 in three cell lines: KD, PK1 and iPK1 cells. 
KD cells reconstituted with moPrP bearing alanine mutations 
K23A.K24A.R25A, Q41A, and mutations within CC2 region 90-111 
demonstrated a significantly reduced ability to propagate prions, with the 
most pronounced reduction exerted by CC2 mutations. These results were 
verified by preparing SCCs (Figure R46). 
Region 23-31 has been previously identified as a replicative surface for 
PrPSc formation116. Here, we propose that the minimal segment that 
contributes to prion propagation in this association is 23-25 (Figures R14, 
R15, R46 and R47). Q41 has been identified in this study as a novel point 
mutation that limits prion propagation. It is also the only residue in region 
23-88 that has an effect on lowering propagation with incredible specificity, 
as it is a single amino acid change and mutation of neighbouring residues 
had no effect on prion propagation (Figures R14 and R16). CC2 region 100-
104 has been identified as the key epitope for prion conversion134. Here, we 
suggest that the entire region 90-111, and not 100-104 alone is significant in 
regulation of prion propagation (Figures R24 and 46). The reduced 
propagation presented in cells expressing these mutations was due to an 
acquired lower susceptibility to RML infection (Figure R49) – a characteristic 
that mutations within CC2 were able to exert in a dominant-negative manner 
(Figure R50). We hypothesise that CC2 acts as a region, which associates 
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with a cellular factor, whose accessory binding sites are at K23.K24.R25 
and Q41. This association allows for the highly efficient propagation of 
prions (Figure R52). 
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3 . 7  M i d d l e  c o n s e r v e d  r e g i o n  1 1 2 - 1 3 5  o f  t h e  
p r i o n  p r o t e i n  m a y  t r a v e r s e  t h e  l i p i d  b i l a y e r  
3.7.1 Experimental strategy  
Residues 111-135 of the prion protein represent the most 
highly conserved domain within the protein, consisting 
almost exclusively hydrophobic residues54. Indeed, when 
the native sequence is threaded into structure prediction 
programs, the nature of the residues within 111-135 leads 
to the same conclusion: that this section of the protein is 
predicted to have a transmembrane helix secondary 
structure (Figure R45). To test this hypothesis and the 
effect of altering the putative transmembrane helix structure 
of the protein on prion propagation, we designed point 
mutations to increase or decrease helix propensity, based 
on data by Li et al287 (Table R8). 
 
Hegde et al. showed that depending on the orientation of PrP across the 
membrane, it may have toxic or protective functions63, 152. Furthermore, 
when the full amino acid sequence of the mature protein is run in a program 
to predict fibril propensity, a large portion of residues that fall in the 
‘amyloidogenic’ region are of the middle region of PrP (Figure R54)288.  
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FIGURE R53: PREDICTION OF THE MIDDLE REGION OF MOPRP AS A MEMBRANE-
TRAVERSING SEGMENT 
Three prediction programs were used to predict the secondary structure of moPrP 
using the amino acid sequence of UniProtKB ID P04925. Each showed that the 
region encompassed within segment 111-135 of the protein is predicted to be a 
membrane traversing domain, indicated with a filled arrow in each instance. 
(A) http://mobyle.pasteur.fr/cgi-bin/portal.py?#forms::toppred 
(B) http://www.ebi.ac.uk/Tools/pfa/phobius/ 
(C) https://www.predictprotein.org/ 
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FIGURE R54: FIBRIL-FORMING SEGMENTS IN THE PRION PROTEIN 
Thompson et al. designed a fibril-prediction program where the amino acid sequence of any protein is analysed six-amino acids at a 
time, across the length of the sequence. The energy of the six-amino acid sequence is calculated by mapping it to previously acquired 
data from their laboratory and if this energy is lower than the threshold value (shown here in red), the segment is predicted to be fibril-
forming.  
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TABLE R8: HELICAL PROPENSITY OF VARIOUS AMINO ACIDS 
Li et al.287 carried out systematic studies of peptides by circular dichroism; shown 
here are results they obtained for association of peptides in SDS micelles, which 
allowed for a ranking order of helical propensity, with isoleucine (Ile) shown to be 
the strongest promoter of helicity and proline the weakest.  
 
Using the rationale that mutations to isoleucine would increase helix 
propensity and those to proline decrease it (Table R8), a total of thirty-seven 
point mutations and two deletion mutations were designed in region 111-
135 of the mouse prion protein via site-directed mutagenesis (Chapter I). 
The mutations were expressed in KD cells and the ability of cells expressing 
these mutations to propagate prions was tested by SCA (Section 3.2).  
There were three main aims of generating mutations in this region and in 
particular, substituting native residues to amino acids other than alanine: (i) 
to test the effects of altering helix propensity on the propagative capacity of 
the altered protein; (ii) to probe the association of the PTM domain with 
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membranes; (iii) to test the possibility of a PrP homodimer through 
association of its PTM domain. From the SCA experiments carried out 
herein, only information on the helix stability and its effects on propagation 
can be deduced. Based on SCA data, we can also infer residues of interest 
within the PTM and whether PrP engages in homodimer interactions that 
contribute to the efficiency of prion propagation. We cannot however, 
answer questions on the membrane association of the protein through this 
domain; this work will be undertaken by other members of the department, 
using the available mutagenic library generated for moPrP (Table R1).   
The changes made span the moPrP sequence from residue 111-135 
(Figures R55-57). These changes are presented in three parts, analysing 
the effects of amino acid replacements on moPrP in region (i) 111-119, (ii) 
121-127 and (iii) 127-135. 
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TABLE R9: MUTATIONS MADE WITHIN REGION 111-119 OF MOPRP 
Mutations made within region 111-119 alter the helix propensity properties of the PTM by increasing or decreasing the helix stability of 
this region by varying degrees. The degree of change is indicated in the ‘overall change’ column where the difference between the 
initial and final values for the native and substituted residues is shown, based on the values provided in Table R8. 
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3.7.2 Scrapie cell assay analysis of mutations in residues 111-119 of 
moPrP  
Point mutations made within moPrP PTM region 111-119 included six 
changes to leucines which are predicted to increase helix propensity, some 
that decrease helix propensity and a substitution to proline which is a 
helix/strand breaker (Table R9). Most of the KD cells reconstituted with 
mutations in this region displayed a propagation profile comparable to wild-
type controls at split 4, the earliest time point where samples were 
analysed, but displayed lower spot numbers for splits 5 and 6 relative to 
wild-type controls (Figure R53).  
This pattern of initially (split 4) high spot numbers followed by successive 
decreases in spot number compared to wild-type-expressing cells was 
observed for KD cells reconstituted with moPrP mutations V111M, A112L, 
G113L, A115G, G118A, G118L, A119L and A119P. For mutation A116L, 
spot numbers of six hundred were recorded for split 4; this number halved 
at split 5, but propagation was re-established with six hundred spots by split 
6.  Both mutations made at position A117, (A117L and A117R) displayed a 
consistent lack of propagation capacity across all splits (Figure R55). 
However, SCA analyses of moPrP in this study have been carried out using 
the last time point, split 6, as the cells should have had, if truly propagating, 
enough time to accumulate maximal levels of ProteinaseK-resistant PrP 
and the initial applied homogenate equally diluted, giving the best 
differential for detection of de novo prions (Section 3.2).  
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FIGURE R55: SCA ANALYSIS OF KDMOPRPALA CELLS WITH MUTATIONS IN REGION 111-
119 
SCA analysis of KD cells reconstituted with various mutations in moPrP. The first 
five cell lines represent three positive controls (PK1 cells, KD cells reconstituted 
with moPrPWT and KD cells reconstituted with moPrP bearing a triple alanine 
mutation at the N-terminus); and two negative controls: KD cells reconstituted with 
empty vector pLNCX2 and un-reconstituted KD cells. The next 11 cell lines 
expressed moPrP bearing point mutations in sequence segment 111-119. 
Significance is denoted by * for P≤0.005; ** for P≤0.0025; *** for P≤0.0002 and ‡ 
for P≤0.0001. For clarity, significance is only shown for split 6, which is taken to be 
the time point with the best differential between detection of applied and de novo 
prions (Section 3.2); calculated using a one-way ANOVA plus Bonferroni correction 
for multiple comparisons. 
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Using these criteria, all mutations made in region 111-119 of moPrP 
displayed reduced propagation compared to wild-type controls at split 6 
(Figure R55). 
Spot numbers, although low for all cells expressing moPrP mutations, 
varied between cell lines such that: A119P< A117L< A117R< A119L< 
G118A< V111M< A115G< G118L< G113L≤ A112L< A116L. Thus, A116L 
affected spot number the least, with split 6 values of six hundred, and 
A119P lowered it the most with spot numbers below fifty and comparable to 
negative controls at the same split (Figure R55).  
The next set of mutations analysed for their ability to propagate RML prions 
were in region 121-127 of the protein’s PTM domain. All cells tested 
expressing single amino acid changes within this segment of the protein 
demonstrated a considerable and significant reduction in their ability to 
propagate prions (Figure R56). Like cells expressing mutations made in 
region 111-119 of the protein, those expressing mutations made in region 
121-127 displayed higher spot counts for split 4 compared to split 6 for 
some replacements: V121A, L124A, L124I, G126L, G126V and Y127F 
(Figure R56).  At split 6, the highest propagation was observed for 
KDmoPrPWT cells, followed by KD cells reconstituted with 
W31A.N32A.T33A, a triple alanine-mutant positive control (Figure R14), and 
then PK1 cells (Figure R56). Of the PTM mutations, highest spot numbers 
at split 6 were recorded for G125A with six hundred spots; 
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TABLE R10: MUTATIONS MADE WITHIN REGION 121-127 OF MOPRP 
Mutations made within region 121-127 alter the helix propensity properties of the PTM by increasing or decreasing the helix stability of 
this region by varying degrees. The degree of change is indicated in the ‘overall change’ column where the difference between the 
initial and final values for the native and substituted residues is shown, based on the values provided in Table R8. 
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FIGURE R56: SCA ANALYSIS OF KDMOPRPALA CELLS WITH MUTATIONS IN REGION 121-
127 
SCA analysis of KD cells reconstituted with various mutations in moPrP. The first 
five cell lines represent three positive controls (PK1 cells, KD cells reconstituted 
with moPrPWT and KD cells reconstituted with moPrP bearing a triple alanine 
mutation at the N-terminus); and two negative controls: KD cells reconstituted with 
empty vector pLNCX2 and un-reconstituted KD cells. The next 11 lines expressed 
moPrP bearing point mutations in sequence segment 121-127. Significance is 
denoted by * for P≤0.005; ** for P≤0.0025; *** for P≤0.0002 and ‡ for P≤0.0001. 
For clarity, significance is only shown for split 6, which is taken to be the time point 
with the best differential between detection of applied and de novo prions (Section 
3.2); calculated using a one-way ANOVA plus Bonferroni correction for multiple 
comparisons.  
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three hundred for V121A and G126L; two hundred for G123A; one hundred 
for G122L, L124V, G126V and Y127F. Cells expressing G122A, L124A and 
L124I however, exhibited spot numbers comparable to negative controls 
(KD cells and KD cells transduced with the empty vector, pLNCX2).  
Additional point mutations were made within 127-135, while one double 
replacement (A117R.Y127R) and two deletion mutations within the PTM 
domain were also tested (Table R11; Figure R57). Of the deletion 
mutations, the one with a smaller change, Δ117-124 propagated RML 
prions better than the larger deletion construct Δ112-129 (Figure R57). 
Similar results as those observed for single amino acid changes in moPrP 
region 111-119 (Figure R55) and region 121-127 (Figure R56) were 
observed for changes made in region 127-135 of the protein (Figure R57), 
in that any changes made in this region reduced the ability of cells 
expressing these constructs to propagate prions. Other than positive control 
cells (PK1, moPrPWT and W31A.N32A.T33A), the highest spot count at split 
6 was observed for deletion mutation Δ117-124 and point mutation G130L 
(approximately five hundred spots); this was followed by S131A, L129A, 
S132L, S134A, M128V, Y127R, R135E, Y127P Δ112-129, A117R.Y127R 
and G130A (Figure R57).    
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TABLE R11: MUTATIONS MADE WITHIN REGION 127-135 OF MOPRP 
Mutations made within region 127-135 alter the helix propensity properties of the PTM by increasing or decreasing the helix stability of 
this region by varying degrees. The degree of change is indicated in the ‘overall change’ column where the difference between the 
initial and final values for the native and substituted residues is shown, based on the values provided in Table R8. 
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FIGURE R57: SCA ANALYSIS OF KDMOPRPALA CELLS WITH MUTATIONS IN REGION 127-
135 
SCA analysis of KD cells reconstituted with various mutations in the PTM region of 
moPrP. The first five cell lines represent three positive controls (PK1 cells, KD cells 
reconstituted with moPrPWT and KD cells reconstituted with moPrP bearing a triple 
alanine mutation at the N-terminus); and two negative controls: KD cells 
reconstituted with empty vector pLNCX2 and un-reconstituted KD cells. The next 
11 entries in the graph represent point mutations in moPrP within the segment 127-
135. Significance is denoted by * for P≤0.005; ** for P≤0.0025; *** for P≤0.0002 
and ‡ for P≤0.0001. For clarity, significance is only shown for split 6, which is taken 
to be the time point with the best differential between detection of applied and de 
novo prions (Section 3.2); calculated using a one-way ANOVA plus Bonferroni 
correction for multiple comparisons. 
  
290 
 
3.7.3 Does helix stability of the PTM region in moPrP correlate well 
with propagation efficiency? 
Various mutations were made along the length of the PTM region in moPrP; 
KD cells were then reconstituted with these mutations and were found 
without exception, to reduce the propagative capacity of these cells relative 
to wild-type controls (Figures R55, R56 and R57). 
An interesting phenomenon observed for some of the expressed mutations 
was a split-to-split drop in spot number which is the inverse trend of a true 
propagating line. This phenomenon is not well reported in the literature, with 
limited mentions ‘acute infection’ versus ‘chronic infection’ as described by 
Vorberg et al where levels of ProteinaseK-resistant fractions of PrP persist 
for a limited phase, or continue to persist long term respectively280. In any 
case, the overall analysis of the expressed mutations reveals that the levels 
of ProteinaseK-resistant PrP are significantly reduced in cells expressing 
PTM mutations at split 6. This does not correlate with the predicted effects 
on helical propensity, i.e. mutations that showed the most severe inhibition 
of propagation included A117L, A117R, A119P (Figure R53), G122A, 
L124A, L124I (Figure R54), G130A and Δ112-129 (Figure R55) – which 
represent both changes to increase and decrease helical propensity, and in 
each case, is altered by varying amounts (Tables R9, R10 and R11).  
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3.7.4 Probing the PrP homodimer hypothesis 
Most non-covalent protein-protein interactions that occur within the 
membrane are mediated mainly through transmembrane domains, with 
specific conserved motifs driving these interactions, the most over-
represented of which is the GXXXG glycine zipper motif289. An interesting 
feature of the PrP PTM domain is that this motif exists as a series of three 
consecutive blocks in PrP, possibly forming a glycine zipper at residues 
118-130 GAVVGGLGGYMLG in moPrP290.  
If such interactions were to occur between PrP molecules, we could 
hypothesise that dimer formation is mediated through its PTM domain – a 
finding reported independently by Warwicker291 and Rambold56, and further 
pursued for its regulation of PrP trafficking to the cell surface292. 
Researchers alluded to the formation of prion protein dimers as early as 
1995293. Warwicker carried out molecular modelling approaches to infer the 
significance of PrP dimers and their membrane interactions291. A dimer 
model was proposed for PrPSc formation through β-hairpin stacking for 
oligomer extension. Furthermore, he suggested  that the large-scale 
rearrangements involved in dimer binding, β-hairpin stacking and extensive 
cross-linking could be related to the measured lag between initial binding of 
PrPC to PrPSc and the attainment of ProteinaseK-resistance291, which is the 
readout for PrPSc formation by most conventional prion detection assays. 
Here, we attempted to investigate the possibility of PrP homodimer 
formations and designed mutations that would disrupt its formation.  
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A helix homodimer model of the human prion protein was generated by 
Laszlo Hosszu within the department, using PyMol software (Figure R58). 
The PTM region is shown within residues 111-135 aligned in parallel, using 
Molecular modelling programs BUDE (University of Bristol; program under 
development) and GrammX294 (Figure R58). This revealed residues A119, 
Y127 and G130 as being within 3Å distance of each other  when analysed 
in BUDE (Figure R58, A) and V111, A115, G130, S134 and R135 observed 
within 3Å of one other  when analysed in GrammX (Figure R58, B).  
We could thus hypothesise that if homodimer associations occur in the cell 
and their maintenance is important for prion propagation, then introducing 
amino acid changes at positions where the side chains between the dimers 
are in close proximity would result in a reduction in spot number as 
measured by SCA. Using the moPrP mutation constructs available in the 
moPrP mutagenesis library (Table R1), SCA data for these PTM region 
mutations was revisited (Figures R55, R56 and R57) in the context of the 
homodimer hypothesis. Mutations tested in the PTM region included 
replacements that were made to increase or decrease helix propensity, 
introduce destability within the helix, and break the PTM helix (Figures R55, 
R56 and R57). Replacements that resulted in spot numbers below two 
hundred at split 6 are summarised below (Figure R58).  
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FIGURE R58: MOLECULAR MODELLING OF THE PTM REGION 110-136 IN THE HUMAN PRION PROTEIN 
Molecular modelling of the PTM region 110-136 of the human prion protein (huPrP), with homodimers shown in: (A) BUDE; (B) 
GrammX; (C) overlay of models generated in BUDE (blue) and GrammX (grey). Residues highlighted in red in (A) and (B) are 
calculated to be within 3Å of one another and thus mutations made at these sites are predicted to interfere with possible dimer 
formation. (Note: since modelling was carried out on the human prion protein sequence, all residues indicated here represent the same 
in the mouse sequence +1, i.e. R135 in moPrP is equivalent to R136 in huPrP). Residues highlighted in red for (A) include A120, Y128 
and G131; for (B), residues in red are V112, A116, G131, S134 and R135. This corresponds to residues A119, Y127 and G130A for 
(A) and V111, A115, G130, M133 and S134 for (B) in the mouse prion protein sequence. 
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FIGURE R59: SUMMARY OF SITES WITHIN THE PTM DOMAIN PREDICTED TO DISRUPT DIMER FORMATION, MATCHED TO SCA DATA 
Combined summary of BUDE, GrammX and SCA results. (A) Table showing the effects of the generated mutations on helix propensity 
of the PTM domain: red – decreased; green – increased. Split 6 spots refer to PK-resistant spots detected following RML infection of 
KD cells reconstituted with moPrP bearing the indicated mutations. Cells reporting spot numbers below 200 are considered to be 
severely restricted in their propagation capacity. Those with spot numbers below 50 are considered to no longer support prion 
propagation at split 6. BUDE and GrammX molecular docking programs were used to predict residues within 3Å of each other in a PrP 
homodimer model: highlighted in blue in (A-D). Mutations tested by SCA that reported split 6 spot numbers equalling or lower than 200 
are indicated in cyan (A-D). (B) The amino acid sequence of moPrP PTM region was entered into PyMol 
(KHVAGAAAAGAVVGGLGGYMLGSAVSR)and a helix built from this; shown in blue are the residues predicted to be within 3Å of each 
other. (C) Using the helix generated in (B), residues in cyan denote sites found to significantly reduce propagation when mutated, as 
tested by SCA, but not predicted by BUDE or GrammX as being spatially proximal (3Å) in the helix dimer model. (D) End-on view of 
the generated helix, highlighting two faces (blue and cyan) that when mutated, severely impact prion propagation. 
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Indeed, spot numbers for residues predicted to be within 3Å of one another 
(by BUDE and GrammX) were below the two hundred mark as analysed by 
SCA and thus labelled as mutations that result in severely limited 
propagation (Figure R12). G130L was the only exception with more than 
four hundred spots, but G130A was the only mutation predicted to affect 
dimer formation by both docking programs and confirmed as reducing 
propagation in SCA (Figure R59). SCA revealed additional sites within the 
PTM domain – not predicted to interfere with the homodimer interface – that 
when altered, resulted in severely limited propagation: A117L/R, G122A/L, 
L124A/I/V and M128V (Figure R59, C). When results of residues predicted 
to be in close proximity as observed in the peptide docking models of BUDE 
and GrammX were combined with SCA experimental data, there appeared 
to be two faces of the PTM domain that were important for prion 
propagation (Figure R59, D).  
Amino acid replacements made in this study that would disrupt GXXXG 
motifs include replacements made at G118, G122, G126 and G130. Of 
these, mutations made at G122 and G130 demonstrated the most severe 
inhibition of prion propagation (Figures R56 and R57). These glycines lie on 
the same side of the PTM helix and along the side of the helix predicted to 
be involved in homodimer formation (Figure R59).  
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FIGURE R60: GLYCINE RESIDUES WITHIN THE PTM DOMAIN 
Superimposition of G122 and G130 on PTM domain helix showing residues 
predicted to affect helix dimerisation, as determined by BUDE and GrammX (blue), 
and residues that when mutated severely impacted prion propagation as tested via 
SCA, but not predicted to affect dimer interface (cyan). The glycine residues of 
interest are better aligned to the side of the helix predicted to be involved in dimer 
interactions (BUDE and GrammX). 
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Neither alanine nor leucine replacements provide the same conformational 
flexibility offered by glycine, but the larger side chain of leucine makes it less 
amenable to helix-helix interactions in the membrane. However, when 
glycines at positions 122 and 130 were replaced by leucines the loss in 
propagation observed in cells expressing these moPrP constructs was less 
severe than equivalent alanine replacements (Figure R56 and R57). The 
reasons for this are not clear and further experiments would have to be 
carried out to fully characterise the interactions of the putative helix 
homodimer interface and reveal the underpinning role of the PTM glycines.  
Harrison et al. showed in both cell and mouse bioassays that when glycine 
mutations in moPrP G118A/L/P, A119P, G122A/P, L124A and G130L/P are 
expressed, the ability of cells expressing these mutations to take up prions 
and propagate them is severely affected295. They further state that the 
glycines present within the PTM sequence constitute GXXXG motifs that 
could possibly function as canonical protein interaction sites296.  
The analyses in this study revealed seven sites within the PTM domain 
predicted by BUDE and GrammX to be possible sites that would impact 
PrP-homodimer formation and, if such formation was pertinent to 
propagation, would also interfere with the propagation process: V111, A115, 
A119, Y127, G130, S134, R135. As confirmed by SCA, mutations at these 
sites did indeed significantly lower the capacity of cells expressing these 
mutations to propagate prions and revealed four additional residues: A117, 
G122, L124 and M128 that also reduced spot numbers, to below two 
hundred, when singly mutated (Figure R59). The results further show that 
any changes made to the PTM region of the protein poison prion 
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propagation, regardless of whether the change is made at a glycine residue 
or not. In fact, even non-glycine-to-glycine mutations, as in A115G, resulted 
in lowered propagation (Figure R55). Harrison et al. also reported that 
mutations G125A and G130A confer partial but not complete resistance to 
prion infection, as mice inoculated with lysate derived from moPrP-
expressing cells with these mutations displayed no clinical signs of 
sickness, but immunohistochemistry on brain slices revealed presence of 
spongiform changes and PrP-reactive plaque deposition typical of prion 
disease pathology295.  
Choi et al. observed that anti-prion monoclonal antibody 1C5 recognises an 
epitope within the PTM region corresponding to the GXXXG motif in PrPSc 
but not PrPC290 and postulated that this region may play a crucial part in the 
initial conversion events leading up to prion propagation290. From the SCA 
data, we observed that all changes made to native glycine residues resulted 
in lowered prion propagation; this is in agreement with the data presented 
by Harrison et al. 295 and give further evidence for the contributions of G122 
and G130 to prion propagation.  
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3.7.5 PTM as a determinant of PrP-membrane association 
The prion protein is a GPI-anchored glycoprotein tethered to the outer 
leaflet of the lipid bilayer. However, numerous reports have alluded to 
single-spanning transmembrane forms of the protein where it uses a middle 
highly hydrophobic sequence to associate with the ER membrane63. The 
phenomenon of PrP existing both as secreted and transmembrane forms 
was first alluded to by Hay et al.297, further investigated in terms of prion 
protein biogenesis298-300 and fully characterised eight years later by Hegde 
et al63.  
Three forms of PrP topology were identified at the ER: PrPCtm, where the C-
terminal half of the protein is inside the ER lumen; PrPNtm, where the N-
terminal half of the protein is in the ER lumen and PrPSec that represents the 
fully secreted protein, with no association to the ER membrane63 (Figure 
R61). Note that these forms of PrP refer to the nascent polypeptide during 
protein biogenesis and its orientation across the ER membrane; it is not to 
be confused with the fully mature protein that is known to be GPI-anchored 
at the cell surface. The PTM domain has been shown to insert itself in the 
ER membrane in either an N-to-C or C-to-N terminus orientation using its 
hydrophobic sequence63; the role of this sequence has been further 
investigated by introducing microdeletions and minimal mutations63, 152. 
Amino acid substitutions in the signal sequence of the protein (residues 1-
22) increased or decreased CtmPrP relative to NtmPrP and SecPrP, whereas 
mutations within the HC domain itself appeared to increase or decrease 
both CtmPrP and NtmPrP relative to SecPrP152. 
300 
 
 
FIGURE R61: TRANSMEMBRANE FORMS OF THE PRION PROTEIN AT THE ER 
A number of transmembrane forms have been reported for PrP where the protein 
is able to span the membrane through its putative transmembrane domain, region 
111-135. Shown in red, black and blue are various forms of transmembrane PrP 
topologies, namely: (A) CtmPrP; (B) SecPrP and (C) NtmPrP. Each topology shows the 
full peptide sequence of moPrP, inclusive of N- and C- terminal signal sequences. 
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The authors suggested that while the HC domain sequence determines the 
ratio of peptides that are membrane-associated (NtmPrP, CtmPrP) or 
membrane-free at the ER (SecPrP), the signal sequence governs the 
proportion of transmembrane peptide that exists in the aberrant form 
(CtmPrP). 
Here, no changes have been made to the signal sequence of moPrP, but 
amino acid replacements within the PTM were analysed for their prion 
propagation propensity (Figures R55, R56 and R57). Increased 
hydrophobicity of the PTM is thought to lead to increased pools of CtmPrP 
and severe neurodegeneration301. Disease-associated mutations P104L, 
G113V, A116V, G130V and A132V (mouse numbering) increase PTM 
hydrophobicity and may exert their neurotoxic effects through CtmPrP 
expression. Positions G113, A116, G130 and A132 were mutated to leucine 
in this study.  
Here, propagation was severely reduced but not abrogated in all instances 
with spot numbers recorded in the range of two- to four hundred (Figures 
R55 and R57). From SCA analyses, mutations made in the C-terminal 
region of the PTM domain had a more severe effect on reducing prion 
propagation compared to those made more N-terminally (Figure R57). 
Since the experiments carried out were primarily propagation-focused in 
terms of mutational effects, the reduced propagation profile was not fully 
characterised in terms of protein trafficking, making it difficult to establish 
direct comparisons to the formation and ratios of topological PrP 
assemblies.  
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Nonetheless, we can use data from Sauvé et al.302 as a guide to predicting 
which amino acid changes would have the largest influences on 
association/disassociation with lipid membranes. They suggest interactions 
between region 111-114 at the micelle-water interface and burial of polar 
residues S131 and S134 within the micelle, with R135 engaged in 
electrostatic interactions with phosphate headgroups of the bilayer302.  
If the model predicted by Sauvé et al. holds true, mutations made at 
positions 111-114 have the potential to interfere with peptide interactions at 
the lipid surface, mutations at S131 and S134 may alter the positioning of 
these residues with respect to the bilayer and R135 mutations, which they 
postulate to be a driving force for initiating the PTM membrane insertion, 
would severely impact this association. Thus, if membrane association and 
indeed membrane insertion is critical for prion propagation, we would 
predict mutations at these sites to have a significant impact on RML 
propagation when tested via SCA (Figure R55, R56 and R57).  
Mutations made between region 111-114 of moPrP PTM include V111M, 
A112L and G113L (Table R8). Of these, V111M appeared to have a 
stronger inhibitory effect on propagation compared to A112L and G113L for 
which propagation inhibition was comparable (Figure R59). In each case, 
spot numbers were comparable to moPrPWT at split 4, indicative of 
uncompromised ability of cells expressing these mutations to be susceptible 
to, and replicate prions. However, propagation was not maintained as a 
considerable drop in spot number was observed at splits 5 and 6 (Figure 
R55). Mutations S134A and R135A severely inhibited propagation, giving 
spot numbers equal to or below two hundred (Figure R57). Analysis of 
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deletion mutations Δ112-129 and Δ117-124 revealed that Δ117-124 was 
able to propagate prions better than Δ112-129 (Figure R57) and this may 
highlight the importance of region 111-117 in prion propagation as 
mutations made here show low spot numbers (Figure R55).  
This data, if applied to the model of Sauvé et al., suggests that association 
of the PTM with lipid membranes facilitates the propagation process. In the 
context of PTM-lipid bilayer interactions therefore, the data presented here 
suggests that residues S134A and R135A have a more significant role to 
play in prion propagation than residues more N-terminal to this sequence 
(111-114) that are reported to associate with the outer layer of the lipid 
bilayer. This suggests then, that the stabilising interactions accomplished 
via R135 strongly influence prion propagation, and though association of 
residues 111-114 with the lipid membrane are perturbed by mutations at 
this site, they do not abrogate propagation (Figures R55 and R57).  
All KD cells reconstituted with moPrP constructs bearing mutations in the 
PTM domain were viable and could be used successfully for SCA analysis 
(Figure R60). For some mutations however, it was not possible to prepare 
stable cultures of KD cells, in particular cells reconstituted with moPrP 
bearing mutations A115L; V120A, as there were no survivors following 
G418 selection. It is possible that the protein expressed in these instances 
was toxic to the cells as expression of these constructs could not be 
established in four independent attempts (Figure R62).  
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FIGURE R62: PHASE CONTRAST IMAGES OF KD CELLS RECONSTITUTED WITH MOPRP 
MUTATIONS IN THE PTM REGION OF THE PROTEIN. MAGNIFICATION AT X20. 
 
The data presented here argues that a better model of PrP dimer 
association, both in association and without the influence of lipid bilayers 
could be established based on the propagation profile of the mutations 
analysed; additionally, the possibility of a dimer system existing ex vivo and 
not occurring in the native system should also be considered, as most 
reported instances of PrP dimers use inducible systems to identify the dimer 
interface56, 260, 293, 303, 304. Indeed, protein prediction and molecular modelling 
programs base interactions on available structural data and cannot always 
emulate the complexity of protein interactions within a crowded cellular 
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environment, but are able to provide clues to assist further understanding of 
protein interactions. 
In summary, analysis of moPrP mutations within the PTM domain of the 
protein revealed that: (i) prion propagation was reduced for some mutations 
(A112L, G113L, A116L, G125A, G130L and Δ117-124), severely 
compromised for others (V111M, A115G, A117L/R, G122A/L, L124V, 
Y127F, Y127P, Y127R, M128V, S134A and S135E) and completely 
abrogated for a few (A119P, G130A, L124A and L124I); (ii) the severity of 
reduction in propagation capacity observed for the expressed mutations did 
not correlate with changes in helical stability, but were clustered on two 
faces of the helix – one of which was predicted to be at the homodimer 
interface; (iii) although the data presented is in agreement with that of other 
researchers in terms of the significance of glycine residues within the 
PTM295, and corroborates  some of the interactions identified for the 
association of the PTM with lipid micelles302, it shows that loss of 
propagation capacity is elicited by changes at multiple sites within the PTM 
and is not exclusive to glycine residues. 
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Chapter 4 
Results summary, conclusions and 
future directions 
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4 . 1  S t r u c t u r a l  i n t e g r i t y  i s  r e q u i r e d  f o r  
p r i o n  p r o p a g a t i o n  a n d  t h r e e  s i t e s  i n  t h e  N -
t e r m i n a l  r e g i o n  m e d i a t e  t h e  e f f i c a c y  o f  
p r o p a g a t i o n  
Following prion infection, propagation of the infectious PrPSc species occurs 
through recruitment of PrPC48. This study and others have shown that in a 
cellular context, N-terminal deletion Δ23-88 results in severely compromised 
propagation. However, expression of moPrPΔ23-88 in transgenic mice still 
culminated in disease, but with longer incubation times. In this study, 
expression of Δ23-88 in the presence of the wild-type protein did not hinder 
prion propagation. Thus N-terminal deletions do not protect against prion 
infection128, 305, but may mediate other aspects of PrP function (Section 3.6). 
In contrast to the much debated role for the N-terminal residues, there has 
always been strong evidence that the C-terminal region of the prion protein 
forms the amyloid core in PrPSc and is largely responsible for PrP 
propagation, with the minimal segment that supports prion propagation – 
the miniprion – shown to be conversion and propagation supportive, despite 
bearing large deletions in the flexible N-terminal domain Δ23-88 and part of 
the structured domain Δ141-17676. 
To obtain a clearer picture of the significance of N-terminal residues on 
prion propagation, and to elucidate the role of surface amino acids in the C-
terminal region of the prion protein, both within and outside the miniprion 
domain, we carried out an alanine mutagenesis screen of the mouse prion 
protein. 
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A library of alanine mutations in moPrP was generated, bearing between 
one and three amino acid replacements at a time. The mutations were 
expressed in a sub-clone of N2a (PK1) cells in which PrP expression had 
been silenced and their contributions to prion propagation assessed by 
challenging them with RML prions in the Scrapie Cell Assay (SCA). This 
approach provided better power compared to deletion mutagenesis, as the 
overall structure of the protein was (in theory) less compromised. Also, we 
did not express mutant PrP proteins in the presence of wild-type protein, 
which allowed us to assess the effect of individual mutations without 
interference from the endogenous protein. 
Single, double and triple alanine substitutions made along the length of the 
moPrP ORF revealed differences in their ability to propagate RML prions 
depending on their position in the primary sequence of the protein. 
Generally, it was found that mutations within the C-terminus of the protein 
had a greater inhibitory effect on RML prion propagation than substitutions 
made in the flexible N-terminus. Exceptions of note were the charge cluster 
regions in the flexible N-terminus and residue Q41: when alanine 
replacements were made at these sites, cells expressing these mutants 
displayed markedly reduced prion propagation. The results highlight the 
importance of structural integrity in the C-terminal domain of the protein for 
successful prion propagation and uncover key sites within the N-terminus 
that regulate prion propagation. 
Thus, while changes in the solvent-exposed structured region of the prion 
protein abrogated propagation, discrete domains within the unstructured 
region also regulated the efficiency of propagation. To summarise, it was 
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found that: (i) charge cluster regions within the flexible N-terminal region of 
the protein, CC1 – specifically residues K23.K24.R25 – and CC2, govern 
the efficiency of prion propagation alongside residue Q41, while mutations 
within OPR regions had no effect on propagation capacity; (ii) CC1 mutation 
K23A.K24A.R25A and Q41A likely hinder propagation through similar 
pathways as expression of K23A.K24A.R25A and Q41A on the same 
construct did not have an additive effect in reducing prion propagation; (iii) 
within the flexible region of the protein only CC2, but not CC1, Q41A, or 
Δ23-88 mutations, were able to exert a dominant negative effect on prion 
propagation; (iv) Alanine replacements in N-terminal regions such as 
K23A.K24A.R25A nor those tested in CC2 were able to cure chronically 
RML-infected cells. (iv) in region123-230 moPrP, no particular ‘face’ when 
mutated to alanine, showed preference for propagation over another – all 
mutations tested severely limited prion propagation, suggesting that 
structural integrity in this region is key to propagative efficiency; this was 
further exemplified by mutations within the hydrophobic core of the protein, 
which displayed equally poor propagation; (v) probing the interactions in the 
PTM domain of the protein showed that increasing or decreasing the helical 
propensity within this region did not correlate with changes in propagation. 
However, most of the point mutations made in this region that severely 
limited or abrogated propagation were on two faces of the PTM helix, and 
provided some evidence in favour of a dimerisation model. 
Taken together, the mutagenic screen of the mouse prion protein showed 
that structural integrity is crucial to prion propagation and that propagation 
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efficiency is regulated by specific interactions at discrete residues within the 
flexible N-terminus (Figure C1).  
Numerous studies have reported that the prion protein interacts with Aβ 
oligomers106, 107, 121, 132, 139 and that the primary Aβ oligomer binding site  on 
PrP is located within CC2 (90-111)106, 121, with CC1 (23-27) also thought to 
play an auxiliary role in binding106, 107. It was shown here that CC1 mutation 
K23A.K24A.R25A, Q41 and all mutations made in the CC2 region 
significantly reduce the capacity of cells expressing these constructs to 
propagate prions, highlighting these regions of the protein as modulators of 
prion propagation. Chen et al. reported that deletion Δ23-89 in human PrP 
displayed no binding to Aβ, whereas Δ51-91 and Δ111-125 showed binding 
characteristics similar to wild-type PrP. They also demonstrated a greater 
loss of Aβ binding in Δ23-50 compared to CC1 deletion Δ23-27106. 
Superimposing the data obtained from our study with the Aβ binding sites 
on PrP, it could be postulated that if similar motifs are involved in aberrant 
PrP processing during prion infection and PrP-Aβ interactions, then the 
increased loss of Aβ binding observed in Δ23-50 may have been due to the 
loss of Q41 contributions. Note that Q41 has never been quoted as a 
residue on PrP that contributes to Aβ oligomer bindings, despite the findings 
of Chen et al.106 or reports by Kang et al., who showed in an epitope 
mapping immunoassay that residues 23-40 represent one of three Aβ 
binding sites within the prion protein140.  
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4 . 2 C o n c l u s i o n s  a n d  f i n a l  r e m a r k s  
The results presented here clearly highlight that the integrity of the 
structured 123-230 domain is critical for efficient propagation of RML prions 
and confirms previous findings that implicate this segment as the crucial 
entity in PrPSc formation. Importantly, this study identified residues 90-111 
of the CC2 region as strong modulators of propagation efficacy, as minimal 
mutations in this region exerted severe limitations on prion propagation. 
Finally, these results show that in addition to CC2, Q41 and CC1 also 
regulate prion propagation, but to a lesser extent than CC2 or the structured 
domain of the protein. CC1 and Q41 most likely mediate events that 
promote but are not essential for successful maintenance of prion 
propagation, whereas CC2 may be more directly involved with PrPSc 
interactions such that initiation of propagation is compromised in cells 
expressing moPrP with CC2 alanine mutations. 
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FIGURE C1: OVERALL SUMMARY OF CUMULATIVE SCA DATA ON KDMOPRPALA CELLS 
Overall summary of cumulative SCA data showing spot numbers observed at split 6; this graph provides a prion propagation 
landscape for the length of the mouse prion protein as tested via mutagenic approaches used in this study. The first three black bars 
represent KDmoPrPWT, KD and KDmoPrPΔ23-88 cell lines, respectively. All the other bars represent KD cells reconstituted with moPrP 
bearing various mutations (alanine replacement, other amino acid substitutions and deletions). Arrows on the right-hand side labelled 
1-4 represent (1) 800 spots – full propagation; (2) 400 spots – reduced propagation; (3) 200 spots – severely limited propagation; (4) 
50 spots – abrogation of prion propagation. CC1: charge cluster 1; OPRs: octapeptide repeats; CC2: charge cluster 2; PTM: putative 
transmembrane domain; SR: structured region. There is an overlap in residues tested between the PTM and SR. Bars are shown for 
mutagenesis in the PTM region where overlap exists, as this analysis covered more point mutations, whereas triple mutations were 
tested in the SR region that were not always sequential. It is important to note that within CC1, only triple mutation K23A.K24A.R25A, 
but not single mutations within this region, significantly lowered propagation. 
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4 . 3  F u t u r e  d i r e c t i o n s  
It is important to note that this study used one combination of cell line and 
prion strain, that is, PK1 cells and RML prions respectively. This is a 
powerful combination due to the sensitivity afforded by these cells to RML 
prions. However, to elucidate whether the findings of the study are cell- 
and strain- specific, or whether a general feature of prion propagation has 
been uncovered, the same screen must be carried out on a different cell 
type with a prion strain that is biochemically distinct from RML prions, such 
as 22L or Me7 prions. Furthermore, by lowering parameters such as the 
dose of infectious inocula applied and the number of cells seeded for the 
ELISPOT assay, the existing mutagenesis library could be assayed for 
mutations that confer increased prion propagation, either using SCA or 
SCEPA formats for analysis and investigate whether there are any 
correlations to the current study. Additionally, we believe the overlap in 
findings that identify residues 23-25, 41 and 90-111 as key mediators of 
propagation, and residues 23-37, 23-50 and 95-110 in as playing an 
important role in PrP-Aβ oligomer binding is striking106, 140. The available 
library of moPrP alanine mutants could be used to better characterise this 
interaction and further pursue the cellular implication of this association. 
Over the years a number of PrP binding partners have been identified by a 
variety of methods such as yeast two-hybrid screening, co-
immunoprecipitation, cross-linking and proteomics approaches. Despite 
this, the biological significance of such interactions in prion infection and 
propagation is not totally clear. Since the differences in propagation 
between KD cells reconstituted with moPrPWT or moPrPAla with changes in 
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the CC2 domain were so stark, it is possible that different sets of 
interacting partners could be identified from them. It would be interesting to 
characterise such binding partners to identify key changes in protein 
complexes obtained from these cell lines, both pre- and post- prion 
infection (Figure C2). Rutishauser et al. have shown correct protein 
sorting, GPI-anchor attachment and cell surface expression for a Myc-
tagged PrP construct195. Using a similar strategy, we could express 
alanine mutants of interest on tagged moPrP, follow the prion propagation 
profiles of the tagged constructs and probe for any correlations with 
cellular interacting proteins – protein complex constituents could be 
identified using co-immunoprecipitation followed by mass spectrometry. 
Depending on the success of identifying differential binding partners for 
moPrPWT and moPrPAla, experiments could be undertaken to determine if 
such factors contribute to efficient infection or propagation. Such 
characterisation of the protein and its interactors, both in the infected and 
non-infected states, may allow for elucidation of a cellular propagation 
pathway (Figure C2). This could potentially be taken forward to in vivo 
studies to identify critical components for PrPSc propagation. Should PrP 
interacting factors that affect in vitro prion propagation be identified, upon 
silencing or overexpression of such factors, the roles they play in prion 
propagation may be investigated in mouse models null for these factors.  
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FIGURE C2: FUTURE DIRECTIONS 
Proposed future work following the findings of the current study.  moPrP (mouse 
prion protein), STrEP (streptavidin tag), Myc (polypeptide tag derived from c-Myc) 
UTR (untranslated region),  KD (knockdown) PKres (ProteinaseK-resistant). IP 
(immunoprecipitation), WB (western blot). SCEPA (Scrapie cell end-point assay), 
SCA (Scrapie cell assay). PAGE (polyacrylamide gel electrophoresis). 
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6 . 1  M O U S E  P R I O N  P R O T E I N  O P E N  R E A D I N G  F R A M E  A S  C L O N E D  I N  
P B L U E S C R I P T S K +  P L A S M I D  V E C T O R  
 
 
10 20 30 40 50 
| | | | | 
GTCATCATGG CGAACCTTGG CTACTGGCTG CTGGCCCTCT   TTGTGACTAT 
GTGGACTGAT  GTCGGCCTCT GCAAAAAGCG GCCAAAGCCT  GGAGGGTGGA 
ACACCGGTGG  AAGCCGGTAT   CCCGGGCAGG GAAGCCCTGG  AGGCAACCGT 
TACCCACCTC  AGGGTGGCAC  CTGGGGGCAG  CCCCACGGTG  GTGGCTGGGG 
ACAACCCCAT  GGGGGCAGCT   GGGGACAACC TCATGGTGGT  AGTTGGGGTC 
AGCCCCATGG   CGGTGGATGG  GGCCAAGGAG GGGGTACCCA  TAATCAGTGG 
AACAAGCCCA  GCAAACCAAA  AACCAACCTC  AAGCATGTGG  CAGGGGCTGC 
GGCAGCTGGG  GCAGTAGTGG GGGGCCTTGG  TGGCTACATG  CTGGGGAGCG 
CCATGAGCAG  GCCCATGATC  CATTTTGGCA  CGACTGGGA  GGACCGCTAC 
TACCGTGAAA  ACATGTACCG  CTACCCTAAC  CAAGTGTACT  ACAGGCCAGT 
GGATCAGTAC  AGCAACCAGA  ACAACTTCGT  GCACGACTGC  GTCAATATCA 
CCATCAAGCA GCACACGGTC  ACCACCACCA  CCAAGGGGGA  GAACTTCACC 
GAGACCGATG  TGAAGATGAT  GGAGCGCGTG GTGGAGCAGA  TGTGCGTCAC 
CCAGTACCAG  AAGGAGTCCC AGGCCTATTA  CGACGGGAGA  AGATCCAGCA 
GCACCGTGCT TTTCTCCTCC CCTCCTGTCA TCCTCCTCAT  CTCCTTCCTC 
ATCTTCCTGA TCGTGGGATG  AGGCTCGAG 
   
FIGURE A1 
The nucleotide sequence of the mouse prion protein open reading frame from template DNA in pBluescriptSK+ shown in a 
5’ to 3’ direction. This sequence was inserted into the native pBluescriptSK+ sequence at the SmaI site of the plasmid’s 
multiple cloning site region. The ATG coding the Methionine start site is indicated in green and the TGA stop site is shown in 
red.  Shown in bold typeface are the 5’ and 3’ restriction site (SalI and HindIII respectively) which were incorporated in the 
untranslated regions of the protein when cloning it into pBluescript. 
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6 . 2  P R I M E R S  D E S I G N E D  F O R  T H E  S I T E - D I R E C T E D  M U T A G E N E S I S  
O F  M O P R P   
  
 
FIGURE A2_1 
moPrP region 23-43. Forward and reverse primers (F and R) shown for mutations designed for use with Stratagene 
QuikChange® site-directed mutagenesis kit (Stratagene, Cat.No.200523).  
 
Site directed mutagenesis Primer Sequence 5' to 3'
1 K23A F CTGATGTCGGCCTCTGCGCCAAGCGGCCAAAGCCTGGAGGG
R CCCTCCAGGCTTTGGCCGCTTGGCGCAGAGGCCGACATCAG
2 K24A F GATGTCGGCCTCTGCAAAGCCCGGCCAAAGCCTGGAGGG
R CCCTCCAGGCTTTGGCCGGGCTTTGCAGAGGCCGACATC
3 R25A F GTCGGCCTCTGCAAAAAGGCCCCAAAGCCTGGAGGGTGG
R CCACCCTCCAGGCTTTGGGGCCTTTTTGCAGAGGCCGAC
4 K23A.K24A.R25A F CTGATGTCGGCCTCTGCGCCGCCGCCCCAAAGCCTGGAGGGTGG
R CCACCCTCCAGGCTTTGGGGCGGCGGCGCAGAGGCCGACATCAG
5 P26A K27A F GGCCTCTGCAAAAAGCGGGCCGCCCCTGGAGGGTGGAACACCGG
R CCGGTGTTCCACCCTCCAGGGGCGGCCCGCTTTTTGCAGAGGCC
6 P28A F CTGCAAAAAGCGGCCAAAGGCCGGAGGGTGGAACACCGG
R CCGGTGTTCCACCCTCCGGCCTTTGGCCGCTTTTTGCAG
7 W31A.N32A.T33A F CGGCCAAAGCCTGGAGGGGCCGCCGCCGGTGGAAGCCGGTATCCCGGG
R CCCGGGATACCGGCTTCCACCGGCGGCGGCCCCTCCAGGCTTTGGCCG
8 S36A.R37A.Y38A F GGAGGGTGGAACACCGGTGGAGCCGCCGCCCCCGGGCAGGGAAGCCCTGG
R CCAGGGCTTCCCTGCCCGGGGGCGGCGGCTCCACCGGTGTTCCACCCTCC
9 Q41A F GGAAGCCGGTATCCCGGGGCCGGAAGCCCTGGAGGCAAC
R GTTGCCTCCAGGGCTTCCGGCCCCGGGATACCGGCTTCC
10 S43A F CGGTATCCCGGGCAGGGAGCCCCTGGAGGCAACCGTTAC
R GTAACGGTTGCCTCCAGGGGCTCCCTGCCCGGGATACCG
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FIGURE A2_2 
moPrP region 47-74. Forward and reverse primers (F and R) shown for mutations designed for use with Stratagene 
QuikChange® site-directed mutagenesis kit (Stratagene, Cat.No.200523).  
 
Site directed mutagenesis Primer Sequence 5' to 3'
11 N47A.R48A.W49A F CAGGGAAGCCCTGGAGGCGCCGCCGCCCCACCTCAGGGTGGCACCTGG
R CCAGGTGCCACCCTGAGGTGGGGCGGCGGCGCCTCCAGGGCTTCCCTG
12 Q52A F GGCAACCGTTACCCACCTGCCGGTGGCACCTGGGGGCAG
R CTGCCCCCAGGTGCCACCGGCAGGTGGGTAACGGTTGCC
13 T55A.W56A F CGTTACCCACCTCAGGGTGGCGCCGCCGGGCAGCCCCACGGTGGTGGCTGG
R CCAGCCACCACCGTGGGGCTGCCCGGCGGCGCCACCCTGAGGTGGGTAACG
14 Q58A F CAGGGTGGCACCTGGGGGGCCCCCCACGGTGGTGGCTGG
R CCAGCCACCACCGTGGGGGGCCCCCCAGGTGCCACCCTG
15 H60A F CCTGGGGGCAGCCCGCCGGTGGTGGCTGGGG
R CCCCAGCCACCACCGGCGGGCTGCCCCCAGG
16 W64A F CAGCCCCACGGTGGTGGCGCCGGACAACCCCATGGGGGC
R GCCCCCATGGGGTTGTCCGGCGCCACCACCGTGGGGCTG
17 Q66A F CACGGTGGTGGCTGGGGAGCCCCCCATGGGGGCAGCTGG
R CCAGCTGCCCCCATGGGGGGCTCCCCAGCCACCACCGTG
18 H68A F GGTGGCTGGGGACAACCCGCCGGGGGCAGCTGGGGAC
R GTCCCCAGCTGCCCCCGGCGGGTTGTCCCCAGCCACC
19 S71A.W72A F GGACAACCCCATGGGGGCGCCGCCGGACAACCTCATGGTGG
R CCACCATGAGGTTGTCCGGCGGCGCCCCCATGGGGTTGTCC
20 Q74A F CATGGGGGCAGCTGGGGAGCCCCTCATGGTGGTAGTTGG
R CCAACTACCACCATGAGGGGCTCCCCAGCTGCCCCCATG
342 
 
 
 
FIGURE A2_3 
moPrP region 76-101. Forward and reverse primers (F and R) shown for mutations designed for use with Stratagene 
QuikChange® site-directed mutagenesis kit (Stratagene, Cat.No.200523).  
  
Site directed mutagenesis Primer Sequence 5' to 3'
21 H76A F GCTGGGGACAACCTGCCGGTGGTAGTTGGGGTCAG
R CTGACCCCAACTACCACCGGCAGGTTGTCCCCAGC
22 S79A.W80A F GGACAACCTCATGGTGGTGCCGCCGGTCAGCCCCATGGCGG
R CCGCCATGGGGCTGACCGGCGGCACCACCATGAGGTTGTCC
23 Q82A F CATGGTGGTAGTTGGGGTGCCCCCCATGGCGGTGGATGG
R CCATCCACCGCCATGGGGGGCACCCCAACTACCACCATG
24 H84A F GTAGTTGGGGTCAGCCCGCCGGCGGTGGATGGGGC
R GCCCCATCCACCGCCGGCGGGCTGACCCCAACTAC
25 W88A F CCCCATGGCGGTGGAGCCGGCCAAGGAGGGGGTAC
R GTACCCCCTCCTTGGCCGGCTCCACCGCCATGGGG
26 Q90A F CATGGCGGTGGATGGGGCGCCGGAGGGGGTACCCATAATCAG
R CTGATTATGGGTACCCCCTCCGGCGCCCCATCCACCGCCATG
27 T94A.H95A.N96A F GGGGCCAAGGAGGGGGTGCCGCCGCCCAGTGGAACAAGCCCAGC
R GCTGGGCTTGTTCCACTGGGCGGCGGCACCCCCTCCTTGGCCCC
28 Q97A.W98A F GGAGGGGGTACCCATAATGCCGCCAACAAGCCCAGCAAACC
R GGTTTGCTGGGCTTGTTGGCGGCATTATGGGTACCCCCTCC
29 N99A.K100A F GGTACCCATAATCAGTGGGCCGCCCCCAGCAAACCAAAAACC
R GGTTTTTGGTTTGCTGGGGGCGGCCCACTGATTATGGGTACC
30 P101A F CATAATCAGTGGAACAAGGCCAGCAAACCAAAAACCAACCTC
R GAGGTTGGTTTTTGGTTTGCTGGCCTTGTTCCACTGATTATG
343 
 
 
FIGURE A2_4 
moPrP region 101-111. Forward and reverse primers (F and R) shown for mutations designed for use with Stratagene 
QuikChange® site-directed mutagenesis kit (Stratagene, Cat.No.200523).  
  
Site directed mutagenesis Primer Sequence 5' to 3'
31 P101L F CATAATCAGTGGAACAAGCTGAGCAAACCAAAAACCAACCTC
R GAGGTTGGTTTTTGGTTTGCTCAGCTTGTTCCACTGATTATG
32 P104A F CAGTGGAACAAGCCCAGCAAAGCCAAAACCAACCTCAAGCATGTG
R CACATGCTTGAGGTTGGTTTTGGCTTTGCTGGGCTTGTTCCACTG
33 P104L F CAGTGGAACAAGCCCAGCAAACTGAAAACCAACCTCAAGCATGTG
R CACATGCTTGAGGTTGGTTTTCAGTTTGCTGGGCTTGTTCCACTG
34 P104T F CAGTGGAACAAGCCCAGCAAAACAAAAACCAACCTCAAGCATGTG
R CACATGCTTGAGGTTGGTTTTTGTTTTGCTGGGCTTGTTCCACTG
35 S102A.K103A F CATAATCAGTGGAACAAGCCCGCCGCCCCAAAAACCAACCTCAAG
R CTTGAGGTTGGTTTTTGGGGCGGCGGGCTTGTTCCACTGATTATG
36 K105A.T106A.N107A F GGAACAAGCCCAGCAAACCAGCCGCCGCCCTCAAGCATGTGGCAGGG
R CCCTGCCACATGCTTGAGGGCGGCGGCTGGTTTGCTGGGCTTGTTCC
37 L108A.K109A F CCCAGCAAACCAAAAACCAACGCCGCCCATGTGGCAGGGGCTGCG
R CGCAGCCCCTGCCACATGGGCGGCGTTGGTTTTTGGTTTGCTGGG
38 K109E F CCAAAAACCAACCTCGAGCATGTGGCAGGGGC
R GCCCCTGCCACATGCTCGAGGTTGGTTTTTGG
39 H110A.V111A F CCAAAAACCAACCTCAAGGCCGCCGCAGGGGCTGCGGCAGCTGGG
R CCCAGCTGCCGCAGCCCCTGCGGCGGCCTTGAGGTTGGTTTTTGG
40 V111M F CCAACCTCAAGCATATGGCAGGGGCTGCGGC
R GCCGCAGCCCCTGCCATATGCTTGAGGTTGG
344 
 
 
FIGURE A2_5 
moPrP region 112-119. Forward and reverse primers (F and R) shown for mutations designed for use with Stratagene 
QuikChange® site-directed mutagenesis kit (Stratagene, Cat.No.200523).  
  
Site directed mutagenesis Primer Sequence 5' to 3'
41 A112L F CCAACCTCAAGCATGTGCTAGGGGCTGCGGCAGC
R GCTGCCGCAGCCCCTAGCACATGCTTGAGGTTGG
42 G113L F CCAACCTCAAGCATGTGGCACTGGCTGCGGCAGCTGGGGCAG
R CTGCCCCAGCTGCCGCAGCCAGTGCCACATGCTTGAGGTTGG
43 A115G F CAAGCATGTGGCAGGGGCTGGGGCAGCTGGGGCAGTAGTGG
R CCACTACTGCCCCAGCTGCCCCAGCCCCTGCCACATGCTTG
44 A115L F CAAGCATGTGGCAGGGGCTCTGGCAGCTGGGGCAGTAGTGG
R CCACTACTGCCCCAGTGCCAGAGCCCCTGCCACATGCTTG
45 A116L F GCATGTGGCAGGGGCTGCGCTAGCTGGGGCAGTAGTGGGG
R CCCCACTACTGCCCCAGCTAGCGCAGCCCCTGCCACATGC
46 A117L F GTGGCAGGGGCTGCGGCACTTGGGGCAGTAGTGGGGGGC
R GCCCCCCACTACTGCCCCAAGTGCCGCAGCCCCTGCCAC
47 A117R F GTGGCAGGGGCTGCGGCACGTGGGGCAGTAGTGGGGGGC
R GCCCCCCACTACTGCCCCACGTGCCGCAGCCCCTGCCAC
48 G118A F GCAGGGGCTGCGGCAGCTGCGGCAGTAGTGGGGGGCCTTG
R CAAGGCCCCCCACTACTGCCGCAGCTGCCGCAGCCCCTGC
49 G118L F GCAGGGGCTGCGGCAGCTCTGGCAGTAGTGGGGGGCCTTG
R CAAGGCCCCCCACTACTGCCAGAGCTGCCGCAGCCCCTGC
50 A119L F GCAGGGGCTGCGGCAGCTGGGCTAGTAGTGGGGGGCCTTGGTGGC
R GCCACCAAGGCCCCCCACTACTAGCCCAGCTGCCGCAGCCCCTGC
345 
 
 
FIGURE A2_6 
moPrP region 119-125. Forward and reverse primers (F and R) shown for mutations designed for use with Stratagene 
QuikChange® site-directed mutagenesis kit (Stratagene, Cat.No.200523).  
  
Site directed mutagenesis Primer Sequence 5' to 3'
51 A119P F GCAGGGGCTGCGGCAGCTGGGCCAGTAGTGGGGGGCCTTGGTGGC
R GCCACCAAGGCCCCCCACTACTGGCCCAGCTGCCGCAGCCCCTGC
52 V120A F GGGCTGCGGCAGCTGGGGCAGCAGTGGGGGGCCTTGGTGGCTAC
R GTAGCCACCAAGGCCCCCCACTGCTGCCCCAGCTGCCGCAGCCC
53 V121A F GCTGCGGCAGCTGGGGCAGTAGCGGGGGGCCTTGGTGGCTACATG
R CATGTAGCCACCAAGGCCCCCCGCTACTGCCCCAGCTGCCGCAGC
54 G122A F GCAGCTGGGGCAGTAGTGGCGGGCCTTGGTGGCTACATGCTG
R CAGCATGTAGCCACCAAGGCCCGCCACTACTGCCCCAGCTGC
55 G122L F GCAGCTGGGGCAGTAGTGCTGGGCCTTGGTGGCTACATGCTG
R CAGCATGTAGCCACCAAGGCCCAGCACTACTGCCCCAGCTGC
56 G123A F GCTGGGGCAGTAGTGGGGGCCCTTGGTGGCTACATGCTG
R CAGCATGTAGCCACCAAGGGCCCCCACTACTGCCCCAGC
57 L124A F GCTGGGGCAGTAGTGGGGGGCGCTGGTGGCTACATGCTGGGGAGC
R GCTCCCCAGCATGTAGCCACCAGCGCCCCCCACTACTGCCCCAGC
58 L124I F GCTGGGGCAGTAGTGGGGGGCATTGGTGGCTACATGCTGGGGAGC
R GCTCCCCAGCATGTAGCCACCAATGCCCCCCACTACTGCCCCAGC
59 L124V F GCTGGGGCAGTAGTGGGGGGCGTTGGTGGCTACATGCTGGGGAGC
R GCTCCCCAGCATGTAGCCACCAACGCCCCCCACTACTGCCCCAGC
60 G125A F GGGCAGTAGTGGGGGGCCTTGCTGGCTACATGCTGGGGAGC
R GCTCCCCAGCATGTAGCCAGCAAGGCCCCCCACTACTGCCC
346 
 
 
FIGURE A2_7 
moPrP region 126-130. Forward and reverse primers (F and R) shown for mutations designed for use with Stratagene 
QuikChange® site-directed mutagenesis kit (Stratagene, Cat.No.200523).  
  
Site directed mutagenesis Primer Sequence 5' to 3'
61 G126A F GTGGGGGGCCTTGGTGCCTACATGCTGGGGAGCGCC
R GGCGCTCCCCAGCATGTAGCCACCAAGGCCCCCCAC
62 G126L F GTAGTGGGGGGCCTTGGTCTCTACATGCTGGGGAGCGCC
R GGCGCTCCCCAGCATGTAGAGACCAAGGCCCCCCACTAC
63 G126V F GTAGTGGGGGGCCTTGGTGTCTACATGCTGGGGAGCGCC
R GGCGCTCCCCAGCATGTAGACACCAAGGCCCCCCACTAC
64 Y127F F GTGGGGGGCCTTGGTGGCTTCATGCTGGGGAGCGCCGTG
R CACGGCGCTCCCCAGCATGAAGCCACCAAGGCCCCCCAC
65 Y127P F GTGGGGGGCCTTGGTGGCCCCATGCTGGGGAGCGCCGTG
R CACGGCGCTCCCCAGCATGGGGCCACCAAGGCCCCCCAC
66 Y127R F GTGGGGGGCCTTGGTGGCCGCATGCTGGGGAGCGCCGTG
R CACGGCGCTCCCCAGCATGCGGCCACCAAGGCCCCCCAC
67 M128L F GTGGGGGGCCTTGGTGGCTACCTGCTGGGGAGCGCCGTGAGCAGG
R CCTGCTCACGGCGCTCCCCAGCAGGTAGCCACCAAGGCCCCCCAC
68 M128V F GTGGGGGGCCTTGGTGGCTACGTGCTGGGGAGCGCCGTGAGCAGG
R CCTGCTCACGGCGCTCCCCAGCACGTAGCCACCAAGGCCCCCCAC
69 L129A F GGCCTTGGTGGCTACATGGCGGGGAGCGCCGTGAGCAGG
R CCTGCTCACGGCGCTCCCCGCCATGTAGCCACCAAGGCC
70 G130A F GGCCTTGGTGGCTACATGCTGGCGAGCGCCGTGAGCAGGCCCATG
R CATGGGCCTGCTCACGGCGCTCGCCAGCATGTAGCCACCAAGGCC
347 
 
 
FIGURE A2_8 
moPrP region 130-141. Forward and reverse primers (F and R) shown for mutations designed for use with Stratagene 
QuikChange® site-directed mutagenesis kit (Stratagene, Cat.No.200523).  
  
Site directed mutagenesis Primer Sequence 5' to 3'
71 G130L F GGCCTTGGTGGCTACATGCTGCTGAGCGCCGTGAGCAGGCCCATG
R CATGGGCCTGCTCACGGCGCTCAGCAGCATGTAGCCACCAAGGCC
72 S131A F GGTGGCTACATGCTGGGGGCCGCCGTGAGCAGGCCCATG
R CATGGGCCTGCTCACGGCGGCCCCCAGCATGTAGCCACC
73 A132L F GGTGGCTACATGCTGGGGAGCCTCGTGAGCAGGCCCATGATCC
R GGATCATGGGCCTGCTCACGAGGCTCCCCAGCATGTAGCCACC
74 S134A F CATGCTGGGGAGCGCCGTGGCCAGGCCCATGATCCATTTTGG
R CCAAAATGGATCATGGGCCTGGCCACGGCGCTCCCCAGCATG
75 R135A F CATGCTGGGGAGCGCCGTGAGCGCCCCCATGATCCATTTTGGCAAC
R GTTGCCAAAATGGATCATGGGGGCGCTCACGGCGCTCCCCAGCATG
76 R135E F CTGGGGAGCGCCGTGAGCGAGCCCATGATCCATTTTGG
R CCAAAATGGATCATGGGCTCGCTCACGGCGCTCCCCAG
77 H139A F GCCGTGAGCAGGCCCATGATCGCCTTTGGCAACGACTGGGAGGACCGC
R GCGGTCCTCCCAGTCGTTGCCAAAGGCGATCATGGGCCTGCTCACGGC
78 G141A F GTGAGCAGGCCCATGATCCATTTTGCCAACGACTGGGAGGACCGCTAC
R GTAGCGGTCCTCCCAGTCGTTGGCAAAATGGATCATGGGCCTGCTCAC
79 Δ112-129 F CCCAGCAAACCAAAAACCAACCTCAAGCATGTGGGGAGCGCCGTGAGCAGGCCCATGATCCATTTTGGC
R GCCAAAATGGATCATGGGCCTGCTCACGGCGCTCCCCACATGCTTGAGGTTGGTTTTTGGTTTGCTGGG
80 Δ117-124 F CCAACCTCAAGCATGTGGCAGGGGCTGCGGCAGGTGGCTACATGCTGGGGAGCGCCGTGAGC
R GCTCACGGCGCTCCCCAGCATGTAGCCACCTGCCGCAGCCCCTGCCACATGCTTGAGGTTGG
348 
 
 
FIGURE A2_9 
moPrP region 123-151. Forward and reverse primers (F and R) shown for mutations designed for use with Stratagene 
QuikChange® site-directed mutagenesis kit (Stratagene, Cat.No.200523). * indicates that this mutation was made to part of 
a larger mutational construct such as in the case of structured region mutations where the amino acids targeted are spatially, 
but not sequentially proximal. 
  
Site directed mutagenesis Primer Sequence 5' to 3'
81 G123A.L124A.G125A F GCAGCTGGGGCAGTAGTGGGGGCCGCCGCCGGCTACATGCTGGGGAGCGCC
R GGCGCTCCCCAGCATGTAGCCGGCGGCGGCCCCCACTACTGCCCCAGCTGC
82 M128A* F GTGGGGGGCCTTGGTGGCTACGCCCTGGGGAGCGCCGTGAGC
R GCTCACGGCGCTCCCCAGGGCGTAGCCACCAAGGCCCCCCAC
83 L129A.S131A* F GGCCTTGGTGGCTACATGGCCGGGGCCGCCGTGAGCAGGCCCATG
R CATGGGCCTGCTCACGGCGGCCCCGGCCATGTAGCCACCAAGGCC
84 S134A.R135A* F CATGCTGGGGAGCGCCGTGGCCGCCCCCATGATCCATTTTGGC
R GCCAAAATGGATCATGGGGGCGGCCACGGCGCTCCCCAGCATG
85 H139A.G141A* F GCCGTGAGCAGGCCCATGATCGCCTTTGCCAACGACTGGGAGGACCGCTAC
R GTAGCGGTCCTCCCAGTCGTTGGCAAAGGCGATCATGGGCCTGCTCACGGC
86 H139A.G141.D146A F GCCTTTGCCAACGACTGGGAGGCCCGCTACTACCGTGAAAACATG
R CATGTTTTCACGGTAGTAGCGGGCCTCCCAGTCGTTGGCAAAGGC
87 N142A.N144A.E145A F CCCATGATCCATTTTGGCGCCGACGCCGCCGACCGCTACTACCGTGAAAAC
R GTTTTCACGGTAGTAGCGGTCGGCGGCGTCGGCGCCAAAATGGATCATGGG
88 *D146A F CATTTTGGCAACGACTGGGAGGCCCGCTACTACCGTGAAAACATG
R CATGTTTTCACGGTAGTAGCGGGCCTCCCAGTCGTTGCCAAAATG
89 R147A.R150A.E151A F GGCAACGACTGGGAGGACGCCTACTACGCCGCCAACATGTACCGCTACCCTAAC
R GTTAGGGTAGCGGTACATGTTGGCGGCGTAGTAGGCGTCCTCCCAGTCGTTGCC
90 Y148A* F GGCACCGACTGGGAGGACCGCGCCTACCGTGAAAACATGTACCGC
R GCGGTACATGTTTTCACGGTAGGCGCGGTCCTCCCAGTCGGTGCC
349 
 
 
FIGURE A2_10 
moPrP region 153-216. Forward and reverse primers (F and R) shown for mutations designed for use with Stratagene 
QuikChange® site-directed mutagenesis kit (Stratagene, Cat.No.200523). * indicates that this mutation was made to part of 
a larger mutational construct such as in the case of structured region mutations where the amino acids targeted are spatially, 
but not sequentially proximal. 
 
  
Site directed mutagenesis Primer Sequence 5' to 3'
91 *M153A F CGCTACTACCGTGAAAACGCCTACCGCTACCCTAACCAAGTG
R CACTTGGTTAGGGTAGCGGTAGGCGTTTTCACGGTAGTAGCG
92 R155A* F CTACCGTGAAAACATGTACGCCTACCCTAACCAAGTGTAC
R GTACACTTGGTTAGGGTAGGCGTACATGTTTTCACGGTAG
93 *Q159A F CATGTACCGCTACCCTAACGCCGTGTACTACAGGCCAGTGGATC
R GATCCACTGGCCTGTAGTACACGGCGTTAGGGTAGCGGTACATG
94 *Y162A* F C TAC CCT AAC CAA GTG TAC GCC AGG CCA GTG GAT CAG TAC   
R GTA CTG ATC CAC TGG CCT GGC GTA CAC TTG GTT AGG GTA G
95 *Q216A F GAG CAG ATG TGC GTC ACC GCC TAC CAG AAG GAG TCC CAG   
R CTG GGA CTC CTT CTG GTA GGC GGT GAC GCA CAT CTG CTC
96 R163A.Y168A* F CCTAACCAAGTGTACTACGCCCCAGTGGATCAGGCCAGCAACCAGAACAACTTCGTG
R CACGAAGTTGTTCTGGTTGCTGGCCTGATCCACTGGGGCGTAGTACACTTGGTTAGG
97 S169A.N170A* F CAGGCCAGTGGATCAGTACGCCGCCCAGAACAACTTCGTGCAC
R GTGCACGAAGTTGTTCTGGGCGGCGTACTGATCCACTGGCCTG
98 F174A* F CAGTACAGCAACCAGAACAACGCCGTGCACGACTGCGTCAATATC
R GATATTGACGCAGTCGTGCACGGCGTTGTTCTGGTTGCTGTACTG
99 F174A.V179A F CAGTACAGCAACCAGAACAACGCCGTGCACGACTGCGCCAATATC
R GATATTGGCGCAGTCGTGCACGGCGTTGTTCTGGTTGCTGTACTG
100 *H176A F GCAACCAGAACAACTTCGTGGCCGACTGCGTCAATATCACC
R GGTGATATTGACGCAGTCGGCCACGAAGTTGTTCTGGTTGC
350 
 
 
FIGURE A2_11 
moPrP region 178-207. Forward and reverse primers (F and R) shown for mutations designed for use with Stratagene 
QuikChange® site-directed mutagenesis kit (Stratagene, Cat.No.200523). * indicates that this mutation was made to part of 
a larger mutational construct such as in the case of structured region mutations where the amino acids targeted are spatially, 
but not sequentially proximal. 
 
  
Site directed mutagenesis Primer Sequence 5' to 3'
101 C178A* F CAGAACAACTTCGTGCACGACGCCGTCAATATCACCATCAAGCAG
R CTGCTTGATGGTGATATTGACGGCGTCGTGCACGAAGTTGTTCTG
102 V179A F CAACTTCGTGCACGACTGCGCCAATATCACCATCAAGCAGCACACG
R CGTGTGCTGCTTGATGGTGATATTGGCGCAGTCGTGCACGAAGTTG
103 V179A.I183A* F CAACTTCGTGCACGACTGCGCCAATATCACCGCCAAGCAGCACACGGTCACC
R GGTGACCGTGTGCTGCTTGGCGGTGATATTGGCGCAGTCGTGCACGAAGTTG
104 I183A F CACGACTGCGTCAATATCACCGCCAAGCAGCACACGGTCACC
R GGTGACCGTGTGCTGCTTGGCGGTGATATTGACGCAGTCGTG
105 V188A.T191A.T192A F CACCATCAAGCAGCACACGGCCACCACCGCCGCCAAGGGGGAGAACTTCACC
R GGTGAAGTTCTCCCCCTTGGCGGCGGTGGTGGCCGTGTGCTGCTTGATGGTG
106 *K193A.E195A F CACACGGTCACCACCACCACCGCCGGGGCCAACTTCACCGAGACCGATGTG
R CACATCGGTCTCGGTGAAGTTGGCCCCGGCGGTGGTGGTGGTGACCGTGTG
107 *T198A.D201A F CCACCAAGGGGGAGAACTTCGCCGAGACCGCCGTGAAGATGATGGAGCGCGTG
R CACGCGCTCCATCATCTTCACGGCGGTCTCGGCGAAGTTCTCCCCCTTGGTGG
108 K203A.E206A.R207A F CTTCACCGAGACCGATGTGGCCATGATGGCCGCCGTGGTGGAGCAGATGTGCGTC
R GACGCACATCTGCTCCACCACGGCGGCCATCATGGCCACATCGGTCTCGGTGAAG
109 M204A F CACCGAGACCGATGTGAAGGCCATGGAGCGCGTGGTGGAG
R CTCCACCACGCGCTCCATGGCCTTCACATCGGTCTCGGTG
110 M204Q.M205Q* F CACCGAGACCGATGTGAAGCAGCAGGAGCGCGTGGTGGAGCAGATG
R CATCTGCTCCACCACGCGCTCCTGCTGCTTCACATCGGTCTCGGTG
351 
 
 
FIGURE A2_12 
moPrP region 178-207. Forward and reverse primers (F and R) shown for mutations designed for use with Stratagene 
QuikChange® site-directed mutagenesis kit (Stratagene, Cat.No.200523). * indicates that this mutation was made to part of 
a larger mutational construct such as in the case of structured region mutations where the amino acids targeted are spatially, 
but not sequentially proximal. 
 
FIGURE A2_13 
Primers designed to anneal to moPrP ORF at amino acid 1 (forward) and amino acid 164 (forward and reverse primers); 
used for sequencing reactions to verify mutated sequence 
  
Site directed mutagenesis Primer Sequence 5' to 3'
111 *V209Q.M212Q F GTGAAGATGATGGAGCGCGTGCAGGAGCAGCAGTGCGTCACCCAGTACCAG
R CTGGTACTGGGTGACGCACTGCTGCTCCTGCACGCGCTCCATCATCTTCAC
112 M204Q.M205Q.V209Q.M212Q F GTGAAGCAGCAGGAGCGCGTGCAGGAGCAGCAGTGCGTCACCCAGTACCAG
R CTGGTACTGGGTGACGCACTGCTGCTCCTGCACGCGCTCCTGCTGCTTCAC
113 E210A.Q211A* F GATGATGGAGCGCGTGGTGGCCGCCATGTGCGTCACCCAGTACCAG
R CTGGTACTGGGTGACGCACATGGCGGCCACCACGCGCTCCATCATC
114 *C213A F GAGCGCGTGGTGGAGCAGATGGCCGTCACCCAGTACCAGAAGGAG
R CTCCTTCTGGTACTGGGTGACGGCCATCTGCTCCACCACGCGCTC
115 K219A.E220A.Q222A F GTGCGTCACCCAGTACCAGGCCGCCTCCGCCGCCTATTACGACGGGAGAAG
R CTTCTCCCGTCGTAATAGGCGGCGGAGGCGGCCTGGTACTGGGTGACGCAC
116 *Y224A F CAGAAGGAGTCCCAGGCCGCCTACGACGGGAGAAGATCC
R GGATCTTCTCCCGTCGTAGGCGGCCTGGGACTCCTTCTG
117 *Y225A F GAAGGAGTCCCAGGCCTATGCCGACGGGAGAAGATCCAGC
R GCTGGATCTTCTCCCGTCGGCATAGGCCTGGGACTCCTTC
Sequencing Primers Primer Sequence 5' to 3'
moPrPaa1_for F GGCGAACCTTGGCTACTG
moPrPaa164_for F GCCAGTGGATCAGTACAG
moPrPaa164_rev R CTGTACTGATCCACTGGC
352 
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FIGURE A3  
Schematics showing moPrP in both pBluescriptSK+ and pLNCX2 vectors; (A) moPrP ORF (in blue )as shown in Figure A1 
was cloned into the pBluescriptSK+ vector at a SmaI site within the multiple cloning site. This construct was used to 
generate all alanine replacements via site directed mutagenesis. (B) Following HindIII/XhoI digestion of (A), moPrPAla was 
cloned into HindIII/SalI linearised pLNCX2. Shown in red are the resistance genes expressed by the vectors, and restriction 
sites  
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FIGURE A4 
Single letter code protein sequence of moPrP. Signal sequences at both N- and C-terminus of the protein are underlined 
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FIGURE A5 
PVDF membrane on a 96-well plate on to which 25,000 PK1 cells were plated. (A) 
Positive control showing that ProteinaseK-resistant material is detected when RML 
homogenate is used to infect  PK1 cells and (B) negative control showing that KD 
cells do not propagate RML prions as no PK-resistant is detected by SCA and 
ELISPOT analysis. 
 
